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Preterm labour and dysfunctional term labour lead to the most pre-eminent problems
in obstetric practice today. We currently lack effective strategies for preventing
spontaneous preterm labour, and prematurity remains the leading cause of perinatal
morbidity and mortality. In contrast, some women do not labour effectively at term,
or pregnancy becomes prolonged, both ofwhich increase the risk of caesarean
section, rates ofwhich are on the rise in this country.
Human labour is an inflammatory process, characterised by an influx of
inflammatory cells into the myometrium and cervix at the onset of labour, and an
increase in production ofproinflammatory cytokines and expression of cell adhesion
molecules. A substantial body of evidence has now accumulated in support of this
theory, but relatively little attention has yet focused on anti-inflammatory pathways
within this process. The resolution of inflammation is now recognised to be an active
process, driven by a variety of endogenous pro-resolution factors. These include the
lipid mediator lipoxin A4 (LXA4), derived from arachidonic acid and signalling
through a G-protein coupled receptor, a member of the formyl peptide receptor
family, FPR2/ALX. Another is Annexin A1 (ANXA1), a glucocorticoid-regulated
peptide that also signals via FPR2/ALX. The aim of this thesis was to explore the
role of these anti-inflammatory and pro-resolution mediators in myometrial and
placental tissues and examine what role they may have within the inflammatory
process of labour.
Expression of the receptor FPR2/ALX and enzymes involved in the synthesis of
LXA4 was determined by quantitative RT-PCR in labouring and non-labouring
tissues of the reproductive tract and FPR2/ALX was localised in these tissues using
immunohistochemistry. It was found that expression of the receptor and the enzyme
5-lipoxygenase (ALOX5) were upregulated in labouring tissues and that the receptor
localised primarily to immune cells. A microarray and functional genomics were
used to examine inflammation in myometrium and interesting parallels were drawn
between artificially-induced inflammation and the process of labour, identifying
pathways of interest for further study. Myometrial tissue was cultured in hypoxia, a
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pro-inflammatory environment, and it was demonstrated by ELISA and quantitative
RT-PCR that LXA4 production was unaffected in these conditions, but that there
may be changes in expression ofALOX5 and FPR2/ALX.
Quantitative RT-PCR and immunohistochemistry were used to explore the
expression ofANXA1 in labouring and non-labouring tissues and found localisation
to immune cells and vascular endothelial cells but no difference in expression in
labour. Tissue culture and quantitative RT-PCR demonstrated glucocorticoid-
regulation ofFPR2/ALX but not ANXA1 in myometrium.
This work has shown that LXA4 and ANXA1 are present in the reproductive tract
during pregnancy and parturition and that a mechanism may exist, via upregulation
of their common receptor, for a role within the inflammatory process of labour.
Further work will aim to clarify the nature of this role and its functional effects, with
the ultimate aim ofbetter understanding the process of inflammation during
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The mechanisms that initiate and drive human parturition are not fully understood,
and despite great advances in medical science over the last century, maternal and
neonatal morbidity and mortality caused by dysfunctional or preterm labour remain a
significant threat to women and their infants worldwide. In the UK, dysfunctional or
delayed parturition at term causes significant complications including caesarean
section, for which the rate is rising, having increased from 9% in 1980 in England
and Wales to 21% in 2001 (Thomas 2001). Worldwide, the World Health
Organisation estimate that 1000 women die every day due to complications
encountered during pregnancy and childbirth. Preterm birth is the major cause of
neonatal mortality and morbidity in developed countries (Norman et al. 2009) with a
rising prevalence currently of 7.6% in Scotland (Norman et al. 2009)and 9.6% of
births worldwide (Martin et al. 2006).
Labour is a complex process, with a multitude of different systems and tissues
combining and interacting to achieve an elegantly choreographed sequence of events
including the remodelling and dilatation of the cervix, rupture of the fetal membranes
and the onset and maintenance of effective uterine contractions, culminating in
delivery of the fetus and placenta. The entire process is followed by involution of the
uterus. In recent years, a growing body of evidence has been published to support the
concept that human labour is overwhelmingly an inflammatory process. A better
understanding of the physiological processes of normal and abnormal parturition
may help us to develop strategies to treat the pathologies associated with childbirth
and reduce both maternal and neonatal mortality and morbidity.
In recent years, it has become apparent that the resolution of inflammation, far from
being a passive process as was traditionally thought, is an active process and that
important mechanisms exist to bring about appropriate resolution of an inflammatory
response and reduce host tissue damage. A number of novel mediators have been
identified with potent anti-inflammatory and pro-resolution activity.
2
The following introduction will describe the process of inflammation, its resolution
and some of the mediators involved in these processes, with particular regard to
those which are relevant to the rest of this thesis. A discussion of the inflammatory
processes of labour then follows.
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1.2.THE IMMUNE SYSTEM, INFLAMMATION AND ITS
RESOLUTION
1.2.1.The immune system
The immune system evolved as a method of defence against infectious disease and
tissue injury. A deficient immune system renders the individual susceptible to
disease from early life and thus a robust response to infection is vital for survival.
However, an immune system that too readily responds to insult may also be
damaging to the individual, with the potential to cause tissue damage and/or chronic
illness (Nathan 2002). The human body possesses some non-specific defences to
protect itself from attack from infectious agents, essentially provided by mechanical
barriers such as skin and respiratory tract cilia, secretory factors such as mucus, tears,
gastric acid, and the development of normal flora of, for example, the gastro¬
intestinal tract and vagina (Kumar et al. 2005). However, an effective response must
be generated should these defences be breached, and this is provided by what has
traditionally been divided into two interacting components: the innate immune
system and the adaptive immune system.
1.2.1.1. The adaptive immune system
The adaptive immune response is provided by cells of lymphoid lineage, namely T-
cells and B-cells (Kumar et al. 2005). It requires recognition of the antigen by
antigen-presenting cells and T-lymphocytes followed by elimination of the antigen
by antibodies, effector T-lymphocytes and also by recruitment and enhancement of
aspects of the innate immune system (Medzhitov and Janeway 1997). Although the
adaptive immune system is able to remember previous initial specific responses and
respond more quickly and efficiently during subsequent exposures, its response to
infection takes time to evolve and act on the invading pathogens. In contrast, the
innate immune system is a non-specific, but rapid response to microbial infection,
allowing time for the adaptive immune system to mount a response.
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1.2.1.2. The innate immune system
The innate immune response is an ancient evolutionary development and
characteristically provides a rapid and non-specific response. It is responsible for
inflammation, a phenomenon which has been recognised for thousands of years.
Classically defined by the four cardinal symptoms of redness, swelling, heat and
pain, inflammation is a response to microbial challenge or tissue injury by which the
host mounts a defence against infection and effects tissue repair and a return to
homeostasis. An inflammatory trigger is recognised by the host, inflammatory
mediators are produced by the sensors that detected the trigger, and these mediators
subsequently act on target tissues to bring about functional changes that allow the
tissue to adapt to the noxious conditions (Medzhitov 2008).
1.2.2. Inflammation
1.2.2.1. Inflammation in response to infection
The pathways by which the acute inflammatory response proceeds are complex,
varied, and differ depending on such factors as the stimulus and the site of insult.
Acute inflammation evoked by bacterial infection is perhaps the pathway which has
been best characterised, and is briefly described here. Receptors of the innate
immune system are able to identify certain components ofmicrobes such as
lipopolysaccharide (LPS) and thus are termed pattern-recognition receptors (PRRs)
(Medzhitov and Janeway 2000). An example of the PRRs are the Toll-like receptors
(TLRs), transmembrane proteins expressed by tissue-resident macrophages,
neutrophils and dendritic cells (DCs) (Beutler and Poltorak 2000). Since their
discovery in the 1990s (Lemaitre et al. 1996; Poltorak et al. 1998), a multitude of
TLRs have been discovered and the scientists that first discovered the TLRs, Bruce
Beutler and Jules Hoffmann, were awarded the The Nobel Prize for Physiology or
Medicine 2011. Recognition of the specific features of microbes by the TLRs results
in activation of the cells on which they are expressed and production of inflammatory
cytokines such as interleukin (IL)-l, IL6 and tumor necrosis factor (TNF)-a (Beutler
2002). These inflammatory mediators act upon blood vessel endothelium to promote
the migration of leucocytes and the leakage of plasma from within the blood vessels
to the site of infection.
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Neutrophils, attracted to the inflammatory site, encounter and phagocytose bacteria
and then expose the phagosomes to proteases contained in cytoplasmic granules, thus
killing and degrading the phagocytosed material (Nathan 2006). Neutrophils can also
release the contents of these granules to the extracellular space without having
engulfed any bacteria, thus creating a toxic environment for any nearby pathogens.
The granular contents are also damaging to host cells and neutrophilic degranulation
causes liquefaction of tissue and the formation of pus. This seemingly damaging by¬
product of inflammation actually serves a beneficial purpose, by containing a
bacterial infection in the early phase (Nathan 2006). Neutrophils become apoptotic
and are cleared from the site of infection by macrophages, which engulf the apoptotic
cells and then leave the site of inflammation via the lymphatic system (Kumar et al.
2005).
1.2.2.2. Sterile tissue injury
Tissue injury is often also associated with concomitant infection, unsurprisingly
when the protective barrier of the skin has been broken and microbes are able to
invade. However, some tissue injury is sterile, for example, following surgical
incision, ischaemic or ischaemia-reperfusion injury. Although the signals and
receptors of initiation of inflammation in sterile injury are less well characterised in
comparison to those in infective inflammation, it is thought that molecules released
from necrotic cells such as heat shock proteins (Vabulas ct al. 2002), hyaluronan
(Jiang et al. 2005)and (3-defensin may be initiators and that the TLRs may be
implicated in the recognition of sterile injury (Biragyn et al. 2002). As with
infection-induced inflammation, there is recruitment of neutrophils and release of
inflammatory mediators. The inflammation acts to help prevent secondary infection
and promote repair of damaged tissue.
1.2.3.The resolution of inflammation
Regardless of the original stimulus of inflammation, it is important that inflammation
resolves once the stimulus has been dealt with, or host tissue damage or chronic
disease may follow. It used to be thought that the resolution of inflammation was a
passive process and that once a microbial invasion had been satisfactorily neutralised
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and tissue repair completed that the chemoattractants and invading inflammatory
response simply 'fizzled out' and the tissues gradually returned to their normal
function. However, it is now recognised that active processes exist to control the
course of inflammation and promote its timely resolution, thus limiting damage to
host tissues (Serhan and Savill 2005). Indeed, the mechanisms by which resolution
occur are initiated even as the acute inflammatory response itself is beginning
(Serhan and Savill 2005).
These mechanisms include the suppression of pro-inflammatory gene expression,
leukocyte migration and activation, followed by clearance of the inflammatory cells
by apoptosis and phagocytosis. For example, the TLRs, described above as potent
sensors of pathogen invasion, not only induce a pro-inflammatory cascade, but also
initiate what ultimately become negative-feedback inhibitors (Liew et al. 2005).
Stromal cells at the site of inflammation such as fibroblasts contribute by
normalising chemokine gradients and withdrawing survival signals, thus promoting
leukocyte apoptosis or exit from the inflammatory sites via the lymphatic system
(Filer et al. 2006). One of the most important mechanisms is the development of
'stop signals', which reduce the infiltration ofpolymorphonuclear neutrophils
(PMNs) and promote the phagocytosis of apoptotic cells, and these stop signals
include the lipoxins, resolvins and protectins (Serhan et al. 2008), and D-series
prostaglandins (Pons et al. 1994; Rajakariar et al. 2007). A phenomenon known as
lipid-mediator class switching is observed in which the production pathways of pro¬
inflammatory eicosanoids such as leukotriene B4 (LTB4) from arachidonic acid
(AA) are diverted away towards the production of pro-resolution mediators in the
form of the lipoxins (Levy et al. 2001).
As described above, the inflammatory response and its resolution is mediated by a
host of different agents including, but not confined to, cytokines, chemokines,
prostaglandins, leukotrienes and lipid mediators. Examples ofmediators particularly
relevant to pregnancy, parturition, the resolution of inflammation and to this thesis
are discussed below.
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1.3. PRO-INFLAMMATORY MEDIATORS OF
INFLAMMATION
1.3.1.Cytokines
Cytokines are soluble proteins or glycoproteins that modulate the functions of other
cell types and act to mediate intra-cellular communication. They operate in a
complex interacting network, being regulated by a multitude of exogenous and
endogenous signals, including each other, and have pleiotropic effects (Hibbert and
Johnston 2001). There are a very large number of cytokines, some ofwhich are pro¬
inflammatory and some ofwhich have anti-inflammatory effects. Examples of
cytokines which have particular relevance either to parturition or to the work in this
thesis are discussed below.
IL-1
IL-1 is a pro-inflammatory cytokine which exists in two forms, IL-1 a and IL-1 p.
Similar in both structure and function, they also both act upon the two IL-1 receptors,
types 1 and 2 (IL1-R1 and IL1-R2) (Sims and Smith 2010). IL-1 is secreted by a
large number of cell types, but particularly by activated macrophages, and secretion
may be activated by a multitude of triggers including LPS and other cytokines such
as tumour necrosis factor alpha (TNF-a). Its potent pro-inflammatory effects include
neutrophil chemotaxis, activation ofmacrophages and epithelial cells, promotion of
the proliferation and differentiation ofT- and B-lymphocytes and stimulation of
other cytokines (Sims and Smith 2010).
TNF-a
TNF-a is a pro-inflammatory cytokine which, like IL-1, is secreted by a multitude of
different cell types and has powerful pro-inflammatory effects on a wide range of
different cell targets. Its secretion is induced by many factors including bacteria,
LPS, IL-6 and IL-1. Effects include neutrophil chemotaxis, and promotion of the
production of endothelial adhesion molecules and other pro-inflammatory cytokines
(Kumar et al. 2005).
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IL-6
IL-6 is a predominantly pro-inflammatory cytokine which, along with IL-1 and TNF-
a is responsible for fever, one of the four classical signs of inflammation, and
regulates other aspects of the acute phase reaction. It is released by and acts upon
many different cell types and is thus implicated in a number of physiological and
pathological inflammatory processes (Heinrich et al. 2003). Again, like IL-1 and
TNF-a, it has an important role to play in the process of human parturition.
1.3.2.Chemokines
Chemokines are a large subset of cytokines that are grouped together in view of their
structural homology and chemotactic properties in stimulating leukocyte movement
and regulating leukocyte infiltration from the vasculature into surrounding tissue.
Consisting of between 70-130 amino acids, they are classified into families on the
basis of the number and location of their N-terminal cysteine residues. The two main
families are CC chemokines, in which the cysteine residues are adjacent, and the
CXC chemokines, in which there is one amino acid separating the two cysteine
residues. A detailed description of chemokine structure and function is found in
Baggiolini et al, 2001. Two chemokines with particular relevance to parturition are
discussed below.
IL-8
IL-8 is a CXC chemokine, also termed CXCL8. It is initially generated as a 99-
amino acid precursor and following cleavage of the leader sequence, the active 72-
amino acid form is formed (Baggiolini et al. 1989). Signalling is via CXCR1 and
CXCR2, both of which are G-protein coupled receptors. IL-8 is released by a number
of cell types including monocytes, macrophages, neutrophils, fibroblasts and
endothelial and epithelial cells. Its major function is on neutrophils, upon which it
induces adhesion, chemotaxis, activation and the release of granule contents
(Baggiolini 2001).
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Chemokine (C-C motif) Ligand 2 (CCL2)
CCL2 is also known as monocyte chemotactic peptide-1 (MCP-1) and has 76 amino
acids (Yoshimura et al. 1989). As its alternative name suggests, CCL2 is chemotactic
for monocytes (Uguccioni et al. 1995), but also for T-cells (Loetscher et al. 1994)
and other immune cells and is involved in macrophage activation (Kohl et al. 2010).
1.3.3.Prostaglandins
Prostaglandins are 20-carbon chain fatty acids synthesised from arachidonic acid,
which is a constituent of cell membrane phospholipids and liberated from these
stores by the action of phospholipases in the first step of prostaglandin synthesis.
Arachidonic acid is then converted to an unstable intermediate prostaglandin, PGG2
and subsequently PGH2 by the action of the cyclo-oxygenase enzymes 1 and 2
(COX1 and COX2). PGH2 is then converted into the various series ofmetabolically
active prostaglandins by specific prostaglandin synthase enzymes to form
thromboxane A2 (TXA2), prostaglandin D, prostaglandin E, prostaglandin F and
prostacyclin (PG12) (Kumar et al. 2005). Prostaglandins are metabolised by the
prostaglandin dehydrogenases (PGDH-1 and PGDH-2), whose principal location is
the lung, but which is also localised to the fetal membrane trophoblast (Cheung et al.
1990).
The prostaglandins signal through a variety of receptors to produce diverse effects in
many different biological systems. These include both pro-coagulant (TXA2) or anti¬
coagulant (PGEs, PGI2) effects, bronchodilatation (PGEs) or bronchoconstriction
(PGFs) and vasodilatation (PGEs, PGI2) and vasoconstriction (PGFs and TXA2).
Prostaglandins have powerful immunomodulatory effects which may be either pro-or
anti-inflammatory and intricate crosstalk with the immune system via cytokine
regulation (for review see (Hansen et al. 1999)). Prostaglandins play a vital role
within pregnancy and parturition, with key effects in parturition including influence
on remodelling and rupture of the fetal membranes (McLaren et al. 2000) and the
induction of cervical remodelling and ripening (Denison et al. 1999).
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1.3.4.Matrix metalioproteinases
Matrix metalloproteinases (MMPs) are a family of zinc dependent enzymes. Their
main function is to degrade proteins of the extra-cellular matrix, and they are thus
involved in a multitude ofphysiological processes. However, they also cleave some
cell surface and pericellular proteins, enabling them to regulate cell behaviour, for
example by altering the activation of cell surface receptors (Sternlicht and Werb
2001). MMPs are secreted by a wide range of tissues and production is inducible by
a variety of factors including cytokines and growth factors. Tissue inhibitors of
metalloproteinases (TIMPs) inhibit their release and activation and also have a role
in restricting their function (Baker et al. 2002). Within the context ofpregnancy and
parturition, MMPs have been demonstrated to have an important role in the
extracellular matrix (ECM) degradation of the cervix and fetal membranes (Riley et
al. 1999), and this is discussed further below.
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The lipoxins are a class of endogenously produced eicosanoids derived from
arachidonic acid that have potent anti-inflammatory and pro-resolution effects. First
identified in 1984 by Serhan and colleagues (Serhan et al. 1984; Serhan et al. 1984),
three pathways have now been identified for the synthesis of lipoxins in humans.
The first of these pathways takes place at the mucosal surfaces. Arachidonic acid is
oxygenated by 15-lipoxygenase (ALOX15) to produce 15S-hydroxyleicosatetreanoic
acid (15S-HETE). Neutrophil-derived 5-lipoxygenase (ALOX5) then converts this
into lipoxin A4 (LXA4) and lipoxin B4 (LXB4) (Serhan et al. 1984; Samuelsson et
al. 1987). LXB4 is a positional isomer ofLXA4, and differs from LXA4 by the
positions of their hydroxyl groups. This pathway not only produces the lipoxins, but
diverts away from the pathway producing pro-inflammatory leukotrienes, the afore¬
mentioned Tipid-mediator class switching' process.
The second pathway takes place in peripheral blood in a platelet-neutrophil
interaction (Serhan and Sheppard 1990). ALOX5 from the leukocytes converts
arachidonic acid to leukotriene A4, which is then released and platelet-derived 12-
lipoxygenase (ALOX12) converts LTA4 to LXA4 and LXB4 (Serhan and Sheppard
1990) (See Figure 1.1).
The third pathway takes place in the presence of aspirin. Aspirin acetylation of
cyclooxygenase-2 (COX-2) inhibits the formation of prostaglandins and promotes
the production of 15R-HETE. This can then be converted by ALOX5 to 15-epimer





















U Increasedadhesion of leukocytes
and neutrophil chemotaxis
Figure 1.1
Pathways involved in lipoxin A4 synthesis
This figure illustrates the two main pathways involved in the synthesis of LXA4. The
ALOX15/ALOX5 pathway takes place in the epithelial cells and neutrophils at
mucosal surfaces and the ALOX5/ALOX12 pathway takes place in the blood in a
platelet neutrophil interaction. Also illustrated is the pathway involved in the
synthesis of Leukotriene B4 which results in pro-inflammatory effects. Figure
adapted from Serhan et al 2008
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1.4.1.2. The formyl peptide receptors
LXA4 binds with high affinity to a seven-transmembrane domain G-protein coupled
receptor, known as the ALX/FPR2 receptor (Ye et al. 2009). This receptor is one of a
small family of receptors called the formyl peptide receptors (FPRs). The FPRs are a
small family of seven-transmembrane (7-TM) domain G protein-coupled receptors
(GPCRs). In humans there are three known members of the family, which share
significant sequence homology and which are encoded by clustered genes. Each of
the three members have been known by various aliases over time as new data about
their structure, function and relationship to each other emerged, but an International
Union of Basic and Clinical Pharmacology (IUPHAR)-recommended nomenclature
was published in 2009, in which the human FPRs are termed FPR1, FPR2/ALX and
FPR3 (Ye et al. 2009).
FPR1
The first member of the family to be characterised was FPR1, with the first reported
complementary deoxyribonucleic acid (cDNA) cloning of the receptor published in
1990 (Boulay et al. 1990; Boulay et al. 1990). Initial characterisation of FPR1
described its interaction with N-formylated peptides, which are bacterial peptides
with powerful neutrophil chemoattractant properties (Schiffmann et al. 1975).
Subsequently, FPR1 has been found to bind with a number of other ligands,
including formylated peptides of host mitochondrial origin (Rabiet et al. 2005), non-
formylated peptides (Gao et al. 1994) and other peptides, dissimilar to the original
bacterial peptides from which the receptor family takes its name. These include an
envelope protein of the human immunodeficiency virus type 1 (HIV-1), T20/DP178
(Su et al. 1999), and also Annexin Al (ANXA1) (Walther et al. 2000) and its N-
terminal peptides Ac2-26 (Gavins et al. 2003) and Ac9-25 (Karlsson et al. 2005).
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FPR2/ALX
FPR2/ALX was first reported in 1992 by a number of investigators and shown to
have significant sequence homology to FPR1 (Bao et al. 1992; Murphy et al. 1992;
Perez et al. 1992; Ye et al. 1992). It comprises 351 amino acids, 69% ofwhich are
shared with FPR1. Like the other members of the FPR family, FPR2/ALX is a
promiscuous receptor, with a wide range of reported ligands. All FPR family ligands
reported to date are peptides, with the notable exception of LXA4, an eicosanoid.
Reported agonists of FPR2/ALX include N-formyl peptides of bacterial, host
mitochondrial and HIV-1 envelope origin, host-derived peptides and LXA4 (for
review see Ye et al (Ye et al. 2009)). Ligands of note amongst the host-derived
peptides include the chemokine CCL23, an N-terminally truncated splice variant of
which is a potent agonist for FPR2/ALX, eliciting the activation ofPMNs and
chemotaxis (Elagoz et al. 2004). Also of interest are amyloidogenic polypeptides,
including serum amyloid A (SAA) (Su et al. 1999), an acute phase protein which
induces pro-inflammatory effects including leukocyte chemotaxis (Badolato et al.
1994) and cytokine (Furlaneto and Campa 2000; He et al. 2003) and
metalloproteinase production (Vallon et al. 2001). FPR2/ALX, like FPR1, is also
activated by the N-terminal peptides ofANXA1 (Perretti et al. 2002), although it
appears that the full-length protein, ANXA1, signals through FPR2/ALX, but not
FPR1 (Walther et al. 2000).
As shown in the brief discussion above of the multitude of ligands for FPR2/ALX,
this receptor is capable of effecting both pro- and anti-inflammatory effects,
depending on the ligand and system in question. Indeed, most of the peptide agonists
for FPR2/ALX stimulate proinflammatory activities, whereas LXA4, the eicosanoid
with a high-affinity for FPR2/ALX, produces powerful anti-inflammatory and pro-
resolution effects. It is likely that alternative downstream signalling pathways exist
depending on the binding ligand, and these mechanisms remain an area for future
study. Competition between ligands for binding of FPR2/ALX is also an area of
research that is, as yet, incompletely understood but it may be that preferential
binding of LXA4 may contribute to its anti-inflammatory properties by blocking
binding by pro-inflammatory agonists.
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FPR3
FPR3 is a 352 amino acid 7-TM receptor which shares 56% sequence homology with
FPR1. It too binds with some N-formyl peptides, and host-derived peptides, notably
F2L, a peptide resulting from cleavage of human heme-binding protein, which
activates FPR3 and promotes chemotaxis (Migeotte et al. 2005).
1.4.1.3. Activity of lipoxins
The lipoxins and ATLs have dual anti-inflammatory and pro-resolution effects,
which have been demonstrated both in vitro and in vivo and in a number of disease
models.
Anti-inflammatory and pro-resolution actions
LXA4 and LXB4 have an inhibitory and thus anti-inflammatory effect on PMNs.
PMNs are attracted to sites of inflammation, adhering to vascular endothelial cells
and transmigrating across epithelial cell layers in order to access the site of
inflammation. LXA4 attenuates nuclear factor kappa B (NF-kB) accumulation and
IL-8 expression in neutrophils (Jozsef et al. 2002), can stop neutrophil-epithelial and
endothelial cell interactions (Papayianni et al. 1996; Filep et al. 1999), and overall
has an inhibitory effect on PMNs, having been demonstrated to reduce chemotaxis,
adherence and transmigration (Serhan et al. 1995) and therefore exerting a 'braking
effect' on PMN-induced tissue injury.
Whereas the lipoxins inhibit PMNs, their effect on monocytes/macrophages is to
activate and promote their actions, thus producing an overall pro-resolution effect.
LXA4 stimulates monocyte chemotaxis, migration and adhesion (Maddox and
Serhan 1996; Maddox et al. 1997), increasing the recruitment ofmonocytes to the
inflammatory exudate. Subsequently, LXA4 stimulates macrophages, promoting the
non-phlogistic phagocytosis of apoptotic neutrophils (Godson et al. 2000; Mitchell et
al. 2002) and enhancing the exit of macrophages from the inflammatory exudates via
the lymphatic system (McMahon et al. 2001).
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Models of disease
Animal models of disease have been used to demonstrate the actions of the lipoxins
and epi-lipoxins in vivo in a variety of systems including the lung, kidney, gut and
eye, and in models of acute inflammation such as peritonitis or dermal inflammation.
In the lung, in a mouse model of asthma, LXA4 inhibited airway hyper-
responsiveness and pulmonary inflammation (Levy et al. 2002). LXA4 has been
found to be present in reduced concentrations in the bronchoalveolar lavage of
patients with cystic fibrosis (CF), and in a mouse model ofCF, administration of
LXA4 suppressed neutrophilic inflammation, pulmonary bacterial burden and
reduced disease severity (Karp et al. 2004). In the kidney, transfection of the
ALOX15 gene into rats in whom glomerulonephritis was then induced, resulted in
decreased neutrophil recruitment, leukocyte rolling and adherence (Munger et al.
1999). In the bowel, mouse models of colitis have been used to demonstrate that
LXA4 attenuates proinflammatory gene expression, reduces the severity of the
disease and inhibits weight loss and inflammation (Gewirtz et al. 2002; Fiorucci et al.
2004). LXA4 accelerates corneal re-epithelialisation and limits the effects of thermal
injury in the mouse (Gronert 2005; Gronert et al. 2005). LXA4 also reduces hind-
limb ischaemia-reperfusion lung injury in mice (Chiang et al. 1999), and LXB4 and
15-epi-LXA4 reduces neutrophil recruitment in dermal inflammation (Takano et al.
1998).
1.4.2.Annexin A1
Annexin Al (ANXA1) is a 37kDa protein. It is a member of a family of proteins,
'The Annexins' which are grouped together in view of their shared similarity in
structural characteristics. Each annexin consists of a core region, made up of four
repeats of 70 amino acids each, attached to a unique N-terminal region (Gerke and
Moss 2002), which in ANXA1 is 42 amino acids in length (Weng et al. 1993). Upon
binding with calcium ions, ANXA1 undergoes a conformational change such that the
N-terminal region, previously buried within the core, becomes available for binding,
thus generating an active form of the protein (Rosengarth and Luecke 2003). Two
short peptides, Ac2-26 and Ac9-25, which correspond to the ANXA1 N-terminal
sequence and which have similar actions to ANXA1 itself, have also been identified.
The peptides signal through both FPR1 and FPR2/ALX, whereas the full length
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protein ANXA1 signals through FPR2/ALX but not FPR1 (Walther et al. 2000;
Hayhoe et al. 2006). ANXA1 was first reported over two decades ago (Di Rosa et al.
1984) and was identified as a key modulator of glucocorticoid-mediated anti-
inflammation (Fetalvero et al. 2008). Previously known as lipocortin 1, it is now
recognised to be a member of the annexin family and termed Annexin Al.
1.4.2.1. Distribution
ANXA1 expression in the human body is widespread, and found in white blood cells,
stromal cells and in biological fluids. High levels are present in monocytes and
granulocytes, particularly neutrophils, where it is mainly stored within gelatinase
granules in the cytoplasm (Perretti et al. 2000). T cells also express ANXA1, but B
cells and platelets do not (Morand et al. 1995). Epithelial cells of the lung, gut and
kidney are notable sources ofANXA1. In the human reproductive tract, ANXA1 is
expressed in the amnion (Lynch-Salamon et al. 1992), chorio-decidua (Myatt et al.
1992) and placental tissue (Bennett et al. 1994), as well as endometrial glandular
epithelium (Li et al. 2008).
Location within the cell depends on the cell type. As previously stated, neutrophilic
ANXA1 is predominantly cytoplasmic within gelatinase granules; within the
macrophage and many other cell types, expression is generally cytoplasmic but has
also been noted within the cell membranes, cytoskeleton and nucleus. ANXA1 does
have an intracellular role, but it can also be exported out of the cell where it may
have autocrine or paracrine function. A number ofmechanisms of secretion are
reported, namely via activation of the ATP-binding cassette (ABC) transporter (Wein
et al. 2004), through phosphorylation followed by membrane localisation (Solito et
al. 2006) or (in neutrophils) by fusion of the ANXA1-containing granules with the
plasma membrane.
1.4.2.2. Modes of action ofANXA1 and its N-terminal fragment peptides
ANXA1 and its N-terminal fragment peptides have potent anti-inflammatory and
pro-resolution effects, which have been demonstrated in a number of experimental
models, including in vitro studies with human cells and tissue, animal models of
acute and chronic inflammation and in the Annexin Al null mouse. Perhaps best
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characterised are ANXAl's inhibitory effects on PMN trafficking, effecting a
reduction in PMN adhesion (Lim et al. 1998; Gavins et al. 2003; Hayhoe et al. 2006)
and migration (Errasfa and Russo-Marie 1989; Perretti et al. 1993; Perretti and
Flower 1993; Getting et al. 1997; Walther et al. 2000). ANXA1 or its related short
peptides also reduce mast cell degranulation (Bandeira-Melo et al. 2005) and
increase the phagocytosis of apoptotic cells by macrophages (Arur et al. 2003). They
have also been shown to have effects on the expression of other inflammatory
mediators, with an inhibitory effect on phospholipase A2 activity (Flower 1988) but
a stimulatory effect on the secretion of the anti-inflammatory cytokine IL-10
(Ferlazzo et al. 2003).
ANXA1 has been identified as an important mediator of the effects of
glucocorticoids (GCs). GCs induce expression ofANXA1, as reported by Goulding
et al, who demonstrated upregulation ofANXA1 in the peripheral blood of human
volunteers who had been given hydrocortisone (Goulding et al. 1990). Further
evidence is supplied by work demonstrating that individuals with endocrine disorders
of either constitutionally high or low levels of endogenous GCs have
correspondingly high or low levels of intracellular ANXA1 (Mulla et al. 2005),
although the exact molecular mechanism ofGC-regulation ofANXA1 is not yet
clear (Perretti and D'Acquisto 2009). Additionally, GCs have also been shown to
induce the expression of the receptor ofANXA1, FPR2/ALX (Sawmynaden and
Perretti 2006; Hashimoto et al. 2007).
1.4.3.The Resolvins and Protectins
Resolvins are endogenous lipid mediators derived from the omega-3 polyunsaturated
fatty acids (PUFAs) eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA),
resulting in two chemically unique structural forms, the E-series of resolvins and the
D-series of resolvins respectively. Resolvins were first identified in exudates that had
been collected from resolving inflammatory sites in mice (Serhan et al. 2000) and
were subsequently defined and their biological actions described by Serhan and
colleagues (Serhan et al. 2002). The consumption of omega-3 PUFAs, found
especially in oily fish, had long been regarded as an important part of a healthy diet
and had been shown to have beneficial effects on health particularly on
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cardiovascular disease and stroke (Simopoulos 2002). However, this was the first
time that the molecular basis behind these dietary effects had been elucidated.
Resolvins can be synthesised from EPA via the actions of COX2 and ALOX5 and
acts upon the receptors Chemokine-Like Receptor 1 (CMKLR1) and the leukotriene
B4 receptor BLT1 (Arita et al. 2007), both ofwhich are GPCRs. Both the D- and E-
series of resolvins have potent effects on the reduction of neutrophil recruitment
(Serhan et al. 2002; Schwab et al. 2007) and have been shown to control
inflammation and promote healing following inflammatory disease in numerous
animal models including periodontitis (Arita et al. 2005; Hasturk et al. 2007) and
kidney ischemia-reperfiision injury (Duffield et al. 2006).
Protectins are another recently identified family of pro-resolution lipid mediator
derived from DHA. Protectin D1 has potent protective properties in inflammatory
systems, by inhibiting neutrophil recruitment (Schwab et al. 2007) and regulating
cytokine production (Marcheselli et al. 2003) and macrophage function (Duffield et
al. 2006).
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1.5. LABOUR AS AN INFLAMMATORY EVENT
Human parturition can be regarded as an inflammatory event and in recent years
there have been many new additions to the body of evidence that have helped this
concept to strengthen and evolve. At its most basic level, this concept is supported
by the demonstration that leukocytes, (largely neutrophils and macrophages, and also
T cells) invade the myometrium, cervix and fetal membranes at or immediately after
the onset of labour (Thomson et al. 1999; Osman et al. 2003), attracted by increased
tissue expression of chemokines and cell adhesion molecules (Winkler et al. 1998;
Ledingham et al. 2001). In parallel, leukocytes circulating in the peripheral blood
increase their expression of cell adhesion molecule ligands such as CD1 la and
CD1 lb (Yuan et al. 2009), facilitating leukocyte emigration into the myometrium
and cervix.
The increased expression of cytokines in the myometrium and cervix in labour
(Osman et al. 2003) arises in part from the invading leukocytes (Young et al. 2002)
with recent evidence suggesting that increased capacity of leukocytes in labour to
express cytokines is initiated in the peripheral circulation (Yuan et al. 2009). These
pro-inflammatory cytokines have a multitude of effects on the reproductive tissues,
including stimulatory effects on myometrial contractility via a number of different
mechanisms, discussed below. Cytokines are also involved in tissue remodelling
(Sennstrom et al. 2000) and attract more leukocytes in a positive feedback
mechanism (Elliott et al. 2000), augmenting the process of parturition. The activity
ofNF-kB, a transcription factor regulating numerous genes involved in a multitude
of cellular processes including inflammation, is also increased in labour (Allport et
al. 2001). The most clearly described increase in NF-kB in association with
parturition occurs in the fetal membranes (Allport et al. 2001), although NF-kB is
also expressed in the myometrium with obvious changes being described in
pregnancy (Chapman et al. 2004). NF-kB may provide a feed forward mechanism for
inflammatory processes in labour, given that it is itself highly inducible by pro¬
inflammatory stimuli (Belt et al. 1999; Kniss et al. 2001; Lappas et al. 2002).
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Taken together therefore, labour is associated with leukocyte invasion, NF-kB
activation and pro-inflammatory cytokine production in some if not all of the
relevant uteroplacental tissues. These data strongly support the hypothesis that labour
is an inflammatory event. The functional effects of these pro-inflammatory events
are described below.
1.5.1.Myometrium
The upregulation of pro-inflammatory cytokines within labouring myometrium
stimulates and potentiates uterine contractions. Tribe et al have demonstrated that
IL-ip induces basal and store operated calcium entry in myometrial smooth muscle
cells, thus directly increasing their contractile potential (Tribe et al. 2003).
Additionally, IL-ip and TNF-a stimulate arachidonic acid release, and expression of
COX-2 thus increasing prostaglandin production in myometrial cell cultures, via
greater NF-kB activity (Hertelendy et al. 1993; Molnar et al. 1993; Belt et al. 1999;
Rauk and Chiao 2000). Prostaglandins have long been known as stimulators of
myometrial contractions (Johnston et al. 1993) thus there is a clear potential causal
link between the upregulation of pro-inflammatory cytokines observed in the
myometrium and the clinical process of parturition.
1.5.2.The cervix
Cervical ripening is characterised by breakdown of collagen and remodelling of the
connective tissue element of the cervix. Leukocyte invasion and the increase in
protein concentrations of IL-8, IL-6 and granulocyte colony stimulating factor (G-
CSF) observed in the human cervical connective tissue at term and subsequently in
labour are likely to be crucial to the process of cervical remodelling to facilitate
opening during parturition (Sennstrom et al. 2000; Osman et al. 2003). Functionally,
IL-8 may stimulate the release of degradative enzymes from neutrophils. These
enzymes include serine proteases and matrix metalloproteinases ((MMP)-8 and
MMP-9)) (Kelly 2002) which then participate in degradation of the collagen and
glycosaminoglycan components of the extracellular matrix thereby leading to
cervical ripening (Hertelendy and Zakar 2004). Production of MMP-1, MMP-3 and
MMP-9 from resident fibroblasts (Ito et al. 1991) and smooth muscle cells (Watari et
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al. 1999) may also be increased by IL-ip in the cervix whilst downregulating the
expression of tissue inhibitor ofmetalloproteinase (TIMP)-2, an endogenous
inhibitor ofMMP-2 (Watari et al. 1999), with these events being further amplified by
NF-kB production. NF-kB itselfmay be activated via TLR-4 by degraded
extracellular matrix proteins such as fragments of fetal fibronectin, degraded during
cervical remodelling, thus reinforcing the ongoing sterile inflammation of labour
(Challis et al. 2009). Thus, at the end of pregnancy and during labour, the cervix
having remained firm and closed despite increasing pressure during pregnancy,
begins, under the influence of a host of inflammatory mediators, to soften and dilate.
1.5.3. Fetal membranes
A similar pro-inflammatory pattern to that observed in the myometrium is seen in the
fetal membranes. The production of IL-8, TNF-a, IL-6 and IL-ip are all increased in
the fetal membranes and amniotic fluid during labour (Young et al. 2002). There are
also increased levels ofMMP-9 (Vadillo-Ortega et al. 1995) and decreased levels of
the TIMPs (Riley et al. 1999). Functionally, an increased MMP /TIMP ratio weakens
the fetal membranes, facilitating fetal membrane rupture which is often the precursor
to labour.
Careful examination of the fetal membranes from pre-labour specimens obtained at
caesarean section has demonstrated that a zone ofweakness exists in the region
overlying the cervix (McLaren et al. 1999). The features of this zone include a
decrease in thickness in comparison to the rest of the fetal membranes, increased
MMP-9 and decreased TIMP-3 and also increased poly (ADP-ribose) polymerase -1
(PARP1) cleavage (El Khwad et al. 2005). PARP1 is an enzyme involved in DNA
repair and apoptosis and thus its increase indicates increased apoptosis (El Khwad et
al. 2005). It would seem therefore that towards the end of pregnancy the fetal
membranes are prepared for labour by a process of remodelling to develop a
weakened area that is the site of rupture. What initiates and develops this process is
not known but a greater understanding of the molecular events leading to membrane
rupture may lead to developing novel therapeutic strategies to halt its premature
onset in preterm labour.
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The fetal membranes are specifically important, as they are the interface between the
fetus and the mother, and may transmit pro-labour signals from the baby to the
mother's myometrium and cervix. Pulmonary derived surfactant proteins and
phospholipids may be key to this: as the fetus matures, increased quantities are
produced and so levels increase in the amniotic fluid. These surfactant proteins may
well contribute to the inflammatory response that can be observed in the fetal
membranes and in the underlying cervix and myometrium (Smith 2007) given that
they stimulate COX-2 activity via TLR-4 in mice (Wang and Hirsch 2003) and
subsequent prostaglandin E2 production in the amnion. Increased prostaglandin E2
(PGE2) production in the amnion could diffuse through the chorion and decidua to
stimulate myometrial cell prostaglandin production and hence contractility (Slater et
al. 1999; Smith 2007). The fetus and placenta may also jointly trigger fetal
membrane rupture, since prostaglandins, TNF-a and corticotrophin releasing
hormone (CRH) (which also rise in the amniotic fluid towards term (Laatikainen et
al. 1988; Alvi et al. 1999) all stimulate the production ofMMP-9, which weakens the
membranes and thus facilitates membrane rupture (Young et al. 2002; Kumar et al.
2006).
1.5.4.The onset of labour, term and preterm
Although much is known about the processes of labour, both term and preterm, what
actually is the initiating event that kickstarts human parturition remains something of
a mystery. In several animal species, events seem to be much more clear-cut, and
indeed we can use our knowledge of other species to gain clues to the human
situation. For example, the phenomenon of progesterone withdrawal, first described
by Csapo in the 1950s (Csapo 1956), and characterised by a sudden drop in serum
progesterone levels just prior to parturition, is a common feature in many mammalian
species. However, in humans, most studies have shown that serum progesterone
levels remain stable towards the end of the third trimester and during labour
(Boroditsky et al. 1978; Mathur et al. 1980). A 'functional progesterone withdrawal'
has been described, whereby there is loss of the quiescent effect of progesterone on
myometrium, despite continuing high systemic and local levels. There have been
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several different mechanisms proposed for this, including local metabolism of
progesterone (Mitchell and Wong 1993), changes in ratios of the progesterone
receptor isoforms (Mesiano et al. 2002) and changes in levels of cofactors affecting
progesterone receptor (PR) function (Condon et al. 2003). It seems that a multitude
of complex and interlinked processes combine to overwhelm the quiescent phase of
pregnancy and initiate labour. Mitchell and Taggart have suggested a model of
'modular accumulation ofphysiological systems' in which multiple interlinking
physiological processes develop in parallel until a critical mass is achieved which
results in parturition (Mitchell and Taggart 2009). Their model also describes how
the premature and inappropriate activation of some of the 'modules' could result in
preterm labour, thus such a concept could explain the onset of both term and preterm
human labour.
Progesterone has long been described as an 'anti-inflammatory steroid' and this is
supported by a wealth of data demonstrating its interactions with the immune system.
Progesterone itself inhibits IL-6 production in fetoplacental arteries (Gotkin et al.
2006), and progestogens such as medroxyprogesterone acetate inhibit a range of pro¬
inflammatory cytokines and chemokines in human myometrium (Shynlova et al.
2008; Youssef et al. 2009). Of particular interest are the interactions of progesterone
with NF-kB, a transcription factor which has key functions within human parturition
(Allport et al. 2001; Elliott et al. 2001). NF-kB activation increases in fetal
membranes in labour (Allport et al. 2001) but is negatively repressed by activation of
the progesterone receptor (Allport et al. 2001). In contrast, NF-kB itself represses
progesterone receptor activity; work from Carole Mendelson's group has
demonstrated that activation ofNF-kB in human myometrium upregulates inhibitory
PR isoforms (Condon et al. 2006). It may be that the removal of the
immunosuppressive, quiescent influences of progesterone by the functional
progesterone withdrawal may in fact itself be initiated by inflammation and
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Putative Mechanisms of Influence of Progesterone
During human pregnancy, progesterone levels are high and progesterone exerts a
quiescent effect on the myometrium.
At the time of labour, increased NF-kB activation decreases PR activation thus
further diminishing the anti-inflammatory influences of progesterone, allowing the
amplification of the proinflammatory cascade.
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Estrogens can induce either proinflammatory or anti-inflammatory effects, depending
on the immune stimuli, the cell types involved, the target organ, estrogen
concentration and receptor expression (Straub 2007). With respect to cytokine
expression, estrogen in the high concentrations seen in pregnancy can inhibit
proinflammatory pathways which include those activated by IL-ip (Polan et al.
1989), IL-6 (Keck et al. 1998; Kikuchi et al. 2000), IL-8 (Rodriguez et al. 2002) and
TNF-a (Rogers and Eastell 2001) as well as inhibiting the activity of natural killer
cells (Seaman and Gindhart 1979). In contrast, the secretion of'anti-inflammatory
interleukins' IL-4 (Kamada et al. 2001), IL-10 (Kanda and Tamaki 1999) and
transforming growth factor (TGF)-|3 (Hatthachote and Gillespie 1999) are stimulated
by estrogen in these high levels. Notwithstanding these clear anti-inflammatory
effects of estrogen, in vivo estradiol can augment the production of pro-inflammatory
cytokines by CD4+ T cells (Maret et al. 2003) likely via a direct effect as circulating
leukocytes express estrogen receptor (ER)-a (Straub 2007). Thus, although estrogen
has a stimulatory effect on myometrium, it also has highly complex interactions with
the immune system that may contribute to the quiescence maintained throughout
pregnancy.
CRH and the hypothalamic-pituitary-adrenal (F1PA) axis are intimately linked with
the immune system and exert complex effects on the human female reproductive
system (Kalantaridou et al. 2004). CRH has been shown to regulate cytokine
production, and in return inflammatory cytokines influence CRH production. For
example both TNF-a and IL-1(3 stimulate production ofCRH (Dudley 1999) and
conversely CRH inhibits the production of IL-1 and IL-6 by peripheral blood
mononuclear cells (Salas et al. 1997). CRH may reduce the cytotoxicity of natural
killer cells (Irwin et al. 1990) and also inhibits T cell proliferation (Jain et al. 1991).
Increasing fetal Cortisol production, perpetuated by increasing CRH production as
described above, is also associated with fetal lung maturation and production of
surfactant proteins and phospholipids which are present in the amniotic fluid. Such
compounds are proinflammatory and it has been proposed (Smith 2007) that they
might stimulate production of prostaglandins and initiation of inflammation in the
fetal membranes.
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Oxytocin and its receptor (OT and OTR) play an important role in parturition,
although their precise role is as yet incompletely understood (Blanks and Thornton
2003). Plasma concentrations of OT rise with labour (Thornton et al. 1992), as do
concentrations ofOT in gestational tissues (Blanks et al. 2003). Clinically, synthetic
oxytocin is used to augment contractions during dystocic labour and OTR
antagonists are licensed as tocolytic agents for the treatment of preterm labour
(Romero et al. 2000). However, OT appears not to be an essential participant in
labour as oxytocin (-/-) null mice can deliver normally (Nishimori et al. 1996; Young
et al. 1996). The oxytocin receptor increases at term in myometrial tissue (Fuchs et
al. 1984) and its increased expression leads to direct contractile effects in
myometrium (Blanks and Thornton 2003). The effect of inflammatory cytokines on
the OTR is somewhat conflicting as described in the literature. Schmid et al reported
a downregulation of OTR messenger ribonucleic acid (mRNA) by IL-ip in a
myometrial cell line (Schmid et al. 2001), and Rauk et al also reported down-
regulation of OTR mRNA following treatment with IL-1J3 and up-regulation after
treatment with IL-6 in primary human smooth muscle cells (Rauk and Friebe-
Hoffmann 2000; Rauk et al. 2001). However, Terzidou et al demonstrated rapid
transient upregulation ofOTR mRNA with treatment of primary human myocytes
with IL-ip (Terzidou et al. 2006) which is more consistent with the actual mileu
present in labour ie increased levels of IL-ip, COX-2 and IL-8. The OTR promoter
contains putative transcription binding sites for C/EBP and NF-kB, which are
transcription factors activated by cytokines such as IL-ip and IL-6 (Terzidou et al.
2006). IL-ip and IL-6 increase the secretion of oxytocin in uterine smooth muscle
cells (Friebe-Hoffmann et al. 2001) and IL-ip has been observed to augment the
oxytocin-stimulated contractility ofmyometrial strips in culture (Molnar et al. 1993).
Thus, it seems likely that the result of the infiltration of inflammatory cells and
increase in pro-inflammatory cytokines is to activate the myometrial tissue (at least
in part via an increase in OTR expression) and to promote contractility.
So if the onset of human labour has features of inflammation and endocrine changes,
which is the predominant regulator ofparturition? There is little compelling evidence
to suggest that in humans a hormonal switch exists that signals the end ofpregnancy
and begins the process of parturition. It is likely that the linkages between such
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processes are dominated by the inflammatory system and that whilst hormones play
an undoubtedly vital part in human parturition; it is the immune system that is the
more important driving force.
1.5.5. Preterm Birth and Inflammation
Preterm labour is defined as labour occurring before 37 completed weeks of
gestation. The clinical implications are profound, as preterm birth is the major cause
of neonatal mortality and morbidity in developed countries (Norman et al. 2009). In
England, Wales and Northern Ireland, 74% of neonatal deaths are in infants born
preterm . Preterm birth has a rising prevalence currently of 5.8% in Scotland
(Norman et al. 2009) and 9.6% of births worldwide (Martin et al. 2006). Preterm
labour (with or without preterm premature membrane rupture) is the cause of preterm
birth in around 75% ofwomen (Norman et al. 2009). Preterm labour may be initiated
by a multitude of different mechanisms, including infection, placental haemorrhage,
cervical insufficiency, and uterine over-distention. The majority ofpreterm births are
idiopathic (Goldenberg et al. 2008; Norman et al. 2009), however, infection is the
single biggest aetiological factor (Goldenberg et al. 2008). Micro-organisms such as
Escherichia coli, Ureaplasma urealyticum and Streptococcus agalactiae are
recognised by the TLRs, which stimulate increased production of inflammatory
cytokines at least in part by NF-kB and initiate the cascade of inflammatory events
described above, resulting in preterm parturition (Peltier 2003).
Intrauterine infection can come via various routes, including ascending infection
from the vagina, transplacental^, retrograde infection via the Fallopian tubes and by
iatrogenic introduction to the intrauterine cavity during invasive procedures such as
amniocentesis. Intrauterine infection may be found in the decidua, the space between
between the amnion and chorion, in the amniotic cavity or even in the fetus.
Clinically, maternal infections such as pyelonephritis, appendicitis and pneumonia
are associated with preterm birth (Goldenberg et al. 2008) and periodontal disease
has also been relatively recently recognised as being linked to preterm birth (Jeffcoat
et al. 2001), although a mechanism of causation is not clear.
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Even in the absence of preterm birth itself, intrauterine infection or inflammation is
damaging to the fetus. This is demonstrated by clinical and epidemiological studies
(Dammann and Leviton 1997; Kadhim et al. 2002; Hagberg et al. 2005) and also by
animal models (Elovitz et al. 2011). This factor complicates the development of
treatments for preterm labour because it means developing a method of keeping the
fetus in utero (thus avoiding prematurity) is not necessarily going to be beneficial to
the infant. The fetus must also be protected from the detrimental effects of
inflammation and infection that may be present during threatened preterm birth.
1.5.6.Animal models of preterm birth
Several animal models of parturition involve stimulation with pro-inflammatory
substances such as LPS or bacteria to mimic the onset of preterm labour. These
include rodent models such as rat (Terrone et al. 2001; Celik and Ayar 2002), and
mouse models (Fidel et al. 1994; Elovitz et al. 2003), and also primate models using
rhesus monkeys (Gravett et al. 1994). Such animal models may be used to develop
potential new strategies for treating preterm birth. For example, the importance of
inflammation is demonstrated by experiments showing that the anti-inflammatory
agent IL-10 not only prevents preterm birth, but also prevents neonatal brain damage
in rats (Terrone et al. 2001; Rodts-Palenik et al. 2004). More recently, Bennett's
group have shown that the anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-
prostaglandin J(2) (15d-PGJ(2)) may have similar dual effects: in their mouse model
15d-PGJ(2) inhibited both LPS induced contractions and preterm delivery and the
upregulation ofNF-kB in the fetal brain (Pirianov et al. 2009). These results
encourage the possibility of the future development of agents that could be used not
only to prevent preterm labour but also to protect the developing fetus from the
damaging effects of surrounding inflammation.
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1.6. PRO-RESOLUTION MEDIATORS IN PARTURITION
Inflammatory regulation is a key feature ofmany physiological processes within the
human reproductive tract (Jabbour et al. 2009), and indeed, evidence is emerging that
pro-resolution mediators have an important role to play within these processes. For
example, in the endometrium, it would seem likely that inflammatory resolution is
involved in the monthly cycle of cell proliferation, disintegration, shedding and
tissue repair, and indeed both ANXA1 and FPR2/ALX have been implicated in this
process (Gurpide et al. 1986; Macdonald et al.2011). Additionally, ANXA1 would
appear to be involved in the pathological process of endometriosis (Li et al. 2008)
and stable LXA4 analogues have shown promising resolution effects on
endometriotic lesions in a mouse model of endometriosis (Chen et al. 2009; Chen et
al.).
Despite the well-established and supported concept of parturition being an
inflammatory process, surprisingly little has yet been published on the potential role
ofpro-resolution mediators such as LXA4 and ANXA1 in pregnancy and parturition.
ANXA1 is known to be upregulated in pregnant compared to non-pregnant tissues
(Romisch et al. 1992; Rehman et al. 2003) but a functional role has yet to be
determined. Our laboratory has recently published work describing an upregulation
and potential role of LXA4 in early pregnancy (Macdonald et al. 2011) but little is
known about its role in later pregnancy and during parturition. It would appear that
there is much to explore for the role of these pro-resolution mediators within
pregnancy and parturition itself.
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1.7. CONCLUSIONS
This introductory chapter has considered the process of inflammation and its
resolution and described some of the mediators involved in these processes that are
particularly relevant to parturition and the work presented in this thesis. It has also
discussed the inflammatory events of human labour, both term and preterm and
speculated on the potential roles of pro-resolution mediators within these events.
The biochemical mechanisms of human parturition in which the membranes weaken
and rupture, the cervix softens and effaces and the uterus is activated to produce
contractions, are both highly complicated and incompletely understood. It is clear
that an intricate web of interactions exists between components of the endocrine and
immune systems in order to regulate this process, and that disorders within it may
lead to significant complications for both mother and infant. As knowledge
accumulates about the mechanisms ofpreterm and term human labour, we can hope
to come closer to effective therapies for preventing preterm or dysfunctional labour,
and providing a healthier environment for the baby should intrauterine inflammatory
pathways be activated prematurely.
Recent advances in the exploration of the inflammatory process ofparturition and the
potential role of pro-resolution mediators have been highly encouraging. It seems
likely that in the future a multi-pronged approach will be necessary to treating
preterm or abnormal term labour and there is much scope for drugs developed from
pro-resolution mediators forming a part of that approach, with potential effects not
only on the inflammatory process of labour, but also in manipulating the detrimental
effects of inappropriate inflammation on the fragile fetal tissues. It is hoped that with
further investigation of the role of pro-resolution mediators in human parturition, we
may find new ways of treating preterm or abnormal term labour and reduce the




Pregnancy is a state of relative inflammatory suppression, culminating in parturition,
which is characterized by a profoundly pro-inflammatory environment within the
myometrium. This concept may be thought of as a 'balance', in which some factors
act to promote the quiescent state ofpregnancy and others act to promote the
inflammation associated with labour. During healthy pregnancy this 'balance' is
tipped in favour of ongoing pregnancy, until such time as the fetus is mature enough
to be born, when the 'balance' tips the other way and labour ensues.
I hypothesised that the onset of parturition is influenced not only by pro¬
inflammatory mediators, but also pro-resolution and anti-inflammatory mediators,
specifically LXA4 and ANXA1, and that their expression would decrease during
labour. Furthermore, I hypothesised that stimulation of non-labouring reproductive
human tissue by stress mediators such as lipopolysaccharide, hypoxia and Cortisol
would result in a rise in pro-resolution/anti-inflammatory mediators, in order to
attenuate the effect of the external stimulus and maintain the quiescent state of
pregnancy.
My aims were:
1. To investigate the mRNA and protein expression of pro-resolution/anti-
inflammatory: LXA4 (and its enzymatic inducers, the lipoxygenases),
ANXA1, and their mutual receptor FPR2/ALX in pregnant human labouring
and non-labouring reproductive tissue.
2. To investigate the overall transcriptomic response of pregnant human non-
labouring myometrium to pro-inflammatory LPS and pro-resolution/anti-
inflammatory LXA4.
3. To investigate the mRNA and protein expression of pro-resolution/anti-
inflammatory LXA4 (and its enzymatic inducers, the lipoxygenases);
ANXA1; and their mutual receptor FPR2/ALX in pregnant human non-
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4. To investigate how Cortisol, a hormone associated with the promotion of





Diagrammatic representation of hypothesis
This figure represents the 'balance' existing between ongoing pregnancy, generally
thought of as a state of relative immune suppression, and the onset of labour, in
which a pro-inflammatory mileu dominates. Cortisol and infection are known to be
associated with the promotion of labour. Tissue hypoxia is a pro-inflammatory
stimulus. I hypothesised that the pro-resolution and anti-inflammatory effects of
LXA4 and ANXA1 promote the continuation of pregnancy and that hypoxia, Cortisol




2.1. THE COLLECTION OF TISSUE FOR A
REPRODUCTIVE TISSUE BIOBANK
2.1.1.Introduction
Biomedical research in reproduction requires volunteers to provide tissue and blood
samples upon which experiments can be performed and hypotheses tested. Tissue
collection can either be prospective, and tailored towards each individual project, or
banked and a resource established from which investigators can apply to have tissue
samples supplied for use in their experiments. Each approach has its advantages and
disadvantages. Prospective collection has the advantage of providing the investigator
with exactly the requirements they have identified as necessary for their project, in
terms ofpatient demographics, specimen type, time of collection, method of
collection and method of storage. However, clearly the disadvantage is that the
investigator needs to invest time and resources into performing the recruitment and
collection themselves, and must wait for the necessary samples to become available,
which may take long periods of time. Furthermore, some projects require
longitudinal outcome measures to be obtained and again, it may be that it takes a
long time to collect this data. In contrast, a tissue bank provides the researcher with a
resource from which they can obtain immediate access to a potentially much larger
group of samples than they would otherwise have been able to obtain. Samples will
have been collected and stored uniformly according to a Standard Operating
Procedure (SOP), and will be accompanied by patient demographic data. Tissue
Banks also allow for samples to be available to multiple researchers, maximising
their use and promoting collaboration. The disadvantage of this approach is that the
available specimens may not meet the exact requirements of the project for which
they are sought, be that in terms of quantity, method of sampling or method of
storage.
In Edinburgh, there has been set up the Edinburgh Reproductive Tissue Biobank to
collect and store samples for use by current researchers, by collaborators within the
department or university and by collaborators at other institutions. The stored
samples are also potentially available for future researchers upon application, both
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from our own institution and from others. Part of the work I undertook over the
course ofmy two-yearMD programme of study was to recruit patients to contribute
tissue for the Biobank, to write and publish SOPs and to organise and train other
members of the research team to recruit patients and perform the tissue collection. In
this section I will describe the remit and scope of the Edinburgh Reproductive Tissue
Biobank, my role within its development, and its current and potential future
applications.
2.1.2.The Edinburgh Reproductive Tissue Biobank
The Biobank is funded by the Piggy Bank Kids and by Tommy's charities that funds
maternal and fetal research, and by the University of Edinburgh. It is managed by a
group of doctors, midwives, scientists and lay members who ensure that the relevant
ethical and legal requirements are adhered to and that the tissue is used appropriately.
The Biobank comprises a collection of blood and tissue samples from pregnant and
post-natal patients who have been recruited from the Simpson's Centre for
Reproductive Health at the New Royal Infirmary of Edinburgh. This is a tertiary
referral maternity unit delivering over 6500 babies each year. The collection also
includes some samples from infants, and a full list of the types of tissue that may be
collected is found in the Appendix. The following paragraphs describe the groups of
women upon whom collection efforts have so far been focused.
2.1.2.1. Metabolic clinic patients
Much of the funding our laboratory receives is from Tommy's, a UK-based charity
that funds research into maternal and fetal health, and a major focus of the team's
research is focused on the problems caused by obesity in pregnancy. Clinical
members of our team run a Metabolic Antenatal Clinic to which pregnant women
booking with a BMI of 40 kg/m2 are invited to attend to receive antenatal care for the
duration of their pregnancy. Women attending the clinic are subsequently invited to
participate in various research studies, including the donation of tissue and blood
samples at the time of delivery. Women with a normal Body Mass Index (BMI) of
between 20 and 25 kg/m2 are also recruited to the studies as control patients and may
also consent to donate blood and tissue samples at the time of delivery. In addition to
the blood and tissue samples donated by this group of patients, a large amount of
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information is collected and archived during the pregnancies and post-natally. This
includes longitudinal data on physical characteristics such as weight, BMI, body fat
percentages, skin fold thicknesses and blood pressure; dietary intake during
pregnancy, fetal growth trajectories, delivery outcomes and neonatal growth and
development. Thus the Biobank stores not only biological material but is also a
resource for storing information. These patients provide a unique dataset and
valuable tissue samples and represent one of the main foci of collection to the
Biobank.
2.1.2.2. Women undergoing elective caesarean section
Many research institutions use the clinical scenario of elective caesarean section as
an opportunity to approach women for recruitment of tissue donation. Some tissues,
for example, myometrium, fat and ovarian tissue can only be collected during a
surgical procedure. A planned operation means there is plenty of time to approach
patients and discuss their participation, and the subsequent collection from recruited
patients takes place at a convenient and predictable time. Many of the women are at
term with uncomplicated and healthy pregnancies, often undergoing caesarean
section due to previous caesarean section or breech presentation. This is of value to
researchers who wish to use tissue in their experiments from 'normal' pregnancies,
either as a control against tissue from pregnancies complicated by the disorder they
are interested in, or to exclude any confounding effect that medical or obstetric
complications may introduce. In our laboratory, many researchers have required
'fresh' tissue for use in their experiments i.e. tissue that has been collected that day,
and these samples are generally collected at elective caesarean section. Alongside
such a collection of 'fresh' tissue, a collection of tissue is also made which is stored
for RNA, protein and immunohistological experiments. There therefore exists in the
Biobank a large collection of stored tissue from women in 'normal' pregnancies that
can be used as controls.
2.1.2.3. Labouring women
In researching parturition and preterm labour, the ability to compare tissue from both
labouring and non-labouring women is obviously very important, but also can be
difficult due to the challenges of recruiting women in labour. The ethics approval of
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the Biobank requires us to use our clinical judgement to avoid approaching women
who are unsuitable to discuss participation, but allows researchers to approach
labouring women, if this is deemed appropriate. Women in early labour are often
willing to be approached to consider donation to the Biobank and frequently consent
to recruitment. Researchers are thus always guided by the advice of the clinical staff
looking after the woman, and their own assessment during discussion, as to whether
a woman should be approached for recruitment. Placental tissue can be collected
easily after both vaginal and caesarean delivery but the collection ofmyometrium
and fat can only be performed at caesarean section. During labour it can be difficult
to predict which patients will end up having an emergency 'in-labour' caesarean
section and so the collection ofmyometrium and fat from labouring women requires
the recruitment of large numbers ofwomen to donate samples at delivery, ofwhom
only a certain number will end up having a caesarean section and actually donating
myometrium and fat. On the whole, my experience of recruiting women in labour
was very positive. Of those women who were willing to speak to a researcher, many
were very willing to take part and help by donating tissue and hopefully this part of
the collection will provide a valuable ongoing resource and be expanded with time.
2.1.2.4. Other groups of women
There are many other groups ofwomen from whom it is valuable to have a banked
collection of tissue. Examples include women with pre-eclampsia and women
delivering preterm, both labouring and non-labouring. Identifying such specific
patients to approach them for recruitment can be difficult and requires help from the
clinical staff looking after them to alert researchers that a suitable patient might be in
the hospital.
2.1.3.My role within the Biobank development
My role within the Biobank has been to help develop the process of recruitment and
collection of delivery samples, to co-author SOPs, to co-ordinate the team of
researchers carrying out daily recruitment at elective caesarean section, and to help
with teaching and supervising new members of the collecting team. The Biobank and
the samples it contains are an important and valuable part of the research work our
laboratory carries out and the whole team is involved in the collection and
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administration of its samples. In the work I have described above, I worked alongside
other team members and would particularly like to acknowledge the following
people for their involvement in the work I carried out: Dr Sarah Barr, Rose Leask,
Zillah Jones and Nanette Hibbert with whom I helped to develop and co-author the
SOPs by which the samples are collected.
2.1.4.Developing the Standard Operating Procedures
The process of collection of the tissues needs to be straightforward, easy to teach and
recall and easily reproducible so that samples are reliably collected and stored in the
same way each time, despite being collected by different individuals. In order for this
to be achieved, it is important to have robust SOPs. The SOPs used in our collection
processes have developed and modified over time and with use, but if earlier samples
are requested for use from the Biobank it is possible to describe in what way sample
collection or storage may differ from the most up-to-date SOP, if applicable.
The SOPs we have produced are designed to be easy to use and possible to refer to
whilst actually performing the collection. A description of the methods used to
collect the tissue samples that are routinely collected at delivery, and how they are
stored in the Biobank, follows in the subsequent paragraphs.
2.1.5. Tissue sampling and storage
2.1.5.1. Methods of harvesting tissue samples at delivery
The following tissue samples may be collected at delivery:
Myometrium: Following delivery of the baby and placenta and prior to closure of
the uterine incision, the operating surgeon incises a strip ofmyometrium from the
upper edge of the lower uterine segment incision using Mayo scissors. The strip is
full thickness of the uterine wall and 1cm by 2-3cm in other dimensions. This sample
is placed into a sterile Gallipot and handed to the researcher by the scrub nurse. The
researcher then dissects off deciduas and divides the sample into pieces that are
stored in several different ways to be used in different kinds of experiments, as
described below.
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Visceral fat: Prior to closure of the rectus sheath, the operating surgeon identifies the
omentum, applies clamps across a small section of the tissue, divides this with Mayo
scissors and ligates the tissue across the clamps with vicryl ties. The sample is placed
into a sterile Gallipot and handed to the researcher, who then divides the sample into
the pieces and places them into storage containers.
Subcutaneous fat: Following closure of the rectus sheath and prior to skin closure,
the operating surgeon excises a small piece of subcutaneous adipose tissue using
Mayo scissors, which is placed into a sterile Gallipot and handed to the researcher,
who then divides the sample into the pieces and places them into storage containers.
During the team's earlier experiences of tissue collection, surgeons used diathermy
to excise a piece of tissue, which had the advantage of excising the sample whilst
simultaneously ensuring haemostasis at the excision site. However, subsequent use
of the tissue in experiments suggested that this collection technique might be
associated with poorer yields ofRNA from the sample, presumably due to thermal
destruction of the tissue close to the line of incision. Surgeons are now therefore
requested to use sharp dissection to produce the sample and then use diathermy to
achieve haemostasis.
Placenta, fetal membranes, umbilical vessel blood and umbilical cord: Following
delivery of the baby, the cord is clamped and cut. A second clamp is then applied to
the umbilical cord to isolate a section of cord from which blood samples may be
obtained. This is important clinically as samples are taken from the umbilical vein
and artery for pH measurements for the neonatal medical record, and where the
mother is Rhesus negative, for determination of the baby's blood group. Midwives
and surgeons are encouraged to place the clamps as far apart as possible to leave as
long a stretch as possible undamaged by the clamps. If suitably trained the researcher
can collect the clinical samples and then collect samples of cord blood for research.
The research samples are collected by piercing the umbilical vein or artery with a
needle and withdrawing blood into a syringe. If insufficient blood is collected from
the umbilical vessels in the cord, blood may be collected from the blood vessels
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covering the fetal side of the placenta. Blood is then transferred into Monovette tubes
and then transferred to the laboratory on ice for storage.
Small sections ofumbilical cord are cut using scissors or a scalpel and placed into
storage containers. Lengths ofumbilical cord to be used immediately in experiments
are transported to the laboratory on ice.
For use in immunohistochemistry, a strip of fetal membrane comprising amnion and
chorio-decidua is cut using scissors. The strip is taken from the rupture site to the
placental edge and includes a tiny amount ofplacental tissue to orientate the sample.
This sample is stored as detailed below and when at the stage of being embedded in
paraffin is rolled into a tight roll of tissue so that when sections are cut the researcher
has a representative slice of amnion, chorio-decidua and placental tissue. Samples of
amnion and chorio-decidua are also cut using scissors and stored for RNA and
protein analysis as described below.
Placental tissue is cut using scissors from the centre of a cotelydon. To ensure
continuity within the collection, samples are taken from a cotelydon close to the
umbilical cord insertion and from a part of the placenta that does not contain any
areas of calcification or large blood vessels. Samples for immunohistochemistry are
full thickness including the covering membranes on the fetal side and the basal plate
on the maternal side. Other stored samples are taken from the centre of the placenta
and do not contain covering membranes or basal plate tissue.
2.1.5.2. Storage of tissue samples for RNA extraction
Samples collected for later RNA extractions are placed into RNAlater solution,
incubated at 4°C overnight and then removed from solution, placed into a fresh
storage tube and frozen at -80°C. The advantage of using RNAlater is that the RNA
in the tissue is stabilised and the expression profile is protected so that subsequent
RNA analyses accurately reflect the expression profile at the time of collection. The
manufacturers advertise that samples can be stored at 4°C for up to 4 weeks, and in
theory could be removed at any time during this period for archival storage.
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However, by dealing with all samples in the same way we can ensure consistency in
the collection.
The exception to this protocol for RNA collection is for fat samples, both visceral
and subcutaneous. RNAlater was not used for these samples as the lipid in the
sample prevents adequate penetration of the stabilization agent through the tissue.
Thus initially, fat samples for RNA were placed into AllProtect, kept at 4°C until the
following day and then transferred to a separate tube and frozen at -80°C. However,
upon thawing these samples and extracting RNA, it was found that poor yields of
RNA were obtained, and that samples that had been frozen on collection without
having been previously incubated in AllProtect actually gave better RNA yields.
Thus, the current protocol for collecting and storing fat samples is to place them dry
into a collection tube and store them immediately at -80°C.
2.1.5.3. Storage of samples for protein extraction
Samples are collected, put into tubes and immediately placed into storage at
-80°C. Initially samples had been snap frozen on dry ice prior to storage at -80°C,
but as there is not a source of dry ice in the hospital itself, this became impractical. It
was determined that the method of freezing the samples by placing them straight into
the freezer was sufficient to allow good yields of protein when subsequently
extracted.
2.1.5.4. Storage of samples for histology
Samples are collected, placed into formalin, transported to the laboratory and stored
at room temperature overnight. The samples are then placed into ethanol and stored
at 4°C. They are then embedded in paraffin and stored ready for use by researchers
when required.
2.1.5.5. Collection of samples for immediate use in experiments
As well as tissues being collected for storage and future use, the Biobank set-up
allows for the collection of 'fresh' tissue, which can then be used immediately in
experiments. Examples of such experiments that have been carried out using tissue
collected by our team include fluorescence-activated cell sorting (FACS), explant
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culture, myometrial contractility studies and harvesting of human umbilical vein
endothelial cells (HUVECs) from umbilical cord. Material obtained from such
experiments, for example RNA extracted from explant studies, can then be placed in
the Biobank and recorded in its database so that future researchers could also take
advantage of this resource. Researchers requiring fresh tissue can apply to the
Biobank management team with a request ofwhat they need and then the fresh tissue
is collected according to their requirements alongside the standard Biobank
collection.
2.1.5.6. 'Out-of-hours' tissue collection
Much of the tissue collected for the Biobank is obtained from women undergoing
elective caesarean section, which is a scheduled operation occurring within normal
working hours and therefore relatively easy to predict and collect. However, many of
the women from whom valuable tissue may be collected do not deliver by elective
caesarean section. Instead they may go into labour spontaneously or be induced, and
may deliver vaginally or by emergency caesarean section. Examples include women
recruited from the Tommy's Metabolic Clinic, both obese and normal-BMI controls;
women delivering pre-term either in labour or not in labour; women with pre¬
eclampsia, and women in labour at term. Clearly these deliveries and thus the
opportunity for collecting tissue samples may occur at any time around the clock and
not just 9-5 Monday-to Friday. Thus, the Biobank team have recruited a team of
medical students who are interested in research and/or Obstetrics and Gynaecology
to perform collections on women who have already been recruited to donate samples
who deliver 'out-of hours'. The students are trained how to perform the collection
and then form an on-call rota, covering 5pm-9am Monday to Friday and all day
Sunday. This system, although time-consuming to set up, has been a great success,
with many valuable samples being added to the collection that would otherwise have
been lost. It has the added advantage of introducing medical students to research, and
perhaps sparking their interest to become further involved in their future careers.
2.1.6.Conclusions
The Edinburgh Reproductive Tissue Biobank is a valuable research tool and being
involved in its development has been a rewarding and educational part ofmy MD
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project. Many women are very keen to be involved in research during their
pregnancy and willing to help researchers. Frequently during the course of speaking
to women during recruitment they would describe experiences of adverse maternal or
fetal outcomes that they had come across, either in their own previous pregnancies or
in friends' or relatives', and express a wish to be involved in our research with the
hope of helping to prevent future such outcomes. Tissue collected for the Biobank
has already provided a large volume of data for the clinicians and scientists working
within the Medical Research Council Centre for Reproductive Health at the
University of Edinburgh, and will no doubt continue to develop as a resource for
both the University of Edinburgh and its collaborators for many years to come.
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All materials and reagents used are detailed in Appendix 1.
Recipes for reagents are provided in Appendix 2.
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2.2. SAMPLE COLLECTION
2.2.1. Ethical approval and consent
Approval from the Lothian Local Research Ethics Committee was granted for all
experimental work described in this thesis. Written information was provided and
informed, written consent was obtained from participants who donated blood or
tissue samples.
2.2.2. Sample collection
2.2.2.1. Samples used in quantitative RT-PCR and
Immunohistochemistry experiments
For the quantitative real time polymerase chain reaction (quantitative RT-PCR)
experiments described in this thesis which compare relative mRNA expression in
labouring and non-labouring term women, tissue samples were collected from a total
of 22 women, 11 labouring and 11 non-labouring. Samples used in
immunohistochemistry analysis of labouring and non-labouring tissues were also
taken from these cohorts of patients. The tissue samples used were myometrium,
placenta, amnion and chorio-decidua. Samples were collected and stored as
described in the sections above until ready for use. Patients were recruited according
to the following inclusion and exclusion criteria and a table of patient demographics
follows (Table 2.1). There was no difference in age, BMI or gestation between the
two groups (t-tests, p>0.05) but non-labouring women were more likely to be parous
than labouring women.
Term Pregnant Non-Labouring Women
Healthy pregnant women at term presenting to hospital for elective caesarean section
were recruited. Term was defined as 37 completed weeks of pregnancy or greater,
based on the Estimated Due Date (EDD) calculated at booking. EDD was calculated
from the ultrasound scan (USS) performed before 16 weeks gestation. In women who
booked after 16 weeks gestation, gestational age was calculated from the last
menstrual period (LMP) correlated with measurements from their first USS. Women
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were excluded if there was discrepancy in dates of greater than seven days or other
uncertainty about gestational age. Indications for elective caesarean section included
breech presentation, previous caesarean section, placenta praevia and maternal
request. Exclusion criteria included hypertensive disorders of pregnancy, diabetes
mellitus and gestational diabetes, multiple pregnancy and the use of regular steroid
medication including inhaled steroids for asthma.
Term Pregnant Labouring Women
Healthy pregnant women in labour at term were recruited. Term was defined as 37
completed weeks of pregnancy or greater, as for non-labouring women. Labour was
defined as regular contractions and dilation of the cervix of greater than or equal to
3cm. The indications for women undergoing emergency caesarean section included
breech presentation, fetal distress and failure to progress in labour or second stage,
with a cervical dilatation of between 3cm and 10cm. Exclusion criteria included
hypertensive disorders of pregnancy, diabetes mellitus and gestational diabetes,
multiple pregnancy, signs of clinical infection and the use of regular steroid
medication including inhaled steroids for asthma. Women who were induced with
vaginal prostaglandins were also excluded. The use of syntocinon infusion was not
















32.91 ± 1.81 23.2 ±0.36 278 ± 1.9 PI
Table 2.1 Labouring and Non-Labouring Demographics
Demographics of 22 patients from whom tissue was collected at caesarean section.
There was no difference in age, BMI or gestation between the two groups (t-tests,
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p>0.05) but non-labouring women were more likely to be parous than labouring
women.
2.2.2.2. Tissue samples used in tissue culture experiments
Where myometrial samples were required for tissue culture experiments, the samples
were placed into Roswell Park Memorial Institute (RPMI) 1640 culture medium and
transported immediately back to the laboratory and stored at 4°C until used that same
day. Where such samples were used, the cohorts of patients and experimental
protocols are described in each relevant chapter.
2.2.2.3. Peripheral venous blood
In the case ofwomen undergoing elective caesarean section, venous maternal blood
samples were drawn from the forearm via a venous catheter at the time of siting. The
venous catheter was sited just before siting of the spinal anaesthetic at the beginning
of the operation. In the case ofwomen in labour, blood samples were either drawn
from the forearm via a venous catheter at the time of insertion, or from an antecubital
vein using a 21-gauge needle. In the case of non-pregnant women or women at
earlier gestation than term, blood samples were drawn from an antecubital vein using
a 21 -gauge needle. Samples were drawn into Sarstedt Monovette serum gel blood-
collection tubes for isolation of serum. Blood samples were put onto ice and
transported back to the lab where they were centrifuged at 2000 revolutions per
minute (rpm) for ten minutes. The serum layers were drawn off and stored at -80°C
until needed. A further description of the patient cohorts from which samples were
obtained is to be found in the Methods section of the relevant chapter.
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2.3. ENZYME LINKED IMMUNOSORBENT ASSAY
(ELISA)
ELISAs are used to quantify the amount of a particular protein in a solution, by
comparing measured levels in a sample with a standard curve derived from samples
containing known concentrations of the protein.
The assay performed in this work was a competitive ELISA. A competitive ELISA
operates on the basis of competition between the enzyme conjugate and the protein
of interest in the sample for a limited number of antibody binding sites. A plate is
used which has wells coated with antibodies raised against the protein which is to be
measured. The solution of interest, or the standard is then added to the plate,
followed by the enzyme conjugate. During incubation, binding takes place in which
both the enzyme conjugate and the protein of interest are competing for binding with
the antibody adherent to the well. After incubation, the plate is washed which
removes all of the unbound material. Next a substrate is added which generates a
colour where binding of the enzyme conjugate is detected. Quantitative results are
obtained by measuring and comparing the absorbance reading of the sample wells
against the standard wells using spectrophotometry.
2.3.1. LXA4 ELISA
A commercially available LXA4 assay kit was used, containing plates pre-coated
with capture antibody, and all required reagents and buffers. Samples and standards
(50pl, range 0.02 to 2 ng/ml) were added to the appropriate wells in duplicate.
Concentrated LXA4 enzyme conjugate was diluted with the supplied EIA buffer,
applied to each well (50pl) and incubated at room temperature for one hour on an
orbital plate shaker. After incubation, the contents of the plate were discarded and the
wells washed with the provided wash buffer for three washings. Substrate was added
to each well (150pl) and the plate was gently shaken and then incubated for 30





Immunohistochemistry is a means by which localisation of an antigen within a
section of tissue is determined by a specific primary antibody. A variety of detection
systems may then be used to detect and visualise the specific staining.
Immunohistochemistry experiments described in this thesis were performed on tissue
samples ofmyometrium, placenta and fetal membranes in the form of rolls of
amnion and chorio-decidua. Collection, fixation of the sample and storage in paraffin
blocks is described previously.
Sections 5pm thick were cut from the paraffin embedded tissues and mounted on
slides, deparaffinised in xylene and rehydrated in a graded alcohol series. Specific
protocols are now described.
2.4.1.Specific protocols
2.4.1.1. FPR2/ALX
Antigen retrieval was performed by pressure cooking for 5 minutes in lOmM citrate
buffer pH 6 and then cooled for 20 minutes at room temperature. Endogenous
peroxidase was blocked using a 3% hydrogen peroxide in methanol solution for 30
minutes followed by washing in water (5 minutes) and phosphate buffered saline
(PBS) (5 minutes). Sections were blocked in normal goat serum diluted 1:5 with PBS
and 5% bovine serum albumin (NGS/PBS/BSA) for 30 minutes, followed by
Avidin/Biotin blocking using a kit according to manufacturers instructions and
washing in between with PBS (5 minutes x 2). Incubation with the primary antibody
was performed overnight at 4°C. The primary antibody used was rabbit polyclonal
anti-FPR2/ALX antibody at 1:200 (diluted in NGS/PBS/BSA). After washing in PBS
(5 minutes x 2) the sections were incubated with goat anti-rabbit biotinylated
secondary antibody diluted 1:500 in blocking serum for 30 minutes and washed
again in PBS (5 minutes x 2). The sections were incubated with Streptavadin-HRP
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diluted 1:1000 in PBS for 30 minutes and washed again in PBS (5 minutes x 2),
followed by 3,3-diaminobenzidine (DAB) detection (DAB diluted at 1 drop/ml).
Colour development was monitored microscopically and stopped by washing in
water. Sections were counterstained in haematoxylin, Scotts tap water used to
provide blue nuclear staining, dehydrated and coverslipped using pertex.
Two negative controls were used, the first with the primary antibody omitted and the
second using a rabbit monoclonal IgGl at the same concentration as the primary
antibody.
2.4.1.2. ANXA1
An identical protocol was used to the protocol described for FPR2/ALX, other than
differing primary and secondary antibodies were used. The primary antibody used
was mouse anti-AnnexinA l at 1: 200 (diluted in NGS/TBS/BSA). Since the primary
antibody was raised in mouse, the secondary antibody used was goat anti-mouse
biotinylated secondary antibody diluted 1:500 in the blocking serum.
Two negative controls were used, the first with the primary antibody omitted and the
second using a mouse monoclonal IgGl at the same concentration as the primary
antibody.
2.4.1.3. Immurtofluoresence to co-localise FPR2/ALX and neutrophil
elastase
Endogenous peroxidase activity was blocked by incubating the sections in 3%
hydrogen peroxide in methanol for 30 minutes. Sections were then blocked in normal
goat serum diluted 1:5 with PBS and 5% bovine serum albumin (NGS/PBS/BSA) for
30 minutes and then incubated with mouse anti-neutrophil elastase (1:500). The
following day slides were washed in PBS (5 minutes x 2), incubated with the
secondary antibody, goat anti-mouse Fab at a concentration of 1:500 in
NGS/PBS/BSA for 30 minutes and washed again in PBS (5 minutes x 2). The
sections were incubated for 10 minutes with tyramide red signal amplification kit,
diluted 1:50 in the supplied buffer, to amplify the staining with red fluorescence, then
washed in PBS (5 minutes x 2). Sections were then pressure-cooked for 5 minutes in
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lOmM citrate buffer, pH 6), cooled for 20 minutes at room temperature and then
blocked with NGS/PBS/BSA for 30 minutes. The sections were then incubated with
rabbit polyclonal anti-FPR2/ALX primary antibody (1:1000) overnight at 4°C. The
following day, sections were washed in PBS (5 minutes x 2) and incubated with goat
anti-rabbit Fab secondary antibody (1:500) for 30 minutes, washed again in PBS (5
minutes x 2) and then were incubated for 10 minutes with tyramide green signal
amplification kit, diluted 1:50 in the supplied buffer, to amplify the staining with
green fluorescence. Sections were washed finally with PBS (5 minutes x 2) and
incubated with nuclear counterstain DAPI for 10 minutes (1:1000), mounted in
Permafluor, coverslipped, and visualised using a laser-scanning microscope (LSM
710; Carl Zeiss, Jena, Germany) using a x40 1.4 numerical aperture oil-immersion
lens. Sections were scanned with 405 (nuclear staining), 488 (FPR2/ALX) and 543
(smooth muscle elastase) laser lines, and images were acquired using Zen 2009 5.5
software (Carl Zeiss).
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2.5.TAQMAN QUANTITATIVE REAL TIME
POLYMERASE CHAIN REACTION (RT-PCR)
2.5.1.RNA extraction
RNA was extracted from the samples using a combined TRIzol and RNeasy columns
protocol. The RNeasy system is a commercially available kit which uses centrifuge
columns containing silica-gel membranes to selectively bind RNA. Salt and ethanol
containing buffers are applied to wash away contaminants and the RNA eluted with
water. An alternative method for extracting RNA involves using TRIzol and other
reagents to separate samples into layers from which RNA can be isolated. This
combined protocol was developed by colleagues in our laboratory and was found to
produce samples of RNA of both good quality and concentration, with low
contamination.
Samples were thawed and removed to secure-lock Eppendorf tubes containing
TRIzol (0.5ml for tissue less than 50mg, 1 ml for tissue between 50 and lOOmg) and
a sterile ball bearing. Samples were homogenized at 25Hz for 4 minutes, with the
plates changed over at 2 minutes. The homogenized samples were then allowed to
incubate for 15 minutes at room temperature to allow dissociation of nucleoprotein
complexes. The samples were centrifiiged at 14000rpm for 10 minutes and the
supernatant transferred to a phase-lock tube. lOOpl of chloroform per 0.5ml TRIzol
was added, the tubes shaken vigorously for 15 seconds and then centrifuged at
12000g for 15 minutes at 4°C. The aqueous phase was removed to a fresh tube, one
volume of 70% ethanol added and mixed by pipetting and then this solution applied
to the RNeasy column. RNA extraction was then completed as per the kit
instructions as follows. Columns were centrifuged for 15 seconds at lOOOOrpm and
the eluate discarded. On-column DNase digestion was then performed using the kit
manufacturer's instructions. This involves applying 80pl ofDNase 1 solution onto
each column and incubating at room temperature for 15 minutes. Following this
700|il of Buffer RW1 was applied to each column and then the columns centrifuged
at lOOOOrpm for 15 seconds. Eluate was discarded and 500 pi of Buffer RPE applied
to each column and then the columns centrifuged at lOOOOrpm for 15 seconds. This
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step was repeated but with a 2 minute centrifugation. The columns were then
transferred to fresh tubes and 30pl DNase-free, RN-ase free sterile water applied to
the membrane. The columns were incubated for 1 minute at room temperature and
then centrifuged at 1 OOOOrpm for 1 minute. The eluates were reapplied to the
membranes and re-centrifiiged. Columns were subsequently discarded, with the
eluate containing the extracted RNA.
2.5.2.Estimation of RNA concentration and integrity
To estimate the concentration ofRNA extracted from tissue samples,
spectophotometry was performed using a Nanodrop 1000 spectophotometer
(ThermoScientific, Wilmington, DE, USA). Absorbancy at 260nm and 280nm was
measured and the concentrations given in ng/pl. A 260:280 value of around 1.8
indicates a pure RNA sample. Ratios of 1.7 to 2.1 were taken to be acceptable. RNA
was stored at -80° for further use.
2.5.3. cDNA synthesis
200ng of total RNA of each sample was reverse transcribed into cDNA using the
GeneAmp RNA PCR kit under manufacturer's instructions. This involved making up
a mixture of Reverse Transcriptase buffer, Reverse Transcriptase, deoxynucleotide
triphosphates (dNTPs), RNase inhibitor (all included in the kit) and RNA sample
according to manufacturer's instructions. Transcription was performed using a G-
Stomi GS1 thermal cycler, with a cycle of 25°C for 10 minutes, 37°C for 120
minutes and 85°C for 5 minutes. Samples were stored at -20°C until needed.
2.5.4.Quantitative RT-PCR
TaqMan quantitative RT-PCR was used to determine relative gene expression. The
probe for the gene of interest was labelled with the reporter dye FAM and the 18S
probe labelled with the reporter dye VIC at the 5'end of the oligonucleotide. A
quencher dye (TAMRA) was used to label the 3' ends of both probes. Expression of
the analysed genes was normalised using an 18S ribosomal RNA (rRNA) reference
gene. The amount of ribosomal 18S in samples is constant, relative to the amount of
cDNA present, thus quantification of the gene of interest can be related to the
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abundance of ribosomal 18S. This value was then related to an internal control
sample.
A reaction mix was made containing PCR reaction Mastermix, 18S control primers
and probes, forward and reverse primers and hybridisation probe specific for the
gene of interest. Samples were run in duplicate, on TaqMan Fast optical PCR plates,
with each replicate containing reaction mix and cDNA. The exact composition of the
reaction mix did vary between experiments depending on the gene of interest and so
recipes for the reaction mix used and further details of the specific primers and
probes are given where appropriate in the Methods sections of the relevant chapters.
Three negative controls were included on each plate as follows. An RT-negative
sample was used to exclude genomic DNA contamination. This sample was
produced at the time of cDNA manufacture by excluding the reverse transcriptase
enzyme from a sample containing RNA template. The second control was an RT-
water sample used to ensure no contamination in the cDNA manufacturing process
and was produced by replacing the RNA template with water. The third control was a
Taqman-reaction negative control which replaced cDNA with water and controlled
for contamination of the reaction mix. Wells were sealed with an optical adhesive
film, and the reaction run on the ABI Prism 7500 Sequence Detection System
(Applied Biosystems, UK). PCR conditions were as follows: 50°C - 2min, 95°C -
lOmin, (95°C - 15secs, 60°C - lmin) x 40 for both genes.
2.5.5. Data analysis
Data analysis was carried out using SDS Version 2.1 program (Applied Biosystems).
The baseline value was set 2 or 3 cycles before the earliest amplification and the
threshold value was set in the linear phase of the exponential region of the
amplification plot. The comparative cycle threshold (Ct) method was used to
determine relative gene expression. Ct is the cycle number at which the PCR signal
crosses the set threshold. The average Ct values for replicate wells was determined.
ACt was then calculated by subtracting the 18S Ct from the target gene Ct. AACt was
calculated by subtracting the ACt of the control sample from the ACt for each
sample. The fold change in target gene expression was compared to the reference
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sample using the formula 2A(-AACt), thus giving a relative value to the control
sample.
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Human labour is an inflammatory event. At or just after the onset of labour, there is
increased tissue expression of pro-inflammatory cytokines (Osman et al. 2003), and
an influx of leucocytes into the myometrium, cervix and fetal membranes (Thomson
et al. 1999; Osman et al. 2003), which provide a further source of pro-inflammatory
cytokines (Young et al. 2002). These cytokines subsequently attract more leucocytes
(Elliott et al. 2000), are involved in tissue remodelling at the cervix (Sennstrom et al.
2000) and in the fetal membranes and have stimulatory effects on myometrial
contractility (Tribe et al. 2003).
It is now recognised that a normal inflammatory response involves pro-inflammatory
processes responding to and neutralising the initiating insult but also, running in
parallel to this, anti-inflammatory and pro-resolution mechanisms. These
mechanisms regulate and limit the pro-inflammatory response and ensure that it is
brought to a timely end in order to limit damage to host tissue (Serhan and Savill
2005; Serhan et al. 2007).
The lipoxins are endogenous lipid mediators which have been demonstrated in other
systems in the human body to have anti-inflammatory and pro-resolution effects. The
anti-inflammatory and pro-resolution properties of LXA4 include inhibition of
neutrophilic chemotaxis, adherence to vascular endothelial cells and trafficking
across epithelial cell monolayers (Serhan et al. 1995; Papayianni et al. 1996; Filep et
al. 1999). It also promotes the phagocytosis of apoptotic neutrophils and clearance
from the site of inflammation (Godson et al. 2000; Mitchell et al. 2002). LXA4 is
generated from arachidonic acid, via the actions of the lipoxygenase enzymes, 5-, 12-
and 15-lipoxygenase (ALOX5, ALOX12 and ALOX15). The pathways involved in
the production of LXA4 are described in more detail in section 1.4.1.1, but
essentially the production is via ALOX15 and ALOX5 at mucosal surfaces
(Samuelsson et al. 1987), or via ALOX5 and ALOX12 in a platelet-neutrophil
reaction (Serhan and Sheppard 1990). The receptor by which LXA4 signals has been
identified as formyl peptide receptor 2 (FPR2/ALX), a G-protein coupled receptor
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(Maddox et al. 1997). FPR2/ALX is a promiscuous receptor, through which a
number of different ligands signal producing both pro- and anti-inflammatory effects
(Ye et al. 2009).
Much data have been published supporting the concept that labour is an
inflammatory process. However, the vast majority of these data focuses on pro¬
inflammatory processes, with relatively little described in regard to anti¬
inflammatory or pro-resolution mechanisms. It may be that pro-resolution mediators
such as LXA4 have an important role to play in the delicate balance between
pregnancy and labour, and possibly in the initiation of labour itself.
3.1.1.Aims
This chapter aims to:
• explore the expression of the enzymes involved in the synthesis of LXA4 and
its receptor in labouring and non-labouring reproductive tissues
• determine the localisation of FPR2/ALX by immunohistochemistry





3.2.1.1. Serum samples for use in ELISA
Women were recruited from four cohorts (detailed in Table 3.1) and written
informed consent to collect blood samples was obtained. All participants were
healthy and pregnant participants had uncomplicated, singleton pregnancies.








premenopausal women 1 sample 9
Cohort 2 Pregnant women 3 samples
24 weeks gestation
31 weeks gestation
37 weeks gestation 8
Cohort 3 Pregnant women at term,




Cohort 4 Pregnant women at term,
during the first stage of
labour, gestation 40+2 ± 2.7
(mean ± SEM)
1 sample 10
Table 3.1 Cohorts of participants from whom blood samples were obtained
3.2.1.2. Tissue samples for use in RT-PCR and Immunohistochemistry
experiments
Groups of labouring (n=l 1) and non-labouring women (n=l 1) were recruited and
informed, written consent was obtained to provide tissue samples as described in




3.2.2.1. Serum samples for use in ELISA
Peripheral venous blood samples were drawn from an antecubital vein into a Sarstedt
Monovette Serum Gel tube, chilled on ice and transported to the laboratory. Serum
was separated by centrifugation (2000 rpm for 10 minutes) and samples stored at -
80°C until further analysis.
3.2.2.2. Tissue samples for use in RT-PCR and Immunohistochemistry
experiments
Samples ofmyometrium, placenta, amnion and chorio-decidua were taken at the time
of elective or emergency caesarean section, as described in section 2.1.5.1.
3.2.3. ELISA for lipoxin A4
Levels of LXA4 were measured in the serum samples by ELISA, as described in
section 2.3.1. This ELISA was performed by Dr David Maldonado-Perez, whose
assistance is gratefully acknowledged.
3.2.3.1. Data analysis
Longitudinal samples taken at intervals during pregnancy were compared to each
other using repeated-measures analysis of variance (ANOVA) and Tukey's multiple
comparison post test. A repeated-measures ANOVA was used because the samples
are matched. When comparing other groups the samples are not matched as they are
different cohorts ofwomen as opposed to repeated samples taken at intervals from
the same women. Therefore a one-way analysis of variance with Tukey's multiple
comparison post test was used. The comparison between labouring and non-labourng
term samples was performed using an unpaired t-test. All statistical calculations were
carried out using GraphPad Prism 5.02 (GraphPad software, CA, USA).
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3.2.4.Immunohistochemistry of FPR2/ALX
Immunohistochemistry was performed on samples of labouring and non-labouring
myometrium, placenta and fetal membranes to localise FPR2/ALX and
immunofluoresent co-localisation with neutrophils in labouring and non-labouring
myometrium was performed.
3.2.4.1. Immunohistochemistry
The protocol used for determining the localisation of FPR2/ALX by
immunohistochemistry is described in section 2.4.1.1 and was performed on sections
cut from myometrial, placental and membrane biopsies, taken either at elective or
emergency caesarean section.
3.2.4.2. Immunofluoresence to co-localise FPR2/ALX and neutrophil
elastase
The protocol used for co-localising FPR2/ALX and neutrophil elastase by
immunohistochemistry is described in section 2.4.1.3 and was performed on sections
cut from myometrial, placental and membrane biopsies, taken either at elective or
emergency caesarean section.
3.2.5.Quantitative RT-PCR
Quantitative RT-PCR was performed to determine relative mRNA expression of
ALOX5, ALOX12, ALOX15 and FPR2/ALX in labouring and non-labouring
myometrium, placenta, amnion and chorio-decidua.
Total RNA was extracted from the biopsies of myometrium, placenta, amnion and
chorio-decidua, RNA concentrations were estimated and cDNA was synthesised, as
described in section 2.5. Quantitative RT-PCR was performed as described in section
2.5. Specific reaction mix composition and primers and probes used are detailed
below.
Primers were designed by Dr David Maldonado-Perez, using the ProbeFinder version
2.42 for Human (Roche Applied Science) and the corresponding probes from the
Universal Probe Library (UPL) Set (Roche Applied Science) were used to identify
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and quantify cDNA. Sequences and probes for the measured genes are described in
Table 3.2.
The reaction mix used for determination of relative gene expression was the same for
ALOX5 and FPR2/ALX, although the primers and probes differed for each gene.
PCR was performed with a final volume of25pl per well, containing 12.5pl 2x
Express Mastermix, 0.25pi of forward primer, 0.25pi reverse primer, 0.25pi probe,
1.25pl 18S primer/probe assay mix, lpl cDNA and 8.65pl RNase-free, DNase-free
sterile water.
For the genes ALOX 12 and ALOX15, an alternative experimental protocol was
followed, using a different 'Mastermix' which had been demonstrated in our
laboratory to have higher sensitivity in picking up low levels of gene expression
(personal communication, Sharon Battersby, Lab Technician, University of
Edinburgh). PCR was performed with a final volume of 25ul per well, containing
12.5ul 2x Express Mastermix, 0.25pl of forward primer, 0.25pl reverse primer,
0.25pl probe, 0.375 18S primer/probe assay mix, lul cDNA and 20.375ul RNase-



































Table 3.2 Sequences and UPL probe numbers used
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3.2.5.1. Data analysis
A Mann-Whitney test was performed to compare relative gene expression in samples
of labouring and non-labouring myometrium, placenta, amnion and chorio-decidua.
To compare the relative levels ofmRNA expression between the four different types
of tissue in the labouring group a Friedman test with Dunns Multiple Comparison
post test was performed. The Friedman test assumes non-parametric data, and that
values in each row represent matched data. This test was chosen in view of the fact
that the four different types of tissue (ie. myometrium, placenta, amnion and chorio-
decidua) were taken from the same eleven women and could therefore be considered
as matched data. The same tests were performed for the data from the non-labouring
group. All statistical calculations were carried out using GraphPad Prism 5.02
(GraphPad software, CA, USA).
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3.3. RESULTS
3.3.1.Circulating lipoxin A4 levels were greater in pregnant
women than in non-pregnant women
LXA4 was detected by ELISA in the peripheral blood of both non-pregnant and
pregnant women, in all the studied samples. Mean levels were higher in pregnant
women at all measured gestations than in non-pregnant women (p<0.0001, Figure
3.1), and at 37 weeks were 14.9-fold greater than the mean non-pregnant levels. As
pregnancy progressed from 24 to 37 weeks of gestation, circulating levels of LXA4
rose, with a 1.5-fold increase between 37 weeks and 24 weeks, which was a
significant difference (p=0.04, Figure 3.1).
Levels of circulating LXA4 were no different in women who were in labour from
women who were not in labour and undergoing elective caesarean delivery (p=0.99,
Figure 3.2). The women in these two cohorts were gestation matched to each other
and had a mean gestation of 40 weeks ±1.7 days. When these two cohorts were
compared to the samples from the women at 37 weeks gestation, the levels were
found to be significantly higher in the 37 week cohort, with a two-fold difference in
the levels (p<0.0001). This suggests that LXA4 levels increase towards term but
actually fall as delivery itself approaches.
Together these data demonstrate an increase in circulating LXA4 levels during
pregnancy, with an increase throughout the second trimester until term, at which
point a peak level was observed. Levels appear to fall in the final few weeks of





Circulating LXA4 levels in pregnant and non-pregnant women
Circulating lipoxin A4 levels are significantly greater in pregnant women at 24, 31
and 37 weeks gestation when compared to non-pregnant women, and increase
between 24 and 37 weeks gestation. This figure illustrates levels ofLXA4 in serum
of non-pregnant women (n=9) and a cohort of pregnant women from whom semm
samples were taken at 24, 32 and 37 weeks gestation (n=8). Longitudinal pregnant
samples were analysed with Repeated Measures ANOVA and Tukey post test,
pregnant vs non-pregnant analyses were performed using one way analysis of
variance and Tukey post test. *P <0.05; ***p <0.001.
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Figure 3.2
Circulating LXA4 levels at term
Circulating levels of lipoxin A4 are not significantly different in term women in
labour compared to term women not in labour. This figure illustrates levels ofLXA4
in serum ofpregnant women at term who were either in labour or not labouring
(n=10 in each group). Unpaired t test, p=0.99.
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3.3.2. mRNA expression of ALOX5 was greater in labouring
myometrium and chorio-decidua than in non-labouring.
Expression of ALOX15 was not detected in any of the tissue samples, either
labouring or non-labouring. Expression of ALOX12 was detected in some, but not all
samples studied, and was present at low levels. It was not possible to reliably
compare relative expression levels of this gene between the labouring and non-
labouring groups due to the low levels of expression.
In contrast, mRNA expression of ALOX5 was detected in all four of the studied
tissues (Figures 3.3-3.6). In myometrium, relative mRNA expression was greater in
labouring tissue when compared to non-labouring, (median fold change 2.6,
p=0.0025, Fig 3.3). Relative expression of ALOX5 was also greater in labouring
chorio-decidua when compared to non-labouring, (median fold change of 4.8,
p=0.0058, Fig 3.6). There was no difference in expression between labouring and
non-labouring placenta (Fig 3.4), nor between labouring and non-labouring amnion
(Fig 3.5).
When relative expression levels were compared between the four non-labouring
tissue types, it was observed that greater expression was found in placenta than in
either amnion or chorio-decidua (Fig 3.7). However, when labouring tissues were
compared, there was no difference in relative expression between any of the tissues,





Figure 3.3 ALOX5 mRNA expression in myometrium
Relative mRNA expression of ALOX5 is significantly greater in labouring
myometrium compared to non-labouring (median fold change 2.6). Data are
presented as medians and inter-quartile ranges with min and max whiskers; n=l 1 in






















Figure 3.4 ALOX5 mRNA expression in placenta
Relative mRNA expression ofALOX5 is not significantly different in labouring
placenta compared to non-labouring. Data are presented as medians and inter-quartile




















Figure 3.5 ALOX5 mRNA expression in amnion
Relative mRNA expression of ALOX5 is not significantly different in labouring
amnion compared to non-labouring. Data are presented as medians and inter-quartile
ranges with min and max whiskers; n=l 1 in each group; p=0.21, Mann-Whitney test.
Chorio-decidua
Figure 3.6 ALOX5 mRNA expression in chorio-decidua
Relative mRNA expression ofALOX5 is significantly greater in labouring chorio-
decidua compared to non-labouring (median fold change 4.8). Data are presented as

























Figure 3.7 ALOX5 mRNA expression in non-labouring tissues
Relative mRNA expression of ALOX5 is greater in placenta than in amnion or
chorio-decidua, but no other statistically significant differences are observed. Data
are presented as medians and inter-quartile ranges with min and max whiskers; n=l 1;
p=0.0008; Friedman test with Dunns post test. ***p<0.001, *p<0.05
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Figure 3.8 ALOX5 mRNA expression in labouring tissues
Relative mRNA expression ofALOX5 is not significantly different in the four
labouring tissues ofmyometrium, placenta, amnion and chorio-decidua. Data are
presented as medians and inter-quartile ranges with min and max whiskers; n=l 1;
p=0.09; Friedman test with Dunns post test.
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3.3.3.mRNA expression of FPR2/ALX was greater in labouring
myometrium, placenta, amnion and chorio-decidua than
in non-labouring.
FPR2/ALX mRNA was detected in term myometrium, placenta, amnion, and chorio-
decidua from both labouring and non-labouring women (Figs 3.9-3.12). Relative
mRNA expression was greater in labouring myometrium (median fold change 7.2,
p=0.0016, Fig 3.9), placenta (median fold change 2.1, p=0.049, Fig 3.10), amnion
(median fold change 6.9, p=0.018, Fig 3.11) and chorio-decidua (median fold change
96, p=0.0016, Fig 3.12).
In the non-labouring women relative mRNA expression of FPR2/ALX was greater in
placenta than in chorio-decidua (mean fold change 2.3) but there were no other
relative differences in expression between the tissues (Fig 3.13). In labouring tissues
there were no significant differences in relative mRNA expression of FPR2/ALX





























Figure 3.9 FPR2/ALX mRNA expression in myometrium
Relative mRNA expression of FPR2/ALX is significantly greater in labouring
myometrium compared to non-labouring (median fold change 7.2). Data are
presented as medians and inter-quartile ranges with min and max whiskers; n=l 1 in

























Figure 3.10 FPR2/ALX mRNA expression in placenta
Relative mRNA expression of FPR2/ALX is significantly greater in labouring
placenta compared to non-labouring (median fold change 2.1). Data are presented as



























Figure 3.11 FPR2/ALX mRNA expression in amnion
Relative mRNA expression of FPR2/ALX is significantly greater in labouring
amnion compared to non-labouring (median fold change 6.9). Data are presented as
medians and inter-quartile ranges with min and max whiskers; n=l 1 in each group;
p=0.018, Mann-Whitney test.
Chorio-decidua
Figure 3.12 FPR2/ALX mRNA expression in chorio-decidua
Relative mRNA expression ofFPR2/ALX is significantly greater in labouring
chorio-decidua compared to non-labouring (median fold change 96). Data are
presented as medians and inter-quartile ranges with min and max whiskers; n=l 1 in
each group; p=0.0016, Mann-Whitney test.
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Figure 3.13 FPR2/ALX mRNA expression in non-labouring tissues
Relative mRNA expression ofFPR2/ALX is significantly greater in non-labouring
(NL) placenta than in NL chorio-decidua (median fold change 2.3), but no other
statistically significant differences are observed. Data are presented as medians and
inter-quartile ranges with min and max whiskers; n=l 1; p=0.048; Friedman test with

























Figure 3.14 FPR2/ALX mRNA expression in labouring tissues
Relative mRNA expression of FPR2/ALX is not significantly different in the four
labouring (L) tissues ofmyometrium, placenta, amnion and chorio-decidua. Data are
presented as medians and inter-quartile ranges with min and max whiskers; n=l 1;
p=0.26; Friedman test with Dunns post test.
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3.3.4. FPR2/ALX localisation
FPR2/ALX immunostaining in term non-labouring and labouring myometrium
revealed localisation of the receptor in uterine myocytes and in neutrophils (Figure
3.15). Immunofluorescence co-localised cells staining for neutrophil elastase and
FPR2/ALX. In non-labouring myometrium, whilst staining was evident in myocytes,
as in the immunohistochemistry, few cells staining for neutrophil elastase were
observed. In labouring tissue, there were a greater number of cells that stained
positively for neutrophil elastase and there was co-localisation of FPR2/ALX,
confirming expression on neutrophils (Figure 3.16).
In placenta, FPR2/ALX immunostaining demonstrated localisation to the
syncytiotrophoblasts in both non-labouring and labouring tissue (Figure 3.17).
In membranes, FPR2/ALX immunostaining demonstrated localisation to the single
epithelial cell layer of the amnion, the chorionic trophoblast and the decidual cells in
both labouring and non-labouring tissue. (Figure 3.18).
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3.15 Immunolocalisation of FPR2/ALX in myometrium
Example of the immunolocalisation of the FPR2/ALX receptor in myometrium from
a woman not in labour (A) and in labour (B). Staining is seen in myocytes and in
endothelial cells surrounding the blood vessel. Stronger staining is seen in
neutrophils (N). Negative control is shown below.
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Figure 3.16 Co-localisation of FPR2/ALX and neutrophil elastase in
myometrium
Example of the co-localisation of FPR2/ALX in labouring myometrium.
Immunofluorescence staining shows that FPR2/ALX (green) is expressed in
neutrophils (indicated by arrows) that have been stained with neutrophil elastase
(red). Nuclear staining is shown in blue. Negative control (image below) shows
only nuclear staining.
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3.17 Immunolocalisation of FPR2/ALX in placenta
Example of the immunolocalisation of the FPR2/ALX receptor in placenta from a
woman not in labour (A) and in labour (B). FPR2/ALX is localised to the
syncytiotrophoblasts, with the strongest staining in the brush border contacting the
maternal circulation. Staining is also observed in endothelial cells surrounding the
blood vessels. Negative control is shown below.
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Figure 3.18 Immunolocalisation of FPR2/ALX in fetal membranes
Example of the immunolocalisation of the FPR2/ALX receptor in fetal membranes
from a woman not in labour (A) and in labour (B). Negative control is shown below.
Staining is seen in in the single epithelial layer of the amnion. There is also staining
in the chorionic trophoblast and decidual cells.
82
3.4. DISCUSSION
The work in this chapter has shown that:
• LXA4 was detectable in circulating peripheral blood of both pregnant and
non-pregnant women.
• Levels of circulating LXA4 were higher in pregnant women than in non¬
pregnant women, and increased during the third trimester from 24 weeks
gestation to 37 weeks gestation.
• Levels of LXA4 were lower in women over 39 weeks gestation, whether in
labour or not in labour, than in the cohort ofwomen at 37 weeks gestation.
• Circulating LXA4 levels were no different in term labouring women than in
gestation-matched non-labouring women.
• mRNA expression ofALOX5 was detectable in human term pregnant
myometrium, placenta, amnion and chorio-decidua and was greater in
labouring myometrium and chorio-decidua than in non-labouring.
• mRNA expression ofALOX15 was not detectable in the four studied tissues
using the experimental techniques described, and only low levels ofALOX12
mRNA expression were detected.
• mRNA and protein expression of FPR2/ALX was detectable in human term
pregnant myometrium, placenta, amnion and chorio-decidua, and relative
mRNA expression was greater in labouring samples compared to non-
labouring.
• Immunohistochemistry localised the FPR2/ALX protein to myocytes and
neutrophils in myometrium, to syncytiotrophoblast in placenta and in
membranes, to the epithelial cell layer of the amnion, the chorionic
trophoblast and to decidual cells.
The work described in this chapter observes for the first time that levels of LXA4 are
greater in pregnant than in non-pregnant women and increase towards term and has
recently been published (Maldonado-Perez et al. 2010). The main described roles of
LXA4 include effects on neutrophil trafficking (Serhan et al. 1995; Papayianni et al.
1996; Filep et al. 1999) and on reduction of secretion of pro-inflammatory cytokines
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(Sodin-Semrl et al. 2000; Gewirtz et al. 2002). The onset of parturition may be
characterised by an influx of inflammatory cells into the reproductive tissues (Osman
et al. 2003) and an increase in secretion ofpro-inflammatory cytokines (Winkler et
al. 1998) and thus, given that LXA4 has, in other systems been observed to influence
these processes, it is possible that LXA4 may have a role in modulating the onset or
progress of normal and/or preterm labour.
Although the causes of preterm labour are not fully understood, infection is
recognised as a major cause (Goldenberg et al. 2008; Norman et al. 2009), and
inflammation without evident infection is also seen, and is associated with poor
neonatal outcome (Shim et al. 2004). In the resolution of inflammation, it is
important that an inflammatory response is brought to an appropriate end once it has
served its purpose to protect the host from injury or microbial invasion. However, it
is also important that an excessively large inflammatory response is not mounted in
response to a minor or trivial insult, and in other systems in the human body, LXA4
has been implicated in having such a 'care-taking' role, in limiting and controlling an
inflammatory reaction where a large response is not necessary. Thus, it may be that
LXA4 is involved in controlling inappropriate inflammatory responses that may
result in the escalation of inflammation and preterm labour, as the more
advantageous result would be continuation of the quiescence ofpregnancy. This
concept would fit with the observed increase in circulating levels of LXA4 during
pregnancy to term.
In my study, levels of LXA4 in the circulating blood were higher in the cohort of
women at 37 weeks gestation than in the two cohorts ofwomen who had blood taken
around the time of delivery, either in labour or not in labour. Although 37 weeks
gestation is considered term, most women do not deliver until closer to 40 weeks
gestation. It would appear that there may be a fall in circulating LXA4 levels as
labour approaches. However, there was no difference in women ofmatched gestation
who were labouring spontaneously compared to those who were yet to labour. It
would be interesting to confirm these results by taking longitudinal samples from a
group ofwomen at regular intervals during the third trimester until the point of
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delivery, as it would give a more reliable answer than comparing non-matched
cohorts, as my study has done. If this were to confirm that levels of LXA4 do reach a
peak a few weeks before labour and then begin to fall, it would then be interesting to
examine if this were the case with women who laboured preterm. This would be a
very useful finding clinically, as it could potentially be used as a biomarker for
estimating the time of onset of labour.
Whilst preterm labour is to be avoided, timely delivery of a term infant is, of course,
necessary. Again, the concept of LXA4 acting as a 'brake' on inappropriate
inflammation fits with the results described in this chapter in that there is no increase
in circulating levels towards the end of pregnancy, and in fact, a fall at the very latter
stages of pregnancy. It is not known what pathways stimulate this increased secretion
ofLXA4 in pregnancy, but it would appear that at term these pathways result in no
further increase in production ofLXA4, perhaps allowing a potential 'brake' to be
eased off.
Circulating LXA4 levels in labouring women at term were no different from levels in
gestation-matched women who were yet to labour. Our group have also shown that
LXA4 is released from term myometrial explants with no differences between
labouring and non-labouring samples (Maldonado-Perez et al. 2010). This suggests
that either labour induces no additional release of LXA4 by myometrium, or that any
additional release was matched by breakdown in this system. The explant system
differs from in vivo conditions in that there is a lack of other tissues or cells and thus
it is possible that the experimental conditions do not reflect actual in vivo conditions.
For example, one of the steps in the synthetic pathway of LXA4 takes place in a
neutrophil-platelet interaction, and this may be reduced or absent in the explant
experiment as the explants are no longer in contact with a blood supply from which
neutrophils and platelets are derived. Therefore it may be difficult to draw
conclusions on whether these results actually reflect myometrial production of LXA4
in labour. However, the results fit with the observed results in circulating blood in
labour and non-labour, and provide further evidence that production of LXA4 is not
increased during labour.
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I have shown in this work that mRNA expression of ALOX5 was upregulated in
labour in myometrium and chorio-decidua, suggesting increased activity in the
pathways of reactions which it catalyses. Brown et al have also demonstrated an
increase in ALOX5 expression in labouring chorio-decidua, and also that expression
was not increased in placenta or amnion (Brown et al. 1999). ALOX5 and ALOX12
mRNA expression have been observed in baboon intrauterine tissue, including
myometrium, cervix and chorio-decidua (Smith et al. 2001), and there was no
difference in labouring expression compared to non-labouring in myometrium.
ALOX5 mRNA expression was increased in labouring baboon decidua, but
decreased in the labouring chorion and decreased in cervix towards term (Smith et al.
2001) and ALOX12 expression was unchanged in labouring and non-labouring
tissues. Thus there are some discrepancies in the published data, but overall, changes
do appear to occur both towards the end of gestation and during parturition and
therefore there are implications for the role of the proteins which are products of the
pathways these enzymes catalyse. The lipoxygenase enzymes are also involved in the
pathways that synthesise leukotrienes and prostaglandins, proteins with established
roles in parturition, but LXA4 may also be a candidate for altered production or
function.
FPR2/ALX expression was increased in labour in all four of the studied tissues, thus
providing a mechanism by which the effects of LXA4 may be amplified, whether the
actual levels of lipoxin are increased or not. It is notable in some of the groups,
particularly in amnion, that there were wide ranges of relative mRNA expression of
FPR2/ALX in the group. This may be for a number of reasons. Firstly, natural
variation between individuals is to be expected. Secondly, the non-labouring women
were delivered prior to the time that they would have gone into labour
spontaneously, and at a presumably variable time from that point. It may be that the
closer to natural labour a woman is may affect tissue expression of FPR2/ALX
mRNA. Thirdly, the sites from which the membrane biopsies were taken were
randomly selected. It is recognised that a zone ofweakness overlying the cervix
exists in fetal membranes at term (McLaren et al. 1999), characterised by thinner
membranes, increased MMP-9 and decreased TIMP3 (El Khwad et al. 2005). It may
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be that the greater variation in expression seen in the amnion biopsies is due to
natural variation dependent on distance from this zone ofweakness. The studies
which have demonstrated this zone of weakness in the membranes identified the area
overlying the cervix prior to delivery and then took biopsies at carefully determined
distances from this zone (El Khwad et al. 2005; El Khwad et al. 2006). It would be
interesting to perform a similar experiment looking at expression of FPR2/ALX to
determine any regional differences in its distribution within the membranes, as this
may also provide further clues as to its potential function within pregnancy and
labour.
The elevated levels of circulating LXA4 in pregnancy, which increase to term,
followed by an upregulation of its receptor during parturition itself, suggest a role for
LXA4 within this process. It may be that dysfunction of the pro-resolution systems
results in abnormalities of labour, for example, preterm labour, or prolonged labour
at term. Currently there is no universally effective treatment for arresting preterm
labour, and indeed is has been observed that attempting to do so and leaving the fetus
in a pro-inflammatory mileu may in fact do more harm than good . The concept of
using anti-inflammatory agents in the treatment of preterm labour therefore excites
interest, and rodent models using anti-inflammatory agents such as IL-10 (Terrone et
al. 2001) and PGJ2 (Pirianov et al. 2009) demonstrating dual effects of inhibiting
labour and providing fetal neural protection are encouraging. It is possible that LXA4
may prove to have therapeutic value in the treatment of preterm labour.
These data suggest a role for LXA4 in human labour, and in order to consider how it
may potentially be exploited to be used for therapeutic purposes in abnormal labour,
more information on its effects in human tissues and the pathways by which it
functions is needed. Work from other members of our group has explored the effects
of LXA4 on myometrial explants treated with LPS to induce inflammation
(Maldonado-Perez et al. 2010). LPS treatment increased the relative mRNA
expression of the pro-inflammatory cytokines IL-6 and IL-8. However, in explants
co-treated with LXA4, whilst there was still increased mRNA expression of IL-6 and
IL-8 than in vehicle-treated explants, this was markedly reduced by the presence of
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LXA4. Thus, a potential functional effect of LXA4 in parturition has been
demonstrated in an in vitro environment. The next step, described in the following
chapter will be to further explore how LXA4 may function in the myometrium.
3.4.1.Summary
LXA4 may have a role within human parturition. Levels of the mediator itself did not
appear to be increased in term parturition, but expression of its receptor was
increased, thus providing a mechanism for greater activity. Early work by our group
would appear to show a mechanism by which LXA4 may modulate other mediators
which have been demonstrated to be involved in the process of labour. In the next
chapter, it is described how this experiment is developed to explore other pathways
by which LXA4 may exert its effects.
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4. Microarray of myometrium
treated with LPS and lipoxin A4
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4.1. INTRODUCTION
The work in the previous chapter described the potential role of LXA4 and its
receptor FPR2/ALX in the process of human parturition. As was discussed, members
of our group have published data demonstrating modulation by LXA4 of the pro¬
inflammatory response to LPS in myometrial explants (Maldonado-Perez et al.
2010). LPS increased mRNA expression of key pro-inflammatory cytokines in
myometrial explant culture, whilst co-culture with LXA4 significantly reduced the
effect of LPS on increased expression. The cytokines studied were IL-6 and IL-8.1L-
1 p was also studied and whilst a trend towards the same pattern was observed, this
inhibition in IL-ip was not significant.
Microarrays examine the expression of a very large number of genes in a single
experiment, providing a wide-ranging survey of the alterations in gene expression
when comparing two or more samples. The data produced may uncover hitherto
unrecognised involvement of certain genes within a biological process, opening up
avenues of investigation that were previously unexplored. Functional analysis of the
differentially expressed genes then allows the investigator to identify pathways by
which a biological process may be progressing, to make links between interacting
genes and to potentially develop ways ofmanipulating that biological process.
Several investigators have used microarray technology and functional genomics to
explore the molecular mechanism of human parturition in labouring and non-
labouring reproductive tissues (Aguan et al. 2000; Esplin et al. 2005; Havelock et al.
2005; Bollopragada et al. 2009; Mittal et al. 2010). Whilst there is some agreement
across studies on some differentially expressed genes, there is also a lack of uniform
gene expression signature, probably due to differences in experimental design,
sample number and tissues types and the platforms used. Two recent functional
genomic studies have reported that human parturition is characterised by
inflammatory pathways, particularly those involving cellular trafficking
(Bollopragada et al. 2009; Mittal et al. 2010).
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Human parturition is a complex process, with many interacting pathways. LXA4 has
been shown to have an effect on the expression of two key cytokines involved in
parturition, as described above. The aim of the work described in this chapter is to
further explore what effects LXA4 may have on human myometrium, and in
particular within the process of inflammation and parturition.
An explant experiment using myometrial tissue from term, pregnant non-labouring
women was performed. LPS treatment was used to induce inflammation in the
explants, whilst other explants were treated with LXA4 or LPS and LXA4 together.
Subsequently, a microarray was performed on RNA extracted from the explants to
observe the effects of the treatments on gene expression within the samples. The
results of the microarray were compared to published comparisons of the myometrial
transcriptome in labouring and non-labouring tissue. Results of the microarray were
validated using quantitative RT-PCR for a selected number of specific genes and
additionally, relative gene expression for the selected genes was determined in




4.2.1.1. Samples for use in explant tissue culture:
Five non-labouring women were recruited to donate myometrial biopsies at elective
caesarean section and informed, written consent was obtained as described in section
2.2.1. The women were all undergoing elective caesarean section (c/s) in an
uncomplicated, singleton pregnancy, at term. Characteristics of the recruited patients
are found in table 4.1.




B040 40 1+2 38+5 Previous c/s
B041 37 0+0 38+0 Placenta
praevia
B044 24 0+0 39+5 Breech
presentation
B045 32 1 + 1 39+0 Previous c/s
B047 22 1+0 39+4 Previous c/s
Table 4.1
Characteristics of the patients whose myometrial biopsies were used for the
microarray experiment.
4.2.1.2. Samples for use in comparison of labouring vs non-
labouring myometrium by quantitative RT-PCR
Groups of labouring (n=l 1) and non-labouring women (n=l 1) were recruited and
informed, written consent was obtained to provide tissue samples as described in




4.2.2.1. Samples for use in explant tissue culture
Myometrial biopsies were taken from the upper margin of the transverse lower
uterine segment incision, after delivery of the baby, as described in section 2.1.5.1.
Biopsies were taken by the operating surgeon using either curved mayo scissors or a
scalpel and were full thickness, up to 1cm width and 2cm length. The biopsies were
placed into RPMI culture medium, transported to the laboratory and used
immediately in the explant culture experiment.
4.2.2.2. Samples for use in comparison of labouring vs non-
labouring myometrium by quantitative RT-PCR:
Samples ofmyometrium were taken at the time of elective or emergency caesarean
section, as described in section 2.1.5.1.
4.2.3.Tissue culture
The myometrial biopsies were washed three times with PBS and then the decidua
was dissected off and the tissue was divided into explants of approximately l-2mm3
using scissors. The explants were placed into fresh RPMI medium in an incubator at
37°C and gassed with room air overnight in order to starve the explants of any
remaining blood that may have been residual after washing. The following morning,
explants were placed into RPMI culture medium supplemented with
penicillin/streptomycin (P/S) (5000 u/ml, 5000punits/ml) and containing one of the
following treatments:
1. Vehicle (sample numbers 1-3)
The LXA4 used was suspended in 100% ethanol, therefore 100% ethanol was
added to the culture medium to give the same concentration as in the samples
treated with LXA4.
2. Lipopolysaccharide (LPS) lOOng/ml (sample numbers 4-6)
3. LXA4 lOOnM (sample numbers 7-9)
4. LXA4 lOOnM and LPS lOOng/ml (sample numbers 10-12)
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In each experiment, the explants and culture medium were placed into wells on a 24
well plate. In each well, 1 ml of culture medium was used and 2 explants were used.
For each treatment 3 triplicate wells were used. In wells in which LPS was used, the
LPS was added after 30 minutes of pre-treatment with either LXA4 or vehicle and
then the plates returned to the incubator.
The plate was placed into culture in an incubator at 37°C for 8 hours. After this time,
the plate was removed from culture. Myometrial explants were removed from culture
and placed into a pre-weighed 2ml Eppendorf tube and immediately placed onto dry
ice to snap freeze the sample. Samples were then transferred for storage at -80°C
until further analysis. Forceps were washed between each separate well.
4.2.4. RNA isolation
RNA was extracted from the explants using the method described in Section 2.4.1.
RNA quality and concentrations were checked using a Nanodrop 1000
spectrophotometer (ThermoScientific, Wilmington, DE, USA). Absorbancy at
260nm and 280nm was measured and the concentrations given in ng/pl. The RNA
extraction and quality check was performed by Sharon Battersby, whose assistance is
gratefully acknowledged.
4.2.5.Microarray
Following RNA extraction the samples were sent to Turku Centre for Biotechnology,
where a microarray was performed using an Illumina Fluman HT-12 v.3 Expression
Beadchip. This chip contains probes for more than 48000 measurement features and
the expression value for each of the probe types is calculated from approximately 15
measurements. The following section describes their methods.
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4.2.5.1. RNA quality assessment, hybridisation and normalisation
Following quality assessment of the samples by Experion capillary electrophoresis
assay, the best quality of the three replicates in each group was selected and
hybridised, leaving a total of 20 samples, i.e. 5 patients and 4 treatment groups.
4.2.5.2. Intensity signal values
For each array feature, a signal intensity value was detected. In any typical
hybridised sample, most array features yield very small intensities and just a few
features have high intensities. This is illustrated in Figure 4.1.
Intensity distribution
intensity
Figure 4.1 Intensity distribution curve
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Curve describing the intensity distribution of a typical hybridised sample. Most array
features yield small intensities (close to background), evidenced by the median peak
towards the left of the curve and only a few features have high intensities.
4.2.5.3. Normalisation
If there are large variations in the distributions between samples, this can indicate
problems with quality. Normalisation compensates for minor variations in
distribution and brings the expression values into the same register so that the
samples can be compared to each other. The data were normalised to remove
variation between samples caused by non-biological reasons ie minor variations
caused by experimental processes. The data were normalised applying the quantile
normalisation. First, each sample's measurement features are arranged in ascending
order based on expression value. Then the expression values are replaced with their
mean on every sample and the means are arranged in the original order based on the
expression values.
4.2.5.4. Sample relations
Sample relationships were studied by means of correlation and cluster analysis. Each
sample was compared with the other samples, taking all measurement features into
consideration. In the analysis, sample similarity is described on a scale of 0 to 1,
where 0 means absolutely no correlation, and 1 means perfect correlation.
Samples were clustered with Pearson's metrics to group the samples according to
their general similarity when all array measurements were taken into account.
4.2.5.5. Group comparisons and identification of differentially
expressed genes
The following groups were compared to detect differentially expressed genes
between the two groups, which are given the following titles:
• LPS vs Vehicle
• Lipoxin vs Vehicle
• LPS&Lipoxin vs Vehicle
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• LPS&Lipoxin vs LPS
• LPS&Lipoxin vs Lipoxin
The statistical package used was R package Limma. This package uses linear
modelling and empirical Bayesian methods to assess differential expression in gene
expression data. Initially a linear model is created for each measurement feature of
the array to give an estimate of the group average expression. This model is then
used to produce the modified t-test p-values of the comparisons between different
groups. Thus, the smallest p-values result from comparisons where the samples
within each group (ie biological replicates) are similar but the values between sample
groups differ.
Statistical t-tests were performed separately for each measurement feature and
because a very large number of tests are performed, calculations are built in for the
potential false positive findings that may statistically result. Limma therefore
calculates an adjusted p-value which is an FDR (false discovery rate) corrected p-
value.
The fold changes and corrected p-values from the statistical comparisons were used
as filtering criteria to create lists of genes which had the strongest evidence for being
differentially expressed between the two groups. Thresholds were set that resulted in
a reasonable number of differentially expressed array features.
4.2.5.6. Volcano plots
Volcano plots were used to visualise the relationships between fold change and p-
values of the filtered array features in the compared groups. The log fold change
between the two groups being compared is plotted on the x-axis and the log 10 of the
p-values is plotted on the y-axis for each array feature. Dotted lines represent the
filtering threshold. Upregulated array features are represented by red dots,
downregulated array features are represented by green dots and array features in
which no significant change was found when comparing the two groups are
represented by black dots. The greater the fold difference between the two groups,
the further away the dots fall from x=0 and the more significant the p-value is, the
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further away the dot falls from y=0. Thus for each comparison the scattering of the
plot demonstrates what effect the given treatment has had, with tighter scattering and
fewer coloured dots indicating a lesser effect, and broader scattering and more
coloured dots indicating more effect. Additionally, a preponderance of red dots is
suggestive of a stimulatory effect of the treatment, whereas a preponderance of green
dots would suggest an inhibitory effect on gene expression in general.
4.2.5.7. Clustering by Principal Component Analysis (PCA)
PCA was also used to visualise the sample relationships in three dimensional space.
PCA analysis orders objects so that similar objects are placed close to one another
and dissimilar objects are placed further apart.
4.2.5.8. Heatmaps
Heat maps use Pearson's metrics to cluster the samples and filtered features. The
clustering is based on the general expression measurement similarity. In the plots,
each row represents a differentially expressed feature, and each column represents
one sample. Red colour indicates high expression and green represents low
expression.
4.2.5.9. Functional analysis
Functional analysis of the data was performed using MetaCore from GeneGo. This
tool is based on a manually curated database of published protein-protein, protein-
DNA and protein compound interactions, metabolic and signalling pathways,
supported by proprietary ontologies and controlled vocabularies. The data gathered
from the array is applied to algorithms developed from these databases to identify
networks and canonical pathway maps relevant to the experiment.
4.2.5.10. Validation with quantitative RT-PCR
Five differentially expressed genes were selected from the array experiment LPS vs
vehicle and the results validated using quantitative RT-PCR. Discussion on the
criteria used to select the five validated genes is found in the corresponding results
section of this chapter.
cDNA was synthesised from the explant RNA samples, as described in section 2.4.
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Quantitative RT-PCR was performed as described in section 2.5 . The primers and
probes used to determine expression of the genes of interest were TaqMan Gene
Expression Assays. These are commercially available predesigned, preformulated
primer and probe sets specific for the selected gene.
The TaqMan Gene Expression Assays used were:
• E-selectin Hs00950401_ml
• Colony stimulating factor 3 (CSF3) Hs00738432_gl
• Intercellular adhesion molecule 1 (ICAMI) Hs00164932_ml
• Matrix metallopeptidase (MMP1) Hs00899658_ml
• Chemokine (C-C motif) ligand 2 (CCL2) Hs00234140_ml
The reaction mix used gave a final volume of 15pl per well, containing 7.5 pi 2x
Express Mastermix, 0.75pl primer/probe gene expression assay mix, 0.225pl 18S
primer/probe assay mix, 0.375pl cDNA and 6.15pl RNase-free, DNase-free sterile
water.
4.2.5.11. Labouring vs non-labouring comparison
It was of interest to examine whether the genes upregulated by LPS were also
upregulated in labour. Therefore, relative mRNA expression of the five
abovementioned genes was also determined in samples of labouring (n=T l) and non-
labouring (n=l l) myometrium. The samples used were the same as those used in the
work in Chapter 3. RNA was extracted and cDNA manufactured as described in
section 2.5.3. Quantitative RT-PCR was performed on these samples according to the
method in section 2.5.4 and the assays and reaction mixes used are described in the
previous paragraphs.
4.2.5.12. Data analysis
A Mann-Whitney test was performed to compare relative gene expression in samples
of labouring and non-labouring myometrium. To compare the relative levels of
mRNA expression between the treatment groups, a Repeated Measures ANOVA
with Bonferroni post test was used. All statistical calculations were carried out using




Assessment ofRNA quality prior to microarray analysis demonstrated that all
samples were of good quality and concentrations were within the range required by
the laboratory at the Turku Centre for Biotechnology to perform the microarray; data
are shown in Table 4.2. Once at the Turku laboratory, the 60 samples were screened
again and the best samples from each group were selected for the hybridisations.
There were no reported problems in the amplification and labelling procedures and
the overall quality of the hybridized samples was good.
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200.29 2.11 146.04 2.1 95.53 2.09 228.12 2.13 123.21 2.04
2
110.1 2.13 171.4 2.1 58.21 2.11 223.7 2.09 179.75 2.02
3
156.6 2.09 102.9 2.06 121.73 2.09 235.08 2.11 101.19 2.03
4
188.32 2.09 123.32 2.1 141.82 2.09 195.2 2.09 100.03 2.02
5
293.35 2.11 142.19 2.1 137.74 2.08 178.89 2.08 128.45 2.06
6
109.31 2.1 179.23 2.11 46.41 2.02 193.22 2.13 41.52 2.01
7
202.83 2.13 168.52 2.08 111.86 2.1 194 2.11 92.49 2.05
8
160.42 2.12 93.6 2.11 130.28 2.08 169.67 2.07 101.71 2.05
9
226.41 2.12 157.91 2.13 89.71 2.14 191.59 2.07 158 2.07
10
187.15 2.1 148.3 2.09 142.8 2.1 139.68 2.09 130.18 2.06
11
204.68 2.1 114.09 2.13 73.92 2.1 272.3 2.08 134.2 2.04
12
298.48 2.11 153.27 2.1 82.29 2.14 211.04 2.08 189.47 2.05
Table 4.2 RNA sample concentrations and qualities
Table shows RNA concentrations and 260/280 absorbance ratios demonstrating good
quality and adequate concentrations ofRNA were obtained from each sample.
Sample numbers 1-12 refer to the well numbers, as described above.
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4.3.2.Hybridisation intensity over the chips
Table 4.3 shows the minimum, mean and maximum intensities of the normalised
samples.
Minimum Median Mean Maximum
48 85 481 38889
Table 4.3 Sample intensity summary
Most of the features of the array are not expressed in most experiments, thus the
median value can be regarded as a rough measure of the background.
These intensity distributions are displayed as box plots before and after normalisation
in Figure 4.2. The chips were evenly hybridised and therefore, as can be seen in the
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Figure 4.2 Expression intensity value distributions
Expression intensity value distributions (log2-transformed) as box plots for
unnormalised and normalised data.
103
4.3.3. Sample relations
Groupwise minimum and mean correlations are given in Table 4.4. In samples that
are biological replicates, correlation of at least 0.95 is expected, so the data in Table
4.4 demonstrate good correlation within the groups.




LPS and Lipoxin 0.963 0.972
Table 4.4
Groupwise minimum and mean correlations
The correlation values are illustrated in Figure 4.3.
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Sample correlations for normalised data.
Figure is illustrated on the previous page.
Correlation in this analysis is described on a scale of 0 to 1, where perfect correlation
has the value 1 and absolutely no correlation has the value 0. In this diagram Value 1
is dark green, and Value 0 is dark orange, with a scale in between as illustrated by
the bar to the right of the diagram. Each individual line represents a sample and the
samples are placed in order by their experimental group, for example, the first five
lines represent the 5 samples from the LPS&lipoxin group. Each individual column
also represents a sample, placed in the same order as the rows, enabling comparison
of each sample to every other sample. Where a sample is compared with itself,
perfect correlation is observed; this can be seen by the line of dark green squares
running diagonally from bottom left to top right. Correlations between samples in the
same group i.e. biological replicates, are generally green, demonstrating that there
was fairly good correlation between biological replicates. Where samples that were
treated with LPS are compared with samples not treated with LPS, correlation tends
to be toward the yellow/orange end of the spectrum, indicating that there were
differences between the samples. However, where samples that were treated with
lipoxin are compared with similar samples that were not treated with lipoxin,
correlations tend to be high, suggesting that treatment with lipoxin has not
demonstrated large differences in the samples.
Samples were clustered with Pearson's metrics to group the samples according to
their general similarity when all array measurements were taken into account. This is
















































Hierarchical clustering for the normal data.
In this dendrogram the samples are placed according to their general similarity, when
all array measurements are taken into account. Samples which are most similar are
placed in the branches closest to each other. The dendrogram shows that the samples
have generally clustered according to LPS treatment into two main clusters, and
samples from the same individual cluster together within the two main clusters. This
shows that LPS is the main differentiating feature between the samples and that the
effect of LXA4 treatment was less significant than differences between biological
replicates.
4.3.4.Group comparisons and identification of differentially
expressed genes
Thresholds were set that resulted in a reasonable number of differentially expressed
array features, and are displayed in Table 4.5. As could be expected from the
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correlation and clustering analysis previously described, there were significant
variations between the comparisons. Where the compared groups differed in LPS
treatment, stricter threshold filters were used and these resulted in the filtered array
features clustering according to treatment groups. However, where the compared
groups did not differ in LPS treatment, the filtered array features clustered by sample
individual as opposed to treatment group, suggesting that the differences in gene
expression between individual patients is greater than the differences caused by the
treatment.
FC logFC PType P Tot Up Down
LPS vs Vehicle 2.0 1.0 FDR 0.001 294 228 66
Lipoxin vs Vehicle 1.2 0.26 P-value 0.05 102 40 62
LPS&Lipoxin vs Vehicle 2.0 1.0 FDR 0.001 293 231 62
LPS&Lipoxin vs LPS 1.2 0.26 P-value 0.05 96 64 32
LPS&Lipoxin vs Lipoxin 2.0 1.0 FDR 0.001 313 260 53
Table 4.5
Filtering summary table.
This table gives the values that were set as thresholds for producing the lists of
differentially expressed genes. As can be seen, different thresholds were used for
different comparisons, which reflects the effectiveness of the respective treatments in
inducing differential gene expression.
4.3.5.Volcano plots
The following volcano plots (Figures 4.5-4.9) provide a graphical representation of
the relationship between the fold change and the p-value for each individual array
feature in each of the group comparisons. Where the difference between the two
compared groups is treatment with LPS, a large number of dots fall outwith the
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threshold lines, and there are more red dots than green, indicating a relatively large
effect on gene expression brought about by LPS treatment and that the predominant
effect is an upregulatory as opposed to a downregulatory effect on gene expression.
Where the difference between the two compared groups is treatment with LXA4,
fewer dots fall outwith the threshold lines, despite the thresholds having been set at
lower levels in these groups. This illustrates graphically that LPS is having a large
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Figure 4.5
Volcano plot for LPS vs Vehicle
LIPOX vs. VEH
• •'
h 1 1—i 1 1—1 i 1 r~
-0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8
logFC
Figure 4.6
Volcano plot for Lipoxin vs Vehicle
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Figure 4.7
Volcano plot for LPS&Lipoxin vs Vehicle
LPS_UPOX vs. LPS
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Figure 4.8
Volcano plot for LPS&Lipoxin vs LPS
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Figure 4.9
Volcano plot for LPS&Lipoxin vs Lipoxin
Figs 4.5 to 4.9 illustrate volcano plots for each of the comparison groups studied. The
loglO of the p-values is on the y-axis and the logFC calculated for the comparison
group vs base level group is on the x-axis. The filtering thresholds (as described in
Table 4.5) are signified by dotted lines. Red dots signify upregulated array features
and green dots signify downregulated array features. Figures 4.5, 4.7 and 4.9 are
similar in that the two groups being compared differ in LPS treatment. Figures 4.6
and 4.8 are similar in that the two groups being compared differ in LXA4 treatment.
Where the groups being compared differ in LXA4 treatment it can be observed that
there are relatively few dots falling beyond the set thresholds. In contrast, where the
groups being compared differ in LPS treatment, it can be observed that many more
dots fall outwith the thresholds.
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4.3.6.Principal Component Analysis (PCA) plots
The following PCA plots (Figures 4.10 to 4.14) use the data from the differentially
expressed genes in each of the group comparisons to produce a three-dimensional
visualisation of the similarity of the samples. Similar objects are placed close
together and dissimilar objects are placed further apart. Where group comparisons
differ because of LPS treatment, it can be seen that the PCA plot draws into two
distinct clusters, separating the LPS-treated group and the non-LPS-treated group.
However, in the group comparisons where the difference is LXA4 treatment, the dots
do not draw into clusters, suggesting that variability between individual patients in
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Figure 4.10
PCA plot for comparison of LPS vs Vehicle
Rotation Angle: 240
Figure 4.11
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Figure 4.12
PCA plot for comparison of LPS&Lipoxin vs Vehicle
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Figure 4.13




PCA plot for comparison LPS&Lipoxin vs Lipoxin
Figs 4.10 to 4.14 illustrate PCA analysis for each of the group comparisons, allowing
sample relationships to be visualised in three-dimensional space. Where the groups
being compared differ by LPS treatment in can be seen that the dots draw apart into
two distinct clusters. However, where the groups being compared differ by LXA4
treatment the dots do not draw into clusters, suggesting that variability between
individual patients within the experiment have greater differences than any
differences induced by LXA4.
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4.3.7. Heatmaps
The following heatmaps (Figures 4.15 to 4.19) provide a graphical representation of
all the differentially expressed genes in each of the group comparisons. Each column
represents an individual sample, and each row represents a differentially expressed
feature, with red indicating upregulation and green representing downregulation. In
comparisons where LPS treatment is the group difference, it can be seen that the
samples tend to cluster by treatment groups (ie LPS treated or non-LPS treated) and
that the columns are fairly similar and tend towards more genes being upregulated
rather than downregulated, demonstrating a significant effect of LPS treatment in
differential gene expression. However, in group comparisons where lipoxin is the
group difference, the samples have clustered by individual patient as opposed to by
treatment group, again suggesting that patient variation is more significant than any
variation caused by lipoxin.
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LPS vs. VEH
Green = low intensity
Red = high intensity
Figure 4.15
HEATMAP plot for comparison of LPS vs Vehicle
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Figure 4.16
HEATMAP plot for comparison of Lipoxin vs Vehicle
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LPSJJPOX vs. VEH
Green = low intensity
Red = high intensity
Figure 4.17
HEATMAP plot for comparison of LPS&Lipoxin vs Vehicle
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LPS LIPOX vs. LPS
Green = low intensity
Red = high intensity
Figure 4.18
HEATMAP plot for comparison of LPS&Lipoxin vs LPS
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Figure 4.19
HEATMAP plot for comparison LPS&Lipoxin vs Lipoxin
In these heat maps Pearson's metrics is used to cluster the samples and filtered
features. The clustering is based on the general expression measurement similarity.
In the plots red colour means high expression and green low expression. Each row
represents one differentially expressed (DE) feature and each column represents one
sample. Again it can be seen that where the groups being compared differ by LPS
treatment the samples cluster into treatment groups, whereas where the groups being
compared differ by LXA4 treatment the samples tend to cluster by individual.
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Figures 4.5 to 4.19 demonstrate that treatment with LPS induced significant changes
in the gene profiles but that LXA4 treatment did not. Fold change thresholds had
been set for the LXA4 treatment at 1.2 but the analysis demonstrates that there is
greater variation between the five individuals than was induced by LXA4 treatment.
This is further discussed in the Discussion section of this chapter. The decision was
made therefore to concentrate on the analysis of the differentially expressed genes
induced by LPS treatment when compared to Vehicle.
4.3.8.Differentially expressed genes LPS vs Vehicle
In the comparison between LPS vs Vehicle, 294 genes were differentially expressed.
228 genes were upregulated and 66 were downregulated. The top 50 differentially
expressed probes upregulated and downregulated by treatment with LPS are listed in
Tables 4.6 and 4.7. Full lists are found in Appendix 3.
Table 4.6
Top 50 differentially expressed upregulated probes in the comparison of LPS vs
Vehicle. The probes are organised by average ranking based on both p-value and fold
change.
Symbol Gene name Fold FDR
change corrected
P-value
SELE E selectin 53.07 2.85E-13
CCL3 chemokine (C-C motif) ligand 3 27.07 3.51E-13
CX3CL1 chemokine (C-X3-C motif) ligand 1 24.93 5.89E-13
CCL4L2 chemokine (C-C motif) ligand 4-like 2 21.19 1.81E-14
CCL3L1 chemokine (C-C motif) ligand 3-like 1 23.16 4.46E-12
lymphotoxin beta (TNF superfamily,
LTB member 3) 19.27 6.45E-13
CCL3L1 chemokine (C-C motif) ligand 3-like 1 19.23 4.76E-12
CCL3L3 chemokine (C-C motif) ligand 3-like 3 22.76 6.72E-11
ILIA interleukin 1, alpha 18.35 7.21E-12
IL1B interleukin 1, beta 42.50 5.96E-10
CCL20 chemokine (C-C motif) ligand 20 23.13 5.38E-10
TRAF1 TNF receptor-associated factor 1 7.79 1.18E-12
colony stimulating factor 3
CSF3 (granulocyte) 13.57 2.02E-10
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Symbol Gene name Fold FDR
change corrected
P-value
tumor necrosis factor, alpha-induced
TNFAIP2 protein 2 10.75 1.43E-10
CCL4L1 chemokine (C-C motif) ligand 4-like 1 10.01 1.07E-10
IL23A interleukin 23, alpha subunit pi9 22.73 6.81E-09
lymphotoxin beta (TNF superfamily,
LTB member 3) 6.93 8.49E-10
CCL8 chemokine (C-C motif) ligand 8 9.46 6.98E-09
GCH1 GTP cyclohydrolase 1 6.87 5.54E-09
ADORA2A adenosine A2a receptor 5.07 3.64E-10
solute carrier family 2 (facilitated
SLC2A6 glucose transporter), member 6 4.92 2.02E-10
C15orf48 chromosome 15 open reading frame 48 5.85 4.20E-09
colony stimulating factor 3
CSF3 (granulocyte) 17.63 2.51E-08
IL1RN interleukin 1 receptor antagonist 6.78 7.98E-09
tumor necrosis factor receptor
TNFRSF4 superfamily, member 4 4.95 8.38E-10
CCL3L1 chemokine (C-C motif) ligand 3-like 1 9.73 2.62E-08
CXCL2 chemokine (C-X-C motif) ligand 2 10.12 4.59E-08
TNIP1 TNFAIP3 interacting protein 1 3.94 2.30E-11
UBD ubiquitin D 12.39 5.35E-08
CFB complement factor B 6.38 2.24E-08
LIPG lipase, endothelial 6.35 2.44E-08
LIPG lipase, endothelial 4.44 7.06E-09
IL7R interleukin 7 receptor 5.26 3.23E-08
colony stimulating factor 2
CSF2 (granulocyte-macrophage) 9.58 1.50E-07
nuclear factor of kappa light polypeptide
NFKB2 gene enhancer in B-cells 2 (p49/pl00) 3.42 2.94E-11
VCAM1 vascular cell adhesion molecule 1 8.90 1.39E-07
nuclear factor of kappa light polypeptide
NFKB2 gene enhancer in B-cells 2 (p49/pl00) 3.18 2.75E-13
G0S2 G0/G1 switch 2 6.41 6.50E-08
Cbp/p300-interacting transactivator,
with Glu/Asp-rich carboxy-terminal
CITED4 domain, 4 4.78 4.58E-08
GPR84 G protein-coupled receptor 84 4.49 4.58E-08
IL32 interleukin 32 3.70 5.28E-09
interleukin-1 receptor-associated kinase
IRAK2 2 3.40 2.73E-09
ZC3H12A zinc finger CCCH-type containing 12A 4.09 3.64E-08
HCK hemopoietic cell kinase 3.27 8.49E-10
nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor,
NFKB1E epsilon 3.66 9.23E-09
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Symbol Gene name Fold FDR
change corrected
P-value
MEOX1 mesenchyme homeobox 1 3.73 1.85E-08
chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating activity,
CXCL1 alpha) 6.90 4.37E-07
C15orf48 chromosome 15 open reading frame 48 3.77 4.91E-08
serpin peptidase inhibitor, clade B
SERPINB2 (ovalbumin), member 2 7.57 6.78E-07
tumor necrosis factor, alpha-induced
TNFAIP6 protein 6 4.11 1.82E-07
Table 4.7
Top 50 differentially expressed downregulated probes in the comparison of LPS vs
Vehicle. The probes are organised by average ranking based on both p-value and
fold change.
Symbol Gene name Fold FDR
change corrected
P-value
GRRP1 glycine/arginine rich protein 1 -5.72 9.87E-09
protein phosphatase 1, regulatory
PPP1R16B (inhibitor) subunit 16B -2.79 5.38E-10
INHBB inhibin, beta B -3.34 1.38E-07
HAVCR2 hepatitis A virus cellular receptor 2 -2.88 6.02E-08
ribonuclease, RNase A family, 1
RNASE1 (pancreatic) -2.48 5.85E-11
LHX6 LIM homeobox 6 -2.72 1.92E-07
caspase recruitment domain family,
CARD 10 member 10 -2.56 3.64E-08
ribonuclease, RNase A family, 1
RNASE1 (pancreatic) -2.32 7.98E-09
GTP cyclohydrolase 1 feedback
GCHFR regulator -2.50 2.55E-07
FPR3 formyl peptide receptor 3 -3.09 2.14E-06
isocitrate dehydrogenase 1 (NADP+),
IDH1 soluble -2.68 1.53E-06
IFI30 interferon, gamma-inducible protein 30 -2.58 1.17E-06
microtubule associated tumor
MTUS1 suppressor 1 -2.47 9.92E-07
GAS1 growth arrest-specific 1 -2.55 1.23E-06
GIMAP6 GTPase, IMAP family member 6 -2.28 1.10E-06
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Symbol Gene name Fold FDR
change corrected
P-value
1CAM2 intercellular adhesion molecule 2 -2.46 2.12E-06
MFNG O-fucosylpeptide 3-beta-N-
MFNG acetylglucosaminyltransferase -2.16 9.29E-07
FUCA1 fucosidase, alpha-L- 1, tissue -2.67 6.45E-06
C6orfl41 chromosome 6 open reading frame 141 -2.26 1.85E-06
lymphatic vessel endothelial hyaluronan
LYVE1 receptor 1 -2.71 7.72E-06
kelch repeat and BTB (POZ) domain
KBTBD11 containing 11 -2.88 1.09E-05
NOSTRIN nitric oxide synthase trafficker -2.03 4.89E-07
MAN 1C1 mannosidase, alpha, class 1C, member 1 -2.10 1.34E-06
CPLX1 complexin 1 -2.22 3.26E-06
HSPA12B heat shock 70kD protein 12B -2.01 1.10E-06
MALL mal, T-cell differentiation protein-like -2.12 3.37E-06
SDS serine dehydratase -3.30 3.31E-05
galactose mutarotase (aldose 1-
GALM epimerase) -2.05 2.75E-06
RNASE6 ribonuclease, RNase A family, k6 -2.60 2.07E-05
N-acetylneuraminate pyruvate lyase
NPL (dihydrodipicolinate synthase) -2.25 9.83E-06
PDE7B phosphodiesterase 7B -2.04 3.27E-06
ADAP2 ArfGAP with dual PH domains 2 -2.01 3.31E-06
MBP myelin basic protein -2.16 1.21E-05
DACH1 dachshund homolog 1 (Drosophila) -2.10 1.03E-05
N-acetylneuraminate pyruvate lyase
NPL (dihydrodipicolinate synthase) -2.15 1.59E-05
CD34 CD34 molecule -2.23 2.62E-05
microtubule associated tumor
MTUS1 suppressor 1 -2.09 1.41E-05
membrane-spanning 4-domains,
MS4A6A subfamily A, member 6A -2.05 1.24E-05
TEK TEK tyrosine kinase, endothelial -2.18 2.04E-05
CD34 CD34 molecule -2.03 1.24E-05
CYTL1 cytokine-like 1 -2.48 4.07E-05
TPD52L1 tumor protein D52-like 1 -2.03 1.44E-05
CYYR1 cysteine/tyrosine-rich 1 -2.15 2.67E-05
LAPTM5 lysosomal protein transmembrane 5 -2.04 1.78E-05
PROX1 prospero homeobox 1 -2.20 3.29E-05
STC2 stanniocalcin 2 -2.05 2.79E-05
vesicle-associated membrane protein 8
VAMP8 (endobrevin) -2.01 2.79E-05
major histocompatibility complex, class
HLA-DMB II, DM beta -2.19 5.62E-05
CD300A CD300a molecule -2.09 4.07E-05
GRAP GRB2-related adaptor protein 2 -2.03 3.34E-05
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4.3.9. Functional analysis
Functional analysis of the data was provided by uploading the lists of differentially
expressed genes into Metacore by GeneGo. This data set is then matched to terms
within GeneGo functional ontologies to produce ranked representations of ontologies
that are most saturated or 'enriched' with the differentially expressed gene list that
was uploaded. GeneGo Process Networks consist of around 110 cellular and
molecular processes which have been defined and annotated by GeneGo. Each
process represents a network of protein interactions characteristic for the process.
The top ten scored Process Networks identified by pathway analysis in the GeneGo
database are listed in Figure 4.20.
















Top ten Process Networks for LPS vs Vehicle. The histogram represents process
networks that were significantly enriched by the data set of differentially expressed
genes in the LPS vs Vehicle experiment. The size of the bar corresponds to -













GeneGo Pathway Maps represent another ontology which consists of a set of about
650 signalling and metabolic maps. They are drawn by GeneGo annotators and
manually curated based on confirmed, published protein interactions. The top ten
most statistically significant canonical Pathway Maps in the GeneGo database for the
experiment LPS vs Vehicle are shown in Figure 4.21 and the top scored map is
illustrated in Figure 4.22.
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Top ten most statistically significant GeneGo Pathway Maps for LPS vs Vehicle.
The histogram represents GeneGo Pathway Maps that were significantly enriched by
the data set of differentially expressed genes in the LPS vs Vehicle experiment. The
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Figure 4.22 Top scored map
The interleukin-17 signalling pathway (GeneGo) Display of differentially expressed
genes in human myometrial explants cultures with LPS vs Vehicle mapped on the
interleukin-17 signalling pathway. Red thermometers indicate uprcgulation of that
gene with LPS treatment. Of note is the area in the bottom right of the diagram in
which an entire network module is upregulated by LPS.
4.3.10. Validation by RT-PCR
I was interested in looking at pathways which might be common to the stimulation of
myometrium by LPS and the changes that may be observed in labouring vs non-
labouring tissue. A recently published paper by Bollopragada et al looked at
differentially expressed genes when mRNA from cervical and lower uterine segment
myometrial biopsies from labouring and non-labouring women were compared
(Bollopragada et al. 2009). This study identified 110 genes that were upregulated in
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both myometrial cervical biopsies of labouring women when compared with non-
labouring. This list of differentially expressed genes was compared with the
differentially expressed upregulated genes from our experiment of LPS vs Vehicle.
19 genes were common to both lists and are listed in Table 4.8. From this list 5 genes
were selected and the results validated using quantitative RT-PCR.
Symbol Gene name Fold change FDR
corrected
P-value
SELE Selectin E 2.84858E-13 53.067
Colony stimulating factor 3
CSF3 (granulocyte) 2.01708E-10 13.566
CCL20 Chemokine (C-C motif) ligand 20 5.37874E-10 23.128
IL1B Interleukin 1, beta 5.96163E-10 42.496
LIPG Lipase, endothelial 7.05514E-09 4.437
CXCL2 Chemokine (C-X-C motif) ligand 2 4.58772E-08 10.115
Phosphodiesterase 4B, cAMP-
PDE4B specific 2.30756E-07 2.611
Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
CXCL1 activity, alpha) 4.37033E-07 6.903
ICAM1 Intercellular adhesion molecule 1 1.0189E-06 2.594
MMP1 Matrix metallopeptidase 1 1.41306E-06 2.428
SLC25A37 Solute carrier family 25, member 37 3.11364E-06 2.77
CCL2 Chemokine (C-C motif) ligand 2 3.77367E-06 3.487
AQP9 Aquaporin 9 9.65526E-06 2.683
Leukemia inhibitory factor
LIF (cholinergic differentiation factor) 1.32622E-05 3.728
CXCL5 Chemokine (C-X-C motif) ligand 5 1.66431E-05 4.998
Triggering receptor expressed on
TREM1 myeloid cells 1 2.37638E-05 2.155
IL8 Interleukin 8 8.57917E-05 3.864
IL6 Interleukin 6 0.00021575 4.121
Prostaglandin-endoperoxide synthase
PTGS2 2 0.000511241 3.313
Table 4.8
Differentially expressed upregulated genes common to LPS vs Vehicle and an array
comparing labouring vs non-labouring myometrium and cervix (Bollopragada et al.
2009). Fold changes and p-values are those from the LPS vs Vehicle comparison.
The genes selected for validation are highlighted in bold.
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For each of the five selected genes, relative mRNA expression was greater in the
LPS and LPS&Lipoxin groups than in the Vehicle or Lipoxin groups (Figures 4.23,
4.25, 4.27, 4.29 and 4.31). This was consistent with the findings of the microarray,
validating its results.
When labouring and non-labouring samples were compared, significantly greater
relative mRNA expression was noted in E-selectin, CSF3, ICAM1 and CCL2
(Figures 4.24, 4.26, 4.28 and 4.32).
Relative mRNA expression of MMP1 appeared to be greater in labouring tissue but
this was not statistically significant (Figure 4.30). Expression levels were extremely
low in all the non-labouring samples, and in some of the labouring samples, but were
very high in others of the labouring samples. This wide variability accounts for the











Figure 4.23 E-selectin mRNA expression in myometrial explants
Relative mRNA expression ofE-selectin in term myometrial explants (n=5) cultured
for 8 hours with vehicle, lipoxin A4 lOOnM, LPS lOOng/ml or lipoxin A4 and LPS
together. Expression was significantly greater in explants treated with either LPS or
LPS & lipoxin A4 when compared to either vehicle or lipoxin A4 alone. Lipoxin A4























Figure 4.24 E-selectin mRNA expression in labouring and non-labouring
myometrium
Relative mRNA expression of E-selectin is greater in labouring term myometrium
than in non-labouring. Data are presented as median and inter-quartile range; n=l 1 in
each group; ** p=0.0058, Mann-Whitney test.
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Colony stimulating factor 3 (CSF3)
***
Figure 4.25 CSF3 mRNA expression in myometrial explants
Relative mRNA expression of CSF3 in term myometrial explants (n=5) cultured for
8 hours with vehicle, lipoxin A4 lOOnM, LPS lOOng/ml or lipoxin A4 and LPS
together. Expression was significantly greater in explants treated with either LPS or
LPS & lipoxin A4 when compared to either vehicle or LXA4 alone. LXA4 alone had
no effect when compared to vehicle. ***p<0.001; ANOVA and Bonferroni's post
test.
Figure 4.26 CSF3 mRNA expression in labouring and non-labouring
myometrium
Relative mRNA expression of CSF3 is greater in labouring term myometrium than in
non-labouring. Data are presented as median and interquartile range; n=l 1 in each
group; ** p=0.0006, Mann-Whitney test.
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Intercellular adhesion molecule 1 (ICAM1)
Figure 4.27 ICAM1 mRNA expression in myometrial explants
Relative mRNA expression of ICAM1 in term myometrial explants (n=5) cultured
for 8 hours with vehicle, lipoxin A4 lOOnM, LPS lOOng/ml or lipoxin A4 and LPS
together. Expression was significantly greater in explants treated with either LPS or
LPS & lipoxin A4 when compared to either vehicle or LXA4 alone. LXA4 alone had
no effect when compared to vehicle. ***p<0.001; ANOVA and Bonferroni's post
test.
Figure 4.28 ICAM1 mRNA expression in labouring and non-labouring
myometrium
Relative mRNA expression of ICAM1 is greater in labouring term myometrium than
in non-labouring. Data are presented as median and interquartile range; n=l 1 in each
group; ** p=0.0004, Mann-Whitney test.
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Matrix metallopeptidase 1 (MMP1)
**
Figure 4.29 MMP1 mRNA expression in myometrial explants
Relative mRNA expression ofMMP1 in term myometrial explants (n=5) cultured for
8 hours with vehicle, lipoxin A4 lOOnM, LPS lOOng/ml or lipoxin A4 and LPS
together. Expression was significantly greater in explants treated with either LPS or
LPS & lipoxin A4 when compared to either vehicle or lipoxin alone. Lipoxin alone














Figure 4.30 MMP1 mRNA expression in labouring and non-labouring
myometrium
Relative mRNA expression of MMP1 is not significantly different in labouring term
myometrium than in non-labouring. Data are presented as median and interquartile
range; n=l 1 in each group; p=0.21, Mann-Whitney test.
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Chemokine (C-C motif) ligand 2 (CCL2)
***
Figure 4.31 CCL2 mRNA expression in myometrial expiants
Relative mRNA expression of CCL2 in term myometrial expiants (n=5) cultured for
8 hours with vehicle, lipoxin A4 lOOnM, LPS lOOng/ml or lipoxin A4 and LPS
together. Expression was significantly greater in expiants treated with either LPS or
LPS & lipoxin A4 when compared to either vehicle or lipoxin alone. Lipoxin alone
had no effect when compared to vehicle. ***p<0.001; ANOVA and Bonferroni's
post test.
**
Figure 4.32 CCL2 mRNA expression in labouring and non-labouring
myometrium
Relative mRNA expression of CCL2 is greater in labouring term myometrium than
in non-labouring. Data are presented as median and interquartile range; n=l 1 in each
group; ** p=0.025, Mann-Whitney test.
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4.4. DISCUSSION
The original design of this experiment aimed to use functional genomics to explore
the anti-inflammatory or pro-resolution functional effects that LXA4 may have on
inflammatory processes within human pregnant myometrium, as has been observed
and published by our group (Maldonado-Perez et al. 2010). Unfortunately, the results
were not as exciting as had been hoped, because the fold changes in differentially
expressed genes in the groups treated with LXA4 were so small as to have
demonstrated no significant effect of LXA4. Subsequently it was discovered that
other groups had also found they had been unable to reproduce results with LXA4
from the same manufacturer, and that spectral analysis demonstrated contamination
of the LXA4 (personal communication Prof C Godson, University College Dublin).
It appears that this contamination of LXA4 may have rendered it inactive. Thus, it is
not possible to draw any conclusions from this experiment on how LXA4 may be
having anti-inflammatory or pro-resolution effects by altering gene expression in
myometrium. However, the microarray results did show profound effects in gene
expression by treating with LPS. These results are of value in identifying
inflammatory networks existing in myometrium, comparing them with the
inflammatory effects of parturition and exploring how these comparisons may be
used in the future to find new ways ofmanipulating abnormal inflammation in
myometrium.
LPS is pro-inflammatory and is widely used in research to mimic the inflammatory
process of labour and pre-term labour, and to induce preterm labour in animal
models (Fidel et al. 1994; Elovitz et al. 2003). This approach provides a useful model
for term and pre-term labour, but of course the conclusions that may be drawn from
such experimental models are limited by the fact that pre-term and term labour
involve complex, multi-faceted pathways, not just those involving inflammation.
Whilst there is a great deal published on the inflammatory effect of LPS on human
pregnant myometrium, to the best ofmy knowledge, this is the first time that a
genomics approach has been used to explore the pathways by which LPS exerts its
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effects in myometrium, and then compares this to known pathways which have been
demonstrated in labour. As would be expected from LPS, I found that the top
processes were related to inflammation, including chemotaxis and cell adhesion
processes. This is consistent with the published data of the effects of LPS, both in
myometrium (Sehringer et al. 2000; Diamond et al. 2007), and in other systems of
the body including the respiratory system (Bannerman and Goldblum 2003),
gastrointestinal tract (Petersson et al. 2011) and brain (Burd et al. 2010). Excitingly,
when the differentially expressed genes, top-scoring processes and maps were
compared with published data on labouring versus non-labouring comparisons, it was
possible to observe some very interesting comparisons.
For example, when the list of differentially expressed genes generated by treating
myometrium with LPS was compared with the list ofdifferentially expressed genes
in labouring vs non-labouring myometrium and cervix from the work published by
Bollopragada et al (Bollopragada et al. 2009), 19 common genes were identified. It
was from this list that 5 genes were chosen to validate the array using quantitative
RT-PCR and indeed it was demonstrated that relative mRNA expression was
increased in both myometrial samples treated with LPS, and in labouring myometrial
samples when compared with non-labouring.
Another recently published functional genomics study of labouring and non-
labouring myometrium reported that the myometrium of term labouring women is
characterised by upregulation of genes of the inflammatory response and leukocyte
chemotaxis (Mittal et al. 2010). In this study the authors also utilised Metacore by
GeneGo to analyse their data and it is interesting to note that the upregulated genes in
their data set also significantly enriched the interleukin-17 signalling pathway, which
was the most highly enriched map by the data from the LPS vs Vehicle experiment
presented in this chapter. Indeed, representation of the genes featured on their
published map is remarkably similar to the upregulated genes represented on the map
illustrated in this chapter in Figure 4.22.
Thus, it may be concluded that there are a number of differentially expressed genes
and molecular processes that are common to both parturition and artificial
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stimulation of inflammation with LPS, providing valuable evidence that using LPS in
animal and explant modelling of parturition can be valid and has great potential for
elucidating new avenues of investigation.
4.4.1. Genes chosen for validation
Five genes were chosen from the list of nineteen that were common to the lists of
differentially expressed genes from the LPS vs Vehicle comparison and the genes
upregulated in labour in Bollopragada et al's analysis (Bollopragada et al. 2009).
E-selectin and ICAM-1 are both leucocyte adhesion molecules and play an important
part in recruiting leucocytes to the site of inflammation (Boyd et al. 1988;
Bevilacqua et al. 1989). Both E-selectin and ICAM-1 expression are widely reported
to be upregulated by LPS via NF-kB activation (Montgomery et al. 1991; Chen et al.
1995; Jersmann et al. 2001) and so the findings of this microarray and subsequent
validation are consistent with this. One of the main anti-inflammatory effects of
LXA4 is to reduce leucocyte trafficking via an inhibitory effect on leucocyte
adhesion molecules (Papayianni et al. 1996; Filep et al. 1999). LXA4 stable analogs
have been reported to reduce the over-expression of E-selectin brought about by LPS
in HUVEC cells (Fiorucci et al. 2003) and by IL-ip in endothelial cells (Nascimento-
Silva et al. 2005), as well as inhibiting ICAM-1 expression via an NF-xB-dependent
mechanism (Decker et al. 2009).
CCL2 is a cytokine also known as monocyte chemotactic protein-1 (MCP-1) that
recruits inflammatory cells to sites of inflammation and is involved in macrophage
activation. It has been shown to be increased in the myometrium (Esplin et al. 2005),
fetal membranes (Esplin et al. 2005) and amniotic fluid (Esplin et al. 2003; Esplin et
al. 2005) of term labouring women and has also been shown to be involved in LPS-
induced preterm labour in the mouse (Diamond et al. 2007). In rats, CCL2 integrates
mechanical and endocrine signals involved in uterine inflammation and parturition
and has been suggested as a potential therapeutic target for preterm labour (Shynlova
et al. 2008). Validation of the results from this array confirmed that CCL2 was
upregulated by both LPS and labour in parturition. LXA4 attenuates TNF-a
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stimulated CCL2 release in colonic mucosal cells (Goh et al. 2001) whereas CCL2
expression is increased by serum amyloid A, a pro-inflammatory mediator signalling
through the FPR2/ALX receptor (Lee et al. 2008). CCL2 and LXA4-FPR2/ALX
interactions may therefore be another interesting starting point for investigation of
the role of LXA4 in parturition.
CSF3 is a cytokine, also known as granulocyte colony-stimulating factor (G-CSF)
that stimulates granulocyte production and function (Welte et al. 1985 519). It also
has an effect on neutrophil function, promoting their survival, proliferation and
function (Begley et al. 1986; Lopez et al. 1986). Its production is stimulated by LPS
(Vellenga et al. 1988; Dower et al. 2008). Recombinant G-CSF is used clinically
within oncology, to treat patients receiving chemotherapy, as it counteracts
chemotherapy-induced neutropenia (Morstyn et al. 1989; Sheridan et al. 1989). G-
CSF has been used in the treatment of septic preterm neonates (Kucukoduk et al.
2002), although a Cochrane review does not recommend its routine use due to lack of
evidence of efficacy (Carr et al. 2003). G-CSF has also been shown to be useful in
limiting tissue damage in the inflammatory states of burn injury and myocardial
infarction and these effects are possibly achieved by promoting homeostasis as
opposed to overstimulation of the immune system (Peter et al. 1999; Baldo et al.
2011). Little is known about its effects in utero-placental tissues or in the process of
parturition, or interactions it may have with LXA4. Given that it is upregulated in
labour and may have positive effects in limiting damage by an over-active immune
response, it may be an interesting target for investigation within the inflammatory
process of labour.
MMP1 is a matrix metalloproteinase that, like the other proteins of the same family,
is involved in the breakdown of ECM in both normal physiological processes and
disease processes (Contasta et al. 1999; Dunleavey et al. 2000). It is involved in the
degradation of the ECM of the fetal membranes that lead to rupture of the
membranes during/prior to labour and genetic polymorphisms ofMMP1 have been
associated with an increased risk of PPROM (Maymon et al. 2000; Fujimoto et al.
2002; Wang et al. 2008). MMP1 production has been reported to be stimulated by
LPS (La et al. 2009), as the array in this chapter also confirms, and chorioamnionitis
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is associated with increased amniotic fluid levels ofMMP1 (Maymon et al. 2000),
likely through increased cytokine induction (Oner et al. 2008). LXA4 has been
shown to decrease LPS-induced production of some pro-inflammatory cytokines
(Maldonado-Perez et al. 2007) and so it would be interesting to explore whether or
not it can suppress LPS-induced production ofMMP1 and other metalloproteinases.
4.4.2.Summary
LXA4 has been demonstrated to have an inhibitory effect on LPS-stimulated
production of IL-6 and IL-8 in human pregnant myometrium. These two interleukins
featured in the top 30 differentially expressed genes of labouring myometrium in
Bollopragada et al's work, and were also upregulated by LPS in the experiment
reported in this chapter. LXA4 also has well established pro-resolution and anti¬
inflammatory effects in other systems of the human body, as detailed in the
introduction of this thesis. Further evidence that LXA4 may potentially have an
effect in the inflammatory process of labour is demonstrated in the finding that its
receptor, FPR2/ALX is upregulated in human parturition. Unfortunately, as
previously discussed, due to contamination of the LXA4 used in this experiment, I
was unable to confirm any effect of LXA4 on IL-6 or IL-8 in the microarray, or to
identify other differentially expressed genes and pathways which may show similar
functional effects of LXA4.
Recent work within our laboratory using an alternative source of LXA4 has begun to
show results consistent with the previously demonstrated functional effects already
published. LPS is successfully used to induce preterm labour in animal models and
has, in this work, been shown using functional genomics to share many of the same
molecular pathways as parturition itself. If it can be demonstrated that it is possible
to manipulate these pathways with pro-resolution mediators, it is possible that in the
future, such mediators may be used in the treatment of abnormal or preterm labour.
Future experiments therefore may include repeating the work presented in this
chapter, using an alternative source of LXA4, or choosing key pathways and
differentially expressed genes in the LPS arm of the experiment and examining the
effects of LXA4 within these pathways.
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5. The effects of hypoxia on the
production of Lipoxin A4
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5.1. INTRODUCTION
The initiation of parturition and the mechanisms which govern it are as yet,
incompletely understood, and the characteristic inflammatory profile that is seen
during labour (Thomson et al. 1999) undoubtedly has many potential triggers. Work
in the previous chapter explored the myometrial transcriptome in induced
inflammation and compared this to the effect seen in labour. Inflammation can lead
to tissue hypoxia, for example, as seen clinically in abscess formation. There is also
evidence that hypoxia may play a role in promoting inflammatory processes.
Hypoxia has been demonstrated to increase expression of key pro-inflammatory
mediators IL-6 (Bowen et al. 2005), IL-8 (Karakurum et al. 1994; Bowen et al.
2005), IL-ip (Malek et al. 2001) and PGE2 (Supramaniam et al. 2004) and there is
also a placental increase noted in such mediators in conditions of pregnancy that are
associated with an inflammatory state such as placental insufficiency (Wang et al.
2003) and chorioamnionitis (Griesinger et al. 2001). Thus it would appear that
relative hypoxia may potentially be one of the features involved in the onset or
continuation of the inflammatory process of labour.
Whilst hypoxia may have a role to play in amplifying the inflammatory environment
necessary for labour, hypoxia within the utero-placental unit can of course be
severely detrimental, both to the process of effective labour, and to the fetus, who
until delivery is entirely dependent upon oxygenation from the maternal circulation
to survive. During labour, regular uterine contractions episodically constrict the
blood vessels that supply the myometrium with oxygen (Borell et al. 1964). Blood
vessel constriction appears to be worse when contractions are augmented with
oxytocin (Li et al. 2003). Uterine contractions may be sufficient to create intermittent
periods of relative hypoxia, both for the myometrial smooth muscle and for the fetus
(Peebles et al. 1994). Hypoxia inhibits myometrial smooth muscle contractions in
vitro in the human (Bugg et al. 2006) and in the rat (Rhee et al. 1996). In vivo,
women undergoing caesarean section for dysfunctional labour have reduced pH of
the myometrial capillary blood compared to women in normal labour or women not
in labour (Quenby et al. 2004). The importance of dysfunctional labour cannot be
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underestimated as it is a common indicator for emergency caesarean section (Thomas
et al. 2000), with all of its attendant implications for maternal morbidity and
mortality (Lyons 2008). Thus, understanding the contribution of hypoxia to
ineffective myometrial contractions is important.
Clearly therefore, a paradox exists in that hypoxia could contribute to the process of
parturition by promoting inflammation, but could also be a detrimental feature, by
making uterine activity and thus labour itself less effective and also potentially
contributing to a damaging environment for the fetus. The effects of hypoxia on
several key pro-inflammatory mediators are noted above. The lipid mediator LXA4
has anti-inflammatory and pro-resolution properties, and in myometrium has been
demonstrated to reduce LPS-induced production of IL-6 and IL-8 (Maldonado-Perez
et al. 2010). However, the effect of hypoxia on anti-inflammatory and pro-resolution
mediators and in particular on LXA4 has not been studied, and has not been looked
at within the context of parturition.
Aims
The work in this chapter aims:
• to explore how hypoxia may affect the production of LXA4 by myometrial
tissue
• to examine the effect of hypoxia on ALOX5 and FPR2/ALX expression in
myometrium
A myometrial explant experiment was designed in which tissue was cultured in
different oxygen conditions and treated with either vehicle, or LPS to simulate the
inflammatory conditions of labour. Vascular endothelial growth factor (VEGF) is a
growth factor which is regulated by hypoxia (Dibbens et al. 1999; Popovici et al.




5.2.1. Recruitment of patients
Six non-labouring women were recruited to donate myometrial biopsies at elective
caesarean section and informed, written consent was obtained as described in section
2.2.1. The women were all undergoing elective caesarean section in an
uncomplicated, singleton pregnancy, at term.
5.2.2.Sample collection
Myometrial biopsies were taken from the upper margin of the transverse lower
uterine segment incision, after delivery of the baby, as described in section 2.1.5.
Biopsies were taken by the operating surgeon using either curved mayo scissors or a
scalpel and were full thickness, up to 1cm width and 2cm length. The biopsies were
placed into RPMI culture medium, transported to the laboratory and used
immediately in the explant culture experiment.
5.2.3.Explant culture
The myometrial biopsies were washed three times with PBS and then the decidua
was dissected off and the tissue was divided into explants of approximately l-2mm3
using scissors. The explants were then placed into fresh RPMI and placed into
culture at 37°C overnight in order to starve the explants of any remaining blood that
may have been residual after washing. The following morning, explants were placed
into wells containing 0.5mls RPMI culture medium supplemented with pen/strep
(penicillin 5000units and streptomycin 5000pg/ml). Two explants were used per
well.
The explants were then placed into culture in six groups, with the following
conditions:
• Room air (21% oxygen (O2), 5% carbon dioxide (CO2)), 37°C.
• Hypoxic conditions (6% O2, 5% CO2), 37°C.
• Very hypoxic conditions (1% O2, 5% CO2), 37°C.
• Room air (21% O2, 5% CO2), 37°C, medium treated with LPS lOOng/ml.
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• Hypoxic conditions (6% O2, 5% CO2), 37°C, medium treated with LPS
lOOng/ml.
• Very hypoxic conditions (1% O2, 5% CO2), 37°C, medium treated with LPS
lOOng/ml.
Hypoxic conditions were generated by using hypoxic chambers. The oxygen
conditions represent maternal inspired oxygen concentration (21%), likely oxygen
concentrations at the feto-maternal interface in normoxic conditions (6%) and
hypoxic conditions at the feto-maternal interface (1%).
The explants were cultured for 24 hours. At the end of culture explants were
removed from the culture medium and placed into weighed Eppendorf tubes and
onto dry ice to snap freeze the tissue. This was performed within the hypoxic
chambers where applicable so that tissue was frozen whilst still at the level of
oxygenation they had been exposed to in culture. Tissue samples were then stored at
-80°C until further use. Culture medium was placed into Eppendorf tubes and stored
at -20°C.
5.2.4.RNA extraction, cDNA manufacture and RT-PCR
Total RNA was extracted from the myometrial explants, RNA concentrations were
estimated and cDNA was synthesised, as described in section 2.5.
Expression ofmRNA for VEGF, ALOX5 and FPR2/ALX was determined using
quantitative RT-PCR according to the methods described in section 2.5.4.
Reaction mixes and primers and probes used for ALOX5 and FPR2/ALX were as
described in Chapter 3.
VEGF primers and probes were designed to span intron junctions and had the
following sequences: forward primer: 5-TACCTCCACCATGCCAAGT-
3, reverse primer 5 -TAGCTGCGCTGATAGACAT-3, and probe 5-
ACTTCGTGATGATTCTGCC-3.
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5.2.5. ELISA for LXA4
Levels of LXA4 were measured in the explant culture media by ELISA, as described
in Section 2.3.
The samples were prepared for use in the ELISA by diluting some samples
appropriately according to the following method. During the explant culture,
inevitably there is some loss of the culture medium by evaporation. In this
experiment three different incubators were used, and although all attempts were
made to ensure similar experimental conditions, slightly varying humidities within
the incubators meant there was some inconsistency of evaporative loss between the
different incubators and on different days. Thus, when preparing the samples, the
volume ofmedium that had been left at the end of culture was measured and the
samples standardized by diluting the samples that had been exposed to higher levels
of evaporative loss to the volume of the sample with the least evaporative loss.
The final values used for statistical analysis were corrected for wet weight of tissue
used in each well (pg/ml/mg of tissue).
5.2.6.Statistical analysis
In this experiment, the effect of two variables on the mRNA expression or protein
production of a gene of interest is examined. Conventionally when two separate
variables may be having an effect, a two-way ANOVA is used which tests what
effect each variable has, and also if there is any interaction between the two variables
on the measured effect. For a two-way ANOVA to be used, certain conditions must
be met, including normal distribution of the data, and equal variance between the
data sets. If the data are not normally distributed, a non-parametric test must be used.
In this experiment the numbers of biological replicates was small (n=6) and, as is
common when using human tissue samples, variation within groups was wide for
some of the data sets. D'Agostino-Pearson tests of normality were used to determine
whether parametric or non-parametric testing was more appropriate and as it was
demonstrated that the data could not be shown to be normally distributed, non-
parametric testing was chosen to analyse effect of the two experimental variables.
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A Friedman test with Dunn's multiple comparison post test was used to compare
relative mRNA expression of the genes of interest or levels of LXA4 in the culture
medium. The Friedman test is used for non-parametric, matched data. As explained
in the previous paragraph, these data were assumed to be non-parametric, and a test
for matched data was chosen because the same patient's myometrium was exposed to
each experimental condition for each of the biological replicates. All calculations
were carried out using GraphPad Prism 5.02 (GraphPad software, CA, USA).
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5.3. RESULTS
5.3.1.Relative mRNA expression of VEGF in myometrial
explants increased with decreasing concentration of
oxygen
Relative mRNA expression of VEGF was measured in the cultured myometrial
explants after 24 hours of culture. There was a significant increase in VEGF
expression as the level of oxygenation decreased, both in the explants that were
treated with LPS and the explants which had no treatment (Figure 5.1). These
changes were significant when comparing untreated 21% O2 and 1% 02 (p<0.01,
median fold change 4.5, n=6) and when comparing LPS-treated 21% 02 and 1% 02
(p<0.05, fold change 3.1, n=6).
Treatment with LPS made no significant difference to relative VEGF mRNA
expression at any of the three oxygenation conditions.
Upregulation of VEGF is a recognized consequence of culture in hypoxic condition
and in this experiment is used to demonstrate that the myometrial explants were

























Figure 5.1 VEGF mRNA expression in myometrial explants
Relative mRNA expression of VEGF in myometrial explants cultured for 24 hours in
varying oxygen concentrations, with or without LPS treatment. VEGF expression
increases with decreasing concentration of oxygen, both when cultured in vehicle
(median fold change between 21% and 1%=4.5) or with LPS (median fold change
between 21% and 1%=3.1). At any given oxygenation, LPS did not affect expression
levels when compared to vehicle, n=6, Friedman test with Dunn's multiple
comparison post test, p=0.0002. Data are presented as median with interquartile
ranges. *p<0.05, **p<0.01.
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5.3.2. Relative mRNA expression of ALOX5 in myometrial
explants decreased with decreasing concentration of
oxygen when treated with LPS 100ng/ml, but not when
treated with vehicle
Relative mRNA expression of ALOX5 mRNA was measured in the myometrial
explants following 24 hours of culture (Figure 5.2). The concentration of oxygen had
no effect on expression ofALOX5 in myometrial tissue treated with vehicle.
However, in the group treated with LPS, expression of ALOX5 was significantly
reduced with decreasing oxygen concentration between 21% CL and 1% O2 (p<0.05,
median fold change 2.7, n=6).
When comparing the effect of LPS with vehicle on relative mRNA expression of
ALOX5 at each oxygen concentration, there was a significant difference only at the
lowest oxygen concentration, 1% O2 (p<0.05, median fold change 2.5, n=6).
Expression of the other enzymes involved in the synthesis of LXA4, ALOX12 and
ALOX15, was not measured because prior work (see Chapter 3) had demonstrated








Figure 5.2 ALOX5 mRNA expression in myometrial explants
Relative mRNA expression ofALOX5 in myometrial explants cultured for 24 hours
in varying oxygen concentrations, with or without LPS treatment. When treated with
vehicle, oxygen concentration does not affect relative ALOX5 mRNA expression.
When treated with LPS, ALOX5 expression decreases with decreasing oxygen
concentration (median fold change between 21% and 1%=2.7). When comparing the
effect of LPS with vehicle on relative mRNA expression of ALOX5 at each oxygen
concentration, there was a significant difference only at the lowest oxygen
concentration, 1% O2 (p<0.05, median fold change 2.5, n=6). n=6, Friedman test
with Dunn's multiple comparison post test, p=0.0002. Data are presented as median
with interquartile ranges. *P <0.05.
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5.3.3.Relative mRNA expression of FPR2/ALX was not
significantly different when treated with LPS or in
different oxygen concentrations.
Relative mRNA expression of FPR2/ALX was measured in the cultured myometrial
explants. There were no significant differences when comparing the six groups.
Thus, expression of FPR2/ALX was not statistically significantly different at
different oxygenations in either the group treated with vehicle or the group treated
with LPS. The data suggest a trend towards decreasing expression ofFPR2/ALX
with decreasing oxygenation in the group treated with vehicle but this was not
statistically significant.
When comparing the effect of LPS treatment, there was no significant difference of




























Figure 5.3 FPR2/ALX mRNA expression in myometrial explants
Relative mRNA expression of FPR2/ALX in myometrial explants cultured for 24
hours in varying oxygen concentrations, with or without LPS treatment. There is no
statistically significant difference between the six groups. n=6, Friedman test with
Dunn's multiple comparison post test. Data are presented as median with
interquartile ranges.
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5.3.4.There was no significant difference in LXA4
concentration in the culture medium of explants
cultured for 24 hours at 21%, 6% or 1% 02, and with
either vehicle or LPS treatment.
ELISA analysis of the culture medium from the six groups of explants demonstrated
that LXA4 was present in the medium from these experiments (Figure 5.4). It was
not present in culture medium alone that had not had myometrial explant in it and
thus the LXA4 must have been produced by the explants. There were six replicates in
this experiment i.e. the experiment was repeated on myometrium from six different
women. In one of the replicates, the sample reading was out of range (lower end of
range) for five out of the six experimental conditions. This sample was the first of the
experiments to have been carried out. Later some of the samples used in this
experiment were included in another LXA4 ELISA, and on this occasion no LXA4
was detected in the culture medium, despite having been demonstrated in this,
previous, experiment. One explanation for this is that LXA4 is degraded quickly and
that the second freeze-thaw cycle may have contributed to degradation of the protein
so that by the time a second ELISA was performed, none was measurable. This is a
potential problem with this experiment as the protein being measured is so fragile. A
possible reason for the first replicate's samples being almost all unmeasurable is that
these samples were the oldest. This replicate was excluded from analysis and thus the
subsequent analysis was performed on a sample size of 5.
There was no significant difference in the concentrations of LXA4 found in the




Figure 5.4 LXA4 levels in myometrial explant culture medium
Level ofLXA4 detected in the culture medium ofmyometrial explants cultured for
24 hours in varying oxygen concentrations. There is no statistically significant
difference in LXA4 level in any of the six groups. n=5, Friedman test with Dunn's




The data in this chapter has shown that:
• Relative mRNA expression ofVEGF in myometrial explants cultured for 24
hours increased with decreasing concentration of oxygen, both when treated
with LPS lOOng/ml, and when treated with vehicle alone.
• Relative mRNA expression ofALOX5 in myometrial explants cultured for
24 hours decreased with decreasing concentration of oxygen when treated
with LPS lOOng/ml.
• When treated with vehicle alone, relative mRNA expression ofALOX5 in
myometrial explants cultured for 24 hours was not affected by decreasing
concentrations of oxygen.
• Neither oxygen tension nor LPS treatment had any effect on myometrial
LXA4 release into culture medium.
• Relative mRNA expression of FPR2/ALX in myometrial explants cultured
for 24 hours was not statistically significantly affected by either oxygen
tension or LPS treatment. There did appear to be a trend towards reduced
expression with reducing oxygen concentrations, which would benefit from
further experimentation with greater numbers.
In this work I have studied for the first time what effect hypoxia might have on an
anti-inflammatory and pro-resolution mediator, LXA4, in human pregnant
myometrium. The samples used for this experiment were taken from non-labouring
patients and so co-treatment with LPS was designed to upregulate inflammatory
mediators and to allow the effect of any anti-inflammatory / pro-resolution mediators
to become apparent.
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Hypoxic treatment conditions caused an upregulation ofmRNA expression of
VEGF. This was an expected finding and was used in this experimental model to
demonstrate an appropriate, dose-related response to hypoxia by the myometrial
explants, as has been illustrated in other tissues (Dibbens et al. 1999; Popovici et al.
1999).
Although it is well recognised that the expression ofVEGF is regulated by hypoxia
in other systems including endometrium (Sharkey et al. 2000), this is the first time
that it has been specifically reported that VEGF could be inducible by hypoxic
culture conditions in myometrial tissue. In HUVEC cells, LXA4 regulates the effects
ofVEGF via an effect on the receptor VEGFR2 and inhibits VEGF-stimulated
expression of IL-6 and TNF-a, whilst augmenting VEGF-stimulated production of
IL-10 (Baker et al. 2009). This study has not attempted to demonstrate functional
effects of LXA4 on VEGF expression.
As one of the enzymes involved in the synthesis of LXA4 it might be anticipated that
increased expression of ALOX5 might result in increased production of LXA4. The
data in this chapter demonstrate that ALOX5 mRNA expression decreases with
decreasing concentrations of 02, but only when treated with LPS. When treated with
vehicle there was no difference in expression ofALOX5 at any of the three 02
concentrations used. Culture with LPS has been demonstrated to reduce the
expression ofALOX5 in astrocytes (Johann et al. 2008) and down-regulate ALOX5
activity (Brock 2002). In my data, ALOX5 mRNA expression was downregulated by
LPS at 1% 02, but a significant effect was not shown at the other levels of
oxygenation. This suggests that the braking effects of LXA4 on inflammation are
likely to be attenuated in hypoxic conditions, i.e. that hypoxia amplifies
inflammation in the myometrium.
ALOX 12 and ALOX 15 expression were not measured in this experiment. This was
because previous work had demonstrated very low or undetectable levels ofmRNA
expression of these genes in similar myometrial explants. The cell types present in
this explant experiment are not identical to those in vivo, and specifically, it is
possible that neutrophil populations are different, particularly as it is known that
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labouring myometrium contains an influx of invading neutrophils (Osman et al.
2003). It is possible that this may have influenced the data produced by this
experiment.
Myometrial explants in each of the experimental conditions examined in this study
produced LXA4 that was present at detectable levels in the culture medium, but there
was no significant difference in LXA4 levels when comparing any of the
experimental conditions. It has been observed previously by our laboratory that
myometrial explants in culture secrete LXA4 into the culture medium (Maldonado-
Perez et al. 2010). In the data presented in this chapter it appears as though levels of
secreted LXA4 were higher than was reported in the previous study, by an order of
magnitude of around 2 to 3. The two experiments were performed in very similar
ways, so the reason for this is unclear. However, in the study described in this
chapter it was noted in subsequent experiments using the same media that LXA4
levels declined significantly after just one further freeze-thaw cycle (data not shown)
and therefore it is possible that the observed discrepancies between the two studies
are due to differences in handling of the culture medium during the ELISA
experiment itself. All media in the experiments described here were handled
identically in terms of being frozen and stored immediately after culture and then
being used in the ELISA immediately after defrosting and so it is reasonable to
assume any degradation of the protein that may have occurred was consistent
throughout the samples. However, it is not known at what rate degradation of LXA4
was occurring in the samples during the 24 hours of culture and whether this was
affected by hypoxia. Equally, it is not known whether substrate for LXA4 synthesis
could have been exhausted in the experiment, whether this may have varied
depending on the experimental conditions and at what time in the experiment this
may have occurred. Given that ALOX5 is required for LXA4 synthesis, it would be
expected that the effect ofALOX5 inhibition would be to reduce LXA4 production
and that less LXA4 would be detected in the culture media of explants cultured in
hypoxia conditions. It is uncertain whether the discrepancies between LXA4 and
ALOX5 expression are due to LXA4 degradation, or whether they reflect continued
LXA4 production despite a decrease in ALOX5. Time course experiments exploring
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the degradation of a known level of LXA4 in the presence of absence of hypoxia
may have helped to answer this question.
The time frame chosen for this experiment was 24 hours. This was chosen based on
previous work produced in our laboratory which had demonstrated that LXA4 was
produced from myometrial explants at both 4 and 24 hours and that there was no
difference in the levels produced at these timepoints. The longer timepoint was
chosen to allow time for any genomic changes to have taken place and be observable
via the quantitative RT-PCR data. Ideally, a number of timepoints would have been
chosen to produce a greater picture of any changes, and their immediacy, but only a
limited number of explants can be obtained from each patient sample.
The effect of hypoxia on FPR2/ALX expression or function has not been previously
tested. In this experiment, mRNA expression of FPR2/ALX was not significantly
affected by either culture with LPS, or by varying levels of oxygen concentration.
The data do appear to show a trend towards downregulation of FPR2/ALX with
reduced oxygen concentration in the group treated with vehicle, although this was
not statistically significant. This may be due to a combination of a small sample size
and data with high standard errors, leading to a type II error. A larger sample size
would help to answer this question more reliably. If there were a change in
FPR2/ALX expression with reduced oxygenation, this could represent a mechanism
by which pro-resolution and anti-inflammatory mediators may have altered effects in
hypoxic conditions.
These data demonstrate that whilst we found no change in production of LXA4 in
myometrium in vitro in hypoxic conditions, there is a decrease in one of its synthetic
enzymes ALOX5. If a reduction in ALOX5 leads to decreased LXA4 over a longer
period of time, then there is a potential mechanism by its function may be altered in
myometrium in hypoxic conditions. It has not been demonstrated what functional
effect this may be, or what effect might subsequently be observed in vivo in
parturition, although it might lead to an attenuation in the inhibitory effect of LXA4
on IL-6 and IL-8 production in myometrium in vitro (Maldonado-Perez et al. 2010)
contributing to an overall pro-inflammatory environment.
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Future work could include examining the production of pro-inflammatory mediators
such as IL-6, IL-8 and COX-2 by the myometrial explants. A study ofmyometrial
smooth muscle cells by Helmer et al showed no difference in production of IL-6 and
IL-8 when cultured in hypoxia (Helmer et al. 2002), although the same study
reported no difference in IL-6 and IL-8 when stimulated with LPS. This is contrary
to our own laboratory's findings on stimulating myometrial tissue explants with LPS
(Maldonado-Perez et al. 2010) and therefore different results may well be observable
on stimulating with hypoxia.
Given that myometrial contractility is affected by hypoxia, it would be interesting to
observe what, if any, effect culture with LXA4 has on myometrial contractility and if
this were altered by culturing in different oxygen conditions. Such data may be
helpful in developing strategies to treat ineffective labour and reduce the burden of
caesarean section on mothers and the health service.
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Annexin A1 (ANXA1) is a protein with powerful anti-inflammatory and pro-
resolution properties. ANXA1 is found throughout the body in a variety of cell types.
In the blood, neutrophils and monocytes are the predominant cellular source of
ANXA1 (Perretti et al. 1996). It is also expressed by epithelial cells in the lung, gut
and kidney, and by fibroblasts (Errasfa et al. 1985; Vervoordeldonk et al. 1994;
Solito et al. 1998; Babbin et al. 2006). In neutrophils, ANXA1 is found within the
cell cytoplasm, from where it is mobilised when the cell is activated, and secreted
from the cell surface (Perretti et al. 2000). ANXA1 subsequently can function in an
autocrine or paracrine fashion to activate signalling of its receptor, FPR2/ALX
(Walther et al. 2000). Related to ANXA1 are Ac2-26 and Ac9-25, short peptides
corresponding to the N-terminal sequence ofANXA1, which have similar functions
and signal not only through FPR2/ALX, but also through FPR1, a closely related
GPCR from the same family of receptors (Hayhoe et al. 2006). The anti¬
inflammatory and pro-resolution actions ofANXA1 include reduction of
transmigration of neutrophils (Perretti et al. 1996; Walther et al. 2000), increase in
the detachment of neutrophils adherent to endothelial cell layers (Lim et al. 1998), an
increase in neutrophil apoptosis (Solito et al. 2003), and phagocytosis of apoptotic
neutrophils (Scanned et al. 2007).
Glucocorticoids have been identified as an important regulator of ANXA1 and
appear to increase its expression by both genomic and non-genomic pathways.
Glucocorticoid administration has been demonstrated to cause an increase in
leucocyte cell surface expression ofANXA1 within 30 minutes in humans (Goulding
et al. 1990). With regard to upregulation of transcription, a specific glucocorticoid-
response element has not been found on ANXA1 and it is possible that
glucocorticoids indirectly bring about upregulation, perhaps via IL-6 (Solito et al.
1998). Furthermore, glucocorticoids have also been shown, in human monocytes, to
induce expression of the receptor, FPR2/ALX, both at an mRNA level and at the
protein level (Sawmynaden and Perretti 2006).
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Glucocorticoids play a crucial role throughout human pregnancy, with effects on
implantation (Arcuri et al. 1997), placental development (Malassine and Cronier
2002), fetal brain development, fetal lung, liver and gastrointestinal maturation
(Challis et al. 2001) and ultimately, in parturition itself. Cortisol increases
prostaglandin synthesis and actions, which has pro-labour effects including inducing
cervical ripening, myometrial contractility and facilitating membrane rupture and
indirect effects on the inflammatory cascades encountered during human parturition.
However, excess Cortisol levels can have a deleterious effect in pregnancy, observed
in restriction of fetal growth (Seckl and Meaney 2004), and also longer term fetal
programming effects (Seckl 2004).
11 P-hydroxysteroid dehydrogenase (1 lpHSD) is an enzyme existing in two isoforms,
1 lpHSDl and 1 ipHSD2 (Brown et al. 1993), which interact in a so-called cortisol-
cortisone shuttle (Edwards and Stewart 1991). 11PHSD2 acts as an oxidase,
converting the active hormone Cortisol, to its inactive form cortisone. 1 lpHSDl on
the other hand has some oxidative function, but mainly functions as a reductase and
converts inactive cortisone to active Cortisol.
Maternal plasma Cortisol levels in pregnancy are in the order of ten times greater
than fetal Cortisol levels (Shams et al. 1998), a state which is maintained by the
actions of 11PHSD2 in the placenta (Murphy et al. 1974; Blasco et al. 1986; Stewart
et al. 1995), acting to convert the active glucocorticoid, Cortisol, to the inactive form,
cortisone. Thus 11PHSD2 has a feto-protective role within the placental unit (Blasco
et al. 1986; Stewart et al. 1995). However, 1 lpHSDl is also produced in the human
placental unit, more notably in the decidua and fetal membranes (Sun et al. 1997),
which is likely to increase local production of Cortisol from cortisone. Cortisol levels
increase during human pregnancy towards term in the amniotic fluid (Murphy et al.
1975), and this is presumed to be increased production from the fetal adrenal. Indeed,
in sheep, this increased Cortisol production by an increasingly mature fetus is likely
the main initiator of parturition, although the human scenario is much more complex
(Golightly et al. 2010). Increased local production of Cortisol towards term or in
labour may contribute further to the initiation of parturition, both normal, and
preterm via increased production of prostaglandins, as described above. However,
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increased Cortisol production may also have an effect on the anti-inflammatory and
pro-resolution mediator ANXA1 in late gestation and parturition, given the influence
of glucorticoids on ANXA1 (Perretti and D'Acquisto 2009).
It has been observed that the mRNA expression of ANXA1 is upregulated in
pregnant myometrium when compared to non-pregnant myometrium (Rehman et al.
2003). Expression has also been reported in placenta (Bennett et al. 1994) and fetal
membranes (Lynch-Salamon et al. 1992; Bennett et al. 1994). However, relatively
little work is published on its potential role within pregnancy or the puerperium.
ANXA1 null mice conceive, gestate their litters, labour normally and deliver
apparently normal pups at an appropriate time (Hannon et al. 2003). This observation
is in contrast to the profoundly abnormal response to other inflammatory events that
such null mice produce (Roviezzo et al. 2002). There are differences in the annexin
systems between mice and humans, therefore it is not entirely reliable to extrapolate
these observations to the human events. Given that human parturition is an
inflammatory event, it may be that ANXA1 has a role in this process, perhaps by
contributing to the delicate balance between the continuation of pregnancy and the
ensuing inflammation of labour.
Aims
The research in this chapter aims:
• to localise the ANXA1 protein within myometrium and placenta, and
compare that localisation between labouring and non-labouring tissues
• to explore the relative mRNA expression ofANXA1 and FPR1 in labouring
and non-labouring tissues of the feto-placental unit
• to explore to what extent expression of the 1 lpHSD enzymes is altered in
term labouring and non-labouring tissues





6.2.1.1. Samples for use in comparison of labouring vs non-labouring
tissue by quantitative RT-PCR:
Groups of labouring (n=l 1) and non-labouring women (n=l 1) were recruited and
informed, written consent was obtained to provide tissue samples as described in
section 2.2.1. Inclusion and exclusion criteria for these groups are described in
section 2.2.2.1.
6.2.1.2. Samples for use in explant tissue culture:
Five non-labouring women were recruited to donate myometrial biopsies at elective
caesarean section and informed, written consent was obtained as described in section
2.2.1. The women were all undergoing elective caesarean section in an
uncomplicated, singleton pregnancy, at term.
6.2.2.Sample collection
6.2.2.1. Samples for use in comparison of labouring vs non-labouring
tissue by quantitative RT-PCR:
Samples ofmyometrium, placenta, amnion and chorio-decidua were taken at the time
of elective or emergency caesarean section, as described in section 2.1.5.1.
6.2.2.2. Samples for use in explant tissue culture:
Myometrial biopsies were taken from the upper margin of the transverse lower
uterine segment incision, after delivery of the baby, as described in section 2.1.5.1.
Biopsies were taken by the operating surgeon using either curved mayo scissors or a
scalpel and were full thickness, up to 1 cm width and 2cm length. The biopsies were
placed into RPMI culture medium, transported to the laboratory and used
immediately in the explant culture experiment.
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6.2.3. Immunohistochemistry
ANXAl was localised in labouring and non-labouring myometrium, placenta and
fetal membranes by immunohistochemistry.
The immunohistochemistry protocol used for determining the localisation ofANXAl
is described in section 2.4 and was performed on sections cut from myometrial,
placental and membrane biopsies, taken either at elective or emergency caesarean
section, as described in section 2.1.5.1.
6.2.4.Myometrial explant culture with Cortisol
The myometrial biopsies were washed three times with PBS and then the decidua
was dissected off and the tissue was divided into explants of approximately l-2mm3
using scissors. The explants were then placed into fresh RPMI and placed into
culture at 37°C overnight in order to starve the explants of any remaining blood that
may have been residual after washing. The following morning, explants were placed
into RPMI culture medium supplemented with P/S (penicillin 5000units and
streptomycin 5000pg/ml) and containing one of the following treatments:
1. Vehicle.
The Cortisol used was suspended in ethanol, therefore ethanol was added to
the culture medium at the same concentration as the highest dose of Cortisol used.
Stock solution of Cortisol was 10 3M, therefore to make a solution of 10"6M, a
dilution of lpl in lOOOpl RPMI+P/S was used. Hence for the vehicle, lpl of Cortisol
was added per lOOOpl of culture medium.
2. Cortisol 10 6M
As described above, stock solution of Cortisol was 10-3M so a dilution of lpl
per lOOOpl RPMI+P/S was used to achieve a concentration of 10-6M.
3. Cortisol 10 7M
4. Cortisol 10"8M
5. Cortisol 10 9M
For the subsequent doses in treatments 3, 4 and 5, treatment 2 was sequentially
diluted with further RPMI+P/S.
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In each experiment, the explants and culture medium were placed into wells on a 24
well plate. In each well, 0.5mls of culture medium were used and 2 explants were
placed. For each treatment 3 triplicate wells were used.
The plate was placed into culture in an incubator at 37°C for either 6 or 24 hours.
After this time, the plate was removed from culture. Myometrial explants were
removed from culture and placed into a pre-weighed 2ml Eppendorf tube and
immediately placed onto dry ice to snap freeze the sample. Samples were then
transferred for storage at -80°C until further analysis. Forceps were washed between
each separate well.
6.2.5.Quantitative RT-PCR
Quantitative RT-PCR was used to determine relative mRNA expression ofANXA1,
FPR1, 1 lpHSDl and 11PHSD2 in labouring and non-labouring tissues.
Total RNA was extracted from the biopsies ofmyometrium, placenta, amnion and
chorio-decidua, RNA concentrations were estimated and cDNA was synthesised, as
described in section 2.5. Quantitative RT-PCR was performed as described in section
2.5. Specific reaction mix composition and primers and probes used are detailed
below.
6.2.5.1. Annexin A1
Expression ofANXA1 mRNA was determined using a TaqMan ® Gene Expression
Assay (Hs00167549_ml, Applied Biosystems) which contains predesigned gene-
specific primers and probes.
6.2.5.2. FPR1
Expression of FPR1 mRNA was determined was determined using TaqMan ® Gene
Expression Assay system (Hs00181830_ml, Applied Biosystems) which contains
predesigned gene-specific primers and probes.
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6.2.5.3. 11PHSD1
Expression of 1 lpHSDl mRNA was determined was determined using TaqMan ®
Gene Expression Assay system (Hs00181830_ml, Applied Biosystems) which
contains predesigned gene-specific primers and probes.
6.2.5.4. 11PHSD2
Expression of 11[3HSD2 mRNA was determined was determined using TaqMan ®
Gene Expression Assay system (Hs00181830_ml, Applied Biosystems) which
contains predesigned gene-specific primers and probes.
The reaction mix used gave a final volume of 15pl per well, containing 7.5 pi 2x
Express Mastermix, 0.75pl primer/probe gene expression assay mix, 0.225pl 18S
primer/probe assay mix, 0.375pl cDNA and 6.15pl RNase-free, DNase-free sterile
water.
6.2.5.5. Quantitative RT-PCR ofANXA1, FPR1 and FPR2/ALX in explant
samples
Quantitative RT-PCR was used to determine relative mRNA expression of ANXA1,
FPR1 and FPR2/ALX in the myometrial samples from the explant experiment
described in 6.2.4.
Total RNA was extracted from the myometrial explants, RNA concentrations were
estimated and cDNA was synthesised, as described in section 2.5. Quantitative RT-
PCR was performed as described in section 2.5. Specific reaction mix composition
and primers and probes used are given for ANXAl and FPR1 in section 6.2.4 and for
FPR2/ALX below.
FPR2/ALX
Expression of FPR2/ALX mRNA was determined using primers designed by Dr
David Maldonado-Perez using the ProbeFinder version 2.42 for Human (Roche
Applied Science, Burgess Hill, UK). The sequences were: forward 5'-
GCACACAGGAAAAGGAGCTTA, reverse 5'-
AGCCAGCAGACTCATAGGACA. The corresponding probe from the Universal
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Probe Library Set was used with each pair of primers. PCR was performed with a
final volume of 25 pi per well, containing 12.5pl 2x Mastermix, 0.3pl of each of the
forward and reverse primers, lpl probe, 1.25pl 18S primer/probe assay mix, lpl
cDNA and 8.65pl RNase-free, DNase-free sterile water.
6.2.6.Statistical analysis
A Mann-Whitney test was performed to compare relative gene expression in samples
of labouring and non-labouring myometrium, placenta, amnion and chorion. To
compare the relative levels ofmRNA expression between the four different types of
tissue in the labouring group a Friedman test with Dunns Multiple Comparison test
was performed. The Friedman test assumes non-parametric data, and that values in
each row represent matched data. This test was chosen in view of the fact that the
four different types of tissue (i.e. myometrium, placenta, amnion and choriodecidua)
were taken from the same eleven women in the labouring group and could therefore
be considered as matched samples. The same tests were performed for the data from
the non-labouring group. In the explant experiment, paired t-tests were used to
compare vehicle and Cortisol treatment where only one treatment dose was measures,
and where a range of treatment doses were measured, a Friedman test with Dunns
Multiple Comparison test was performed. All statistical calculations were carried out
using GraphPad Prism 5.02 (GraphPad software, CA, USA).
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6.3. RESULTS
6.3.1. Immunohistochemistry of Annexin A1 in labouring and
non-labouring myometrium, placenta and fetal
membranes
Immunohistochemistry of non-labouring myometrium (Fig 6.1A) demonstrated
localisation to myocytes with staining diffusely through the cell. There was also
staining evident in the endothelial cells of the blood vessels within the myometrium.
Strong staining was seen in neutrophils, which were generally located within the
intravascular space. Labouring myometrium (Fig 6.IB) demonstrated a similar
staining pattern in that there was staining of the myocytes, endothelial cells and
neutrophils.
In non-labouring (Fig 6.2A) and labouring (Fig 6.2B) placenta, there was staining of
the syncytiotrophoblasts, with the strongest staining in the brush border of these
cells, contacting the maternal circulation. Staining was also seen in endothelial cells
of the placental blood vessels, and in neutrophils of the maternal circulation.
In fetal membranes, amnion and chorio-decidua both showed positive staining.
Staining was similar in non-labouring (Fig 6.3A) and labouring (Fig 6.3B) samples.
ANXA1 localised to the amnionic epithelial cell layer, to the chorionic mesoderm
and to trophoblastic cells.
Localisation of FPR2/ALX by immunohistochemistry is described in Chapter 3. It
would also have been interesting to perform localisation for FPR1, but efforts to
optimise an antibody were not complete in time to perform the experiments for
inclusion in this work.
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Figure 6.1
Immunolocalisation of ANXA1 in myometrium
Immunohistochemistry demonstrating staining for ANXA1 in (A) non-labouring
myometrium and (B) labouring myometrium. Negative control is shown below.
Staining is seen in myocytes, endothelial cells (EC) and neutrophils (N).
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Figure 6.2
Immunolocalisation of ANXA1 in placenta
Immunohistochemistry demonstrating staining for ANXA1 in (A) non-labouring
placenta and (B) labouring placenta. Negative control is shown below. Staining is
seen in the syncytiotrophoblasts (S), endothelial cells (EC) and neutrophils (N).
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Figure 6.3
Immunolocalisation of ANXA1 in fetal membranes
Immunohistochemistry demonstrating staining for ANXA1 in (A) non-labouring
fetal membranes and (B) labouring fetal membranes. Negative control is shown
below. Staining is seen in the amnion epithelial cell (EC), in the chorionic mesoderm
(M) and in the trophoblastic cells (T).
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6.3.2. Relative mRNA expression of Annexin A1 did not differ
in labouring and non-labouring myometrium, placenta,
amnion and chorio-decidua
When expression was compared between labouring and non-labouring tissue of the
same type, there were no significant differences in relative mRNA expression of
ANXA1 in labouring and non-labouring myometrium (Figure 6.4, p=0.12); placenta
(Figure 6.5, p=0.29); amnion (Figure 6.6, p=0.10) and chorio-decidua (Figure 6.7,
p=0.29).
When expression was compared in the non-labouring tissues, relative mRNA
expression of ANXA1 was greater in placenta (median fold change of 4.2) and
amnion (median fold change of 3.5) than in myometrium (p<0.0001, Fig 6.8).
When expression was compared in labouring tissue, relative mRNA expression of
ANXA1 was greater in placenta and amnion than it was in myometrium (median fold
changes 4 and 4.3 respectively) and in chorio-decidua (median fold changes 2.1 and




Figure 6.4 ANXA1 mRNA expression in myometrium
Relative mRNA expression ofANXA1 is not significantly different in labouring
compared to non-labouring myometrium. Data are presented as medians and inter¬





















Figure 6.5 ANXA1 mRNA expression in placenta
Relative mRNA expression ofANXA1 is not significantly different in labouring
compared to non-labouring placenta. Data are presented as medians and inter-quartile


























Figure 6.6 ANXA1 raRNA expression in amnion
Relative mRNA expression ofANXA1 is not significantly different in labouring
compared to non-labouring amnion. Data are presented as medians and inter-quartile


























Figure 6.7 ANXA1 mRNA expression in chorio-decidua
Relative mRNA expression ofANXA1 is not significantly different in labouring
compared to non-labouring chorio-decidua. Data are presented as medians and inter¬
quartile ranges with min and max whiskers; n=l 1 in each group; p=0.29, Mann-
Whitney test.
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Figure 6.8 ANXA1 mRNA expression in non-labouring tissues
Relative mRNA expression ofANXA1 is greater in non-labouring (NL) placenta and
amnion than in myometrium. Data are presented as medians and inter-quartile ranges





Figure 6.9 ANXA1 mRNA expression in labouring tissues
Relative mRNA expression ofANXA1 is greater in labouring (L) placenta and
amnion than in myometrium and chorio-decidua. Data are presented as medians and
inter-quartile ranges with min and max whiskers. Friedman test (p<0.0001) with
Dunns post-test comparison. ***p<0.001, *p<0.05
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6.3.3. Relative mRNA expression of FPR1 was greater in
labouring than in non-labouring myometrium, placenta,
amnion and chorio-decidua
Relative mRNA expression of FPR1 was greater in labouring myometrium
(p=0.0002, Fig 6.10), placenta (p=0.007, Fig 6.11), amnion (p=0.018, Fig 6.12) and
chorio-decidua (p=0.0005, Fig 6.13) when compared with non-labouring tissue of the
same type. Fold changes of the median values were 10.9, 3, 4.3 and 26.2
respectively. Thus the most pronounced fold changes were seen in myometrium and
chorio-decidua, as was the case for FPR2/ALX, as reported in Chapter 3.
In both non-labouring (Fig 6.14) and labouring tissues (Fig 6.15) there were no



























Figure 6.10 FPR1 mRNA expression in myometrium
Relative mRNA expression of FPR1 is significantly greater in labouring compared to
non-labouring myometrium (median fold change 10.9). Data are presented as

























Figure 6.11 FPR1 mRNA expression in placenta
Relative mRNA expression of FPR1 is significantly greater in labouring compared to
non-labouring placenta (median fold change 3). Data are presented as medians and





























Figure 6.12 FPR1 mRNA expression in amnion
Relative mRNA expression of FPR1 is significantly greater in labouring compared to
non-labouring amnion (median fold change 4.3). Data are presented as medians and




















Figure 6.13 FPR1 mRNA expression in chorio-decidua
Relative mRNA expression of FPR1 is significantly greater in labouring compared to
non-labouring chorio-decidua (median fold change 26.2). Data are presented as













Figure 6.14 FPR1 mRNA expression in non-labouring tissues
Relative mRNA expression of FPR1 was not significantly different in the four non-
labouring (NL) tissues of myometrium, placenta, amnion and chorio-decidua. Data
are presented as medians and inter-quartile ranges with min and max whiskers.










Figure 6.15 FPR1 mRNA expression in labouring tissues
Relative mRNA expression of FPR1 was not significantly different in the four
labouring (L) tissues ofmyometrium, placenta, amnion and chorio-decidua. Data are
presented as medians and inter-quartile ranges with min and max whiskers. Friedman
test with Dunns post-test comparison.
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6.3.4. Relative mRNA expression of 11pHSD1 did not differ in
labouring and non-labouring myometrium, placenta,
amnion and chorio-decidua
mRNA expression of 1 lpHSDl was detected in all of the studied tissues. There were
no significant differences in relative mRNA expression of 1 lpHSDl in labouring
and non-labouring myometrium (Fig 6.16), placenta (Fig 6.17), amnion (Fig 6.18)
and chorio-decidua (Fig 6.19).
Relative 11PHSD1 expression was greater in chorio-decidua than in placenta and





Figure 6.16 lipHSDl mRNA expression in myometrium
Relative mRNA expression of 1 lpHSDl is not significantly different in labouring
compared to non-labouring myometrium. Data are presented as medians and inter¬





Figure 6.17 lipHSDl mRNA expression in placenta
Relative mRNA expression of 1 lpHSDl is not significantly different in labouring
compared to non-labouring placenta. Data are presented as medians and inter-quartile
























Figure 6.18 lipHSDl mRNA expression in amnion
Relative mRNA expression of 1 lpHSDl is not significantly different in labouring
compared to non-labouring amnion. Data are presented as medians and inter-quartile
ranges with min and max whiskers; n=l 1 in each group; p=0.22, Mann-Whitney test.
Chorio-decidua
Figure 6.19 lipHSDl mRNA expression in chorio-decidua
Relative mRNA expression of 1 lpHSDl is not significantly different in labouring
compared to non-labouring chorio-decidua. Data are presented as medians and inter¬








Figure 6.20 lipHSDl mRNA expression in non-labouring tissues
Relative mRNA expression of 1 lpHSDl is greater in non-labouring (NL) chorio-
decidua than in placenta and amnion. Data are presented as medians and inter¬
quartile ranges with min and max whiskers. Friedman test (p<0.0001) with Dunns
post-test comparison. ***p<0.001
Figure 6.21 lipHSDl mRNA expression in labouring tissues
Relative mRNA expression of 1 lpHSDl is greater in labouring (L) chorio-decidua
than in placenta and amnion. Data are presented as medians and inter-quartile ranges
with min and max whiskers. Friedman test (p<0.0001) with Dunns post-test
comparison. ***p<0.001
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6.3.5. Relative mRNA expression of 11pHSD2 did not differ in
labouring and non-labouring myometrium, placenta,
amnion and chorio-decidua
mRNA expression of 11PHSD2 was detected in all of the studied tissues. There was
no significant difference in relative mRNA expression of 11(3HSD2 in labouring and
non-labouring myometrium (Fig 6.22), placenta (Fig 6.23), amnion (Fig 6.24) and
chorio-decidua (Fig 6.25).
Expression was greater in placenta than in myometrium, amnion and chorio-decidua,




















Figure 6.22 11PHSD2 mRNA expression in myometrium
Relative mRNA expression of 1 ipHSD2 is not significantly different in labouring
compared to non-labouring myometrium. Data are presented as medians and inter¬























Figure 6.23 lipHSD2 mRNA expression in placenta
Relative mRNA expression of 11PHSD2 is not significantly different in labouring
compared to non-labouring placenta. Data are presented as medians and inter-quartile





















Figure 6.24 lipHSD2 mRNA expression in amnion
Relative mRNA expression of 11PHSD2 is not significantly different in labouring
compared to non-labouring amnion. Data are presented as medians and inter-quartile


















Figure 6.25 11PHSD2 mRNA expression in chorio-decidua
Relative mRNA expression of 1 ipHSD2 is not significantly different in labouring
compared to non-labouring chorio-decidua. Data are presented as medians and inter¬
























Figure 6.26 lipHSD2 mRNA expression in non-iabouring tissues
Relative mRNA expression of 11PHSD2 is greater in non-labouring (NL) placenta
than in myometrium, amnion and chorio-decidua. Data are presented as medians and
inter-quartile ranges with min and max whiskers. Friedman test (p<0.0001) with


























Figure 6.27 lipHSD2 mRNA expression in labouring tissues
Relative mRNA expression of 1 ipHSD2 is greater in labouring (L) chorio-decidua
than in placenta and amnion. Data are presented as medians and inter-quartile ranges
with min and max whiskers. Friedman test (p<0.0001) with Dunns post-test
comparison. ***p<0.001, **p<0.01
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6.3.6. Treatment of myometrial explants with Cortisol for 6 or
24 hours did not significantly alter relative mRNA
expression of ANXA1 compared to vehicle
There was no significant difference in relative mRNA expression ofANXA1 in
myometrial explants treated for 6 hours with Cortisol, at concentrations from 10"9M
to 10"6M, or with vehicle, (Fig 6.28).
Treatment with the highest dose of Cortisol (10"6M) for 24 hours also had no effect on







Figure 6.28 ANXA1 mRNA expression in myometrial explants, 6 hour culture
Relative mRNA expression ofANXA1 was not significantly different in myometrial
explants treated with Cortisol (range of concentrations 10~9 to 10"6M) compared to
vehicle. Myometrial explants treated for 6-8 hours at 37°C in room air. Data are





Figure 6.29 ANXA1 mRNA expression in myometrial explants, 24 hour culture
Relative mRNA expression ofANXA1 was not significantly different in myometrial
explants treated with 10"6M Cortisol for 24 hours compared to vehicle. Myometrial
explants treated for 24 hours at 37°C in room air. Data are presented as means
+SEM; n=5, paired t-test, p=0.81.
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6.3.7. Treatment of myometrial explants with Cortisol for 6
hours upregulated relative mRNA expression of both
FPR1 and FPR2/ALX
Treatment with Cortisol at a concentration of 10"6M for 6 hours upregulated the
mRNA expression of FPR2/ALX in myometrial explants compared to treatment with
vehicle (Fig 6.30) (n=5, Friedman test, p=0.0028, with Dunn's multiple comparison
test, p<0.05, relative mean fold change 16.5). Statistically significant different
relative levels were also observed when comparing the lowest dose of 10"9M with the
highest dose of 10"6M (n=5, Friedman test, p=0.0028, with Dunn's multiple
comparison test, p<0.05, relative mean fold change 15.3). At lower doses, ranging
from 10"9M to 10"7M, there was no significant difference in relative expression
between cortisol-treated explants from those treated with vehicle.
There was a trend towards increased relative mRNA expression of FPR2/ALX (Fig
6.31) in myometrial explants treated with 10"6M Cortisol for 24 hours compared with
treatment with vehicle. However, this did not quite reach statistical significance
(n=5, paired t-test, p=0.07).
Since the effect of Cortisol on FRP2/ALX expression was only observed at 10~6M
concentration, I subsequently investigated the effect of this dose of Cortisol on FPR1
mRNA expression. Treatment with 10"6M Cortisol for 6 hours upregulated the mRNA
expression of FPR1 in myometrial explants compared with treatment with vehicle
(Fig 6.32) (n=5, paired t-test, P=0.04, relative mean fold change 7.4). There was a
trend towards increased relative mRNA expression of FPR1 (Fig 6.33) in myometrial
explants treated with 10"6M Cortisol for 24 hours compared with treatment with
vehicle. However, this did not quite reach statistical significance (n=5, paired t-test,
p=0.06).
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Figure 6.30 FPR2/ALX mRNA expression in myometriai explants, 6 hr culture
Relative mRNA expression of FPR2/ALX was greater in myometriai explants treated
with Cortisol at a dose of 10~6M for 6 hours than in explants treated with vehicle
(relative mean fold change 16.5). Treatments ofCortisol at a dose of 10"7M or lower
did not result in significantly different expression levels. Explants were cultured for
6-8 hours at 37°C in room air. Data are presented as means +SEM; n=5; p=0.0028,
Friedman test with Dunn's multiple comparison test, *p<0.05.
Treatment
Figure 6.31 FPR2/ALX mRNA expression in myometriai explants, 24 hr culture
Relative mRNA expression of FPR2/ALX was not significantly different in
myometriai explants treated with 10-6M Cortisol for 24 hours compared to treatment
with vehicle. Myometriai explants were treated for 24 hours at 37°C in room air.




Figure 6.32 FPR1 mRNA expression in myometrial explants, 6 hour culture
Relative mRNA expression of FPR1 was greater in myometrial explants treated with
Cortisol at a dose of 10"6M than in explants treated with vehicle for 6 hours (relative
mean fold change 7.1). Explants were cultured for 24 hours at 37°C in room air. Data
are presented as means +SEM; n=5; p=0.04, paired t-test.
Figure 6.33 FPR1 mRNA expression in myometrial explants, 24 hour culture
Relative mRNA expression of FPR1 was not significantly different in myometrial
explants treated with Cortisol 10"6M compared to vehicle, when treated for 24 hours.
Myometrial explants treated for 24 hours at 37°C in room air. Data are presented as
means +SEM; n=5, paired t-test, p=0.06.
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6.4. DISCUSSION
The work in this chapter demonstrates that:
• mRNA and protein expression ofANXA1 was detectable in human term
pregnant myometrium, placenta, amnion and chorio-decidua.
• Immunohistochemistry localised the ANXA1 protein to myocytes,
endothelial cells and neutrophils in myometrium, and to syncytiotrophoblasts
and endothelial cells in placenta.
• There was no significant difference in relative expression ofANXA1 mRNA
in labouring myometrium, placenta, amnion or chorio-decidua than in non-
labouring samples.
• mRNA expression of the receptor FPR1 was also detectable in myometrium,
placenta, amnion and chorio-decidua and relative mRNA levels were
increased in labouring tissue when compared to non-labouring tissue. This
finding is in concert with the observation made in Chapter 3 that the
FPR2/ALX receptor was upregulated in labouring tissues.
• 1 lpHSDl and 11PHSD2 mRNA was expressed in human term pregnant
myometrium, placenta, amnion and chorio-decidua, and there was no
significant difference in relative expression of these genes in labouring
myometrium, placenta, amnion or chorio-decidua than in non-labouring
samples.
• Treatment ofmyometrial explants with Cortisol for 6 hours did not
significantly alter relative mRNA expression ofANXA1 compared to
vehicle.
• Treatment ofmyometrial explants with Cortisol for 6 hours upregulated
relative mRNA expression of both FPR1 and FPR2/ALX.
In myometrium, I showed that ANXA1 localised to myocytes, neutrophils and
endothelial cells surrounding the blood vessels. Strongest staining was seen in the
neutrophils and vascular endothelial cells. This pattern of staining was observed in
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both labouring and non-labouring tissues, although in labouring tissues there were
increased numbers of invading neutrophils.
In placenta, I showed that ANXA1 localised to the syncytiotrophoblasts, with the
strongest staining in the brush border contacting the maternal circulation. Staining
was also observed in the cells surrounding the blood vessels and in neutrophils.
Similar findings were reported by Sun et al, who also reported no observable
difference in distribution between labouring and non-labouring tissues (Sun et al.
1996).
In fetal membranes, ANXA1 localised to the amnionic epithelial cell layer, to the
chorionic mesoderm and to trophoblastic cells. The immunohistochemical techniques
reported here do not allow comment on changes in concentration or expression levels
of the protein or its RNA; only on distribution, but expression levels ofmRNA
determined by quantitative RT-PCR are discussed below.
In this study, relative expression ofANXA1 mRNA was not different in labouring
myometrium, placenta, amnion or chorio-decidua compared to non-labouring tissues
of the same kind. Previous investigators have reported different findings regarding
expression ofANXA1 in the placenta and fetal membranes, as I shall now discuss.
Myatt's group used Northern and Western blots to quantify mRNA and protein levels
in amnion (Lynch-Salamon et al. 1992), and protein levels in chorion (Myatt et al.
1992). They found that levels ofANXA1 mRNA were significantly reduced in
amnion after labour, and that protein levels were correspondingly reduced in both
amnion and chorion following labour. However, Bennett et al, again using Northern
blotting, reported a decrease in total RNA expression ofANXA1 in labouring
amnion and placenta, but an increase in labouring chorio-decidua (Bennett et al.
1994). They also looked at annexin 2, which was increased only in labouring amnion
and at phospholipase A2 and annexin 5, both ofwhich demonstrated no difference in
the labouring and non-labouring tissues. There are therefore some contradictions
between these data, and between them and the results in my study. It may be that
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discrepancy between this published work and my study reflects differences
encountered when using the older technique of Northern blotting to look at RNA
expression, whereas my study has used the more sensitive technique of quantitative
RT-PCR.
There was also a difference in the timings of when samples were collected in the
previously reported studies. Both Bennett's and Myatt's studies compared placentae
taken at elective caesarean section (pre-labour) and placentae delivered vaginally
(post-labour) whereas our study compares placentae taken at elective caesarean
section (pre-labour) or at emergency caesarean section (during labour). Thus we have
compared pre-labour tissue with tissue in the second stage of labour, whereas the
other work compare pre-labour tissue with tissue sampled after completion of the
third stage of labour (Lynch-Salamon et al. 1992; Myatt et al. 1992; Bennett et al.
1994). Clearly the function of the placenta and membranes varies greatly during the
second and third stage of labour. During the second stage the placenta is still
adherent to the uterine wall and is exchanging oxygen, CO2 and other metabolites
between the maternal and fetal circulations. During the third stage the fetus is no
longer dependent on the placenta for oxygen and is indeed often detached from the
placenta, and the placenta detaches from the uterine wall and is expelled. The
function of the uterus also changes dramatically at completion of the third stage. It is
then required to expel the placenta and membranes and change from producing
regular contractions to achieving a tonic contraction which involutes the organ,
constricts spiral vessels and limits postpartum haemorrhage. It may be therefore that
the differences in the reported results actually reflect differences in the expression of
ANXA1 between the second stage and completion of the third stage. Given that the
previously published work has used different laboratory techniques to this work, it
would be interesting to use our quantitative RT-PCR technique to compare vaginally
delivered tissue with the current groups already studied.
In addition to their findings in RNA, Lynch-Salamon et al also reported a reduction
in protein levels ofANXA1 in post-delivery amnion when compared to pre-labour
amnion (Lynch-Salamon et al. 1992). My study has not examined protein levels of
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ANXA1, although this would be an interesting subsequent study, as it may be that
mRNA levels are not necessarily representative of the protein levels. Furthermore,
levels of protein do not necessarily reflect activation status of the protein i.e. the
tissue may contain protein that has not been mobilised to the cell surface and is
currently not available to bind to the receptor.
PMNs contain high levels ofANXA1 (Perretti et al. 2000), with an estimated 2-4%
protein content represented by ANXA1. A large proportion of this is contained in
granules or vesicles (Perretti et al. 1996; Perretti et al. 2000) and upon activation and
adhesion of the PMN the protein is mobilised to the membrane compartment and the
cell surface (Perretti et al. 2000). Thus, given that parturition is heralded by an influx
of neutrophils into myometrium (Thomson et al. 1999), it could be expected that
increased levels ofANXA1 might have been observed. Although in the
immunolocalisation studies presented here the strongest staining was to be seen in
PMNs, there was also staining throughout the myocytes. Even if increased numbers
of neutrophils did produce increased amounts of ANXA1, it may be that the
background level ofANXA1 represented by production from myocytes was
sufficient to mask any increase represented by the invading neutrophils. The data
presented in this chapter looks at the expression ofmRNA levels ofANXA1, and
this may not be representative of either protein levels or indeed active levels of
protein.
Ultimately therefore, whilst it is interesting that labour does not appear to upregulate
de novo synthesis ofANXA1 in reproductive tissues, further work is necessary to
clarify what actual levels of active and available ANXA1 protein may be present
either in circulating blood, or locally in the reproductive tissues in labour. Currently
within our laboratory, work is underway to develop an assay to determine ANXA1
levels, and this will no doubt produce interesting future data. Given the discussion
regarding location ofANXA1 expression and whether or not any increase in levels
may be contributed by myocytes, or whether expression is overwhelmingly
neutrophilic in origin, fluorescence-activated cell sorting (FACS) may help in
answering this question. FACS is a technique by which different types of cell are
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sorted based upon their individual fluorescent and light scattering characteristics.
Thus a sample of tissue could be analysed by FACS using markers to identify the cell
types, for example, myocytes and neutrophils, and other fluorescent markers to
demonstrate the presence or absence ofANXA1 within the different cell groups.
Labouring and non-labouring tissues could then be compared to determine in which
cell type, if any, differences in ANXA1 protein expression could be observed. Again,
this work was outwith the scope of this project, but will be interesting in future work.
As reported in Chapter 3 of this thesis, the FPR2/ALX receptor is upregulated in
human labour. Thus, ANXA1 may have a role in labour via increased availability of
its receptor, even in the absence of increased levels of the ligand. Whilst full-length
ANXA1 has been demonstrated to signal exclusively through FPR2/ALX (Walther et
al. 2000; Hayhoe et al. 2006), the short peptides which are cleavage products of
ANXA1 signal through both FPR2/ALX and the closely related receptor FPR1
(Hayhoe et al. 2006). Thus, we also looked at mRNA expression levels of FPR1 in
the same samples as those which had demonstrated an increase in FPR2/ALX mRNA
in labour, to see if this finding was matched for FPR1.
FPR1 mRNA expression was upregulated in labour in myometrium, placenta,
amnion and chorio-decidua with median fold changes of 10.9, 3, 4.3 and 26.2
respectively. This finding mirrors the finding discussed in Chapter 3 in which the
FPR2/ALX receptor is also upregulated in the same samples, demonstrating an
upregulation of the whole system. FPR1 and FPR2/ALX are closely related and both
have been demonstrated to be upregulated by glucocorticoids (Sawmynaden and
Perretti 2006; Ehrchen et al. 2007), thus it is interesting to note a similar response by
both receptors to labour. Although we have not demonstrated evidence that there are
increased levels ofANXA1 in labour, there is certainly upregulation ofboth of the
receptors through which it and its cleavage peptides signal, thus providing a potential
mechanism by which its effects may be amplified.
Both FPR1 and FPR2/ALX are promiscuous receptors and have a number of
different reported ligands, both agonists and antagonists, in addition to LXA4 and
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ANXA1 (Ye et al. 2009), which have been studied in this work. Indeed, although
both LXA4 and ANXA1 induce anti-inflammatory and pro-resolution effects when
signalling through FPR2/ALX, there are also ligands which induce pro-inflammatory
effects (Ye et al. 2009). For example, the acute-phase protein serum amyloid A
(SAA) has been reported in neutrophils to induce the secretion of IL-8 by signalling
through FPR2/ALX (He et al. 2003). It could be that a number of ligands compete
for binding of FPR2/ALX during parturition and the effect of FPR2/ALX ligand
interaction will be crucially dependent on the nature of that ligand.
6.4.1.The effect of Cortisol on the ANXA1-FPR1/2 system
The data in this thesis have demonstrated detectable mRNA levels ofboth 1 lpHSDl
and 11PHSD2 in myometrium, placenta, amnion and chorio-decidua. 1 lpHSDl was
most highly expressed in chorio-decidua, whilst 11PHSD2 was most highly
expressed in placental tissue. When comparing labouring tissue with non-labouring
tissue of the same type, there were no significant differences seen. High levels of
placental 11PHSD2 are well documented in the literature, and it is thought this is a
protective measure to convert Cortisol to the inactive cortisone to reduce exposure of
the fetus to high levels ofmaternal Cortisol, thus shielding it from its potentially
deleterious effects. Similarly, it has been shown that the fetal membranes express
high levels of 1 lpHSDl and the theory has been put forward that the subsequent
local control of Cortisol levels may be involved in the process of parturition.
1 lpHSDl protein has previously been shown to be found in placenta (Pepe et al.
1999), amnion and chorio-decidua (Sun et al. 1997; Pepe et al. 1999; Alfaidy et al.
2003) using immunohistochemical techniques and western blotting, with western
blotting demonstrating higher levels of protein in the amnion and chorion than in the
placenta (Alfaidy et al. 2003). Sun et al observed no differences in strength of
immunohistochemical staining between labouring and non-labouring placenta,
amnion and chorion (Sun et al. 1997), but later work from the same group found that
Western analysis found more 1 lpHSDl in labouring amnion and chorion than in
their non-labouring counterparts, although this was only significant in amnion
(Alfaidy et al. 2003). 1 lpHSDl increases in both protein levels and activity in fetal
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membranes with advancing gestation, but there is no gestational-age related change
in placenta (Alfaidy et al. 2003). The work reported from my study is broadly in
agreement with previously published work in that mRNA for 1 lpHSDl has been
demonstrated to be found in placenta, amnion and chorio-decidua, with much higher
levels in chorio-decidua than in placenta. In contrast, my samples demonstrated
mRNA levels in amnion to be more similar to those in placenta than in chorio-
decidua, whereas other reports describe similar levels in amnion and chorion
(Alfaidy et al. 2003). This may be a reflection of the different analyses (western vs
quantitative RT-PCR), or it may be a reflection of the variation in individual
samples. Our samples showed large variation in mRNA expression between
individual samples in the fetal membranes, and this is also observed by other
researchers (Sun et al. 1997). The fetal membranes are acknowledged to have widely
varying enzyme expression and activity in differing areas of the same membrane (El
Khwad et al. 2005). This may be particularly relevant when considering their
production of PGDH, the enzyme that degrades prostaglandins (Cheung et al. 1990),
because prostaglandins also modulate 1 lpHSDl levels (Alfaidy et al. 2003). The
work presented here has focused on mRNA expression and attempted to explore any
differences between labouring and non-labouring tissues. In concordance with most
of the published data on protein levels, I observed no differences between labouring
and non-labouring 1 lpHSDl. Thus, it would appear that although 1 lpHSDl
increases towards term (Alfaidy et al. 2003), which may have an influence on local
Cortisol production towards the end of gestation, this influence is not acutely altered
during labour itself. Little data is published on the expression of 1 lpHSDl in
myometrium, and my data has shown that there is indeed mRNA expression of this
enzyme in both labouring and non-labouring myometrium, although, as for the other
studied tissues, no difference in parturition is seen. However, expression levels of
1 lpHSDl mRNA in myometrium were low in comparison to that seen in chorio-
decidua, being more similar to those observed in amnion and placenta, suggesting
therefore that myometrium is a much less important site for local control of Cortisol
levels than the fetal membranes.
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11PHSD2 is found in abundance in placenta (Krozowski et al. 1995; Sun et al. 1997;
Pepe et al. 1999), and this finding was also true in my samples, with significantly
larger expression in placenta than in any other tissues. Sun et al detected 11(3HSD2
mRNA by Northern blot analysis in placenta, but not in amnion or chorion (Sun et al.
1997), therefore my work showing its presence in amnion, chorio-decidua and
myometrium, is contrary to that. Certainly the levels were much lower than those
shown in placenta and it is likely that the main site of action is indeed in the placenta.
The differential distribution of the 1 lpHSD enzymes in the feto-maternal unit in term
pregnancy are likely to provide a mechanism by which local concentrations of
Cortisol may be controlled. Relevant functional consequences already described
include shielding of the fetus from excess glucocorticoid and potential influences on
prostaglandin production during parturition, and a further consequence may be the
effect that altered Cortisol levels may have on ANXA1, its production, release and
activity during pregnancy and parturition.
In the study reported here, Cortisol did not affect ANXA1 mRNA expression in
myometrial explants, a finding which is supported by the observation that ANXA1
mRNA was not upregulated in labour, a state in which Cortisol levels are increased.
Zhang et al report that whilst Cortisol upregulates ANXA1, as determined by
immunoblotting, the upregulation is weak in comparison to the upregulation seen
with more potent glucocorticoids such as betamethasone and dexamethasone (Zhang
et al. 2010). It would be interesting to repeat my experiment with other
glucocorticoids, particularly since both betamethasone and dexamethasone are used
clinically in administration to mothers in threatened preterm labour to aid maturation
of the fetal lung. Despite there being no change in measurable mRNA levels of
ANXA1 in myometrial explants with Cortisol treatment, mRNA levels of both
receptors, FPR1 and FPR2/ALX were significantly upregulated by treatment with
Cortisol. Again, this mirrors the upregulation demonstrated in labouring tissues and
may provide a mechanism by which the effects ofANXA1 may be amplified.
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6.4.2.Conclusions
A diagrammatic representation of the interactions between Cortisol, the FPRs and
ANXA1 and its N-terminal peptides is illustrated in Figure 6.34.
ANXA1 mRNA expression is unchanged in myometrium, placenta, amnion and
chorio-decidua in labour, although the mRNA expression of the receptors FPR1 and
FPR2/ALX are increased. Thus there is a potential role for ANXA1 in the process of
parturition via increased expression of the receptors and thus increased activity of
ANXA1.
In other systems, the main described functions ofANXA1 essentially focus on an
effect on neutrophil trafficking, by reducing neutrophilic invasion into a site of
inflammation (Perretti et al. 1996), by promoting their apoptosis (Solito et al. 2003)
and promoting clearance of apoptotic cells by macrophages (Scanned et al. 2007). In
labour, there is an influx ofneutrophils into the myometrium and cervix that produce
pro-inflammatory cytokines, which are felt to be one of the driving forces of the
complex process of parturition. To what end would it be beneficial for this process to
be opposed? It may be that the role ofANXA1 lies within the resolution of this
inflammatory process; in ensuring that when labour is over the uterus is able to
return to its pre-labour and pre-pregnancy state. Alternatively ANXA1 may have a
role during pregnancy itself in ensuring that mild inflammatory insults are
neutralised and resolved without escalating into an inflammatory process that results
in labour. Further work exploring ANXA1, its N-terminal peptides and FPR1&2
levels during pregnancy and in pre-term labour may help provide clues as to whether
this theory is valid. It would also be interesting to expose ANXA1 null mice to LPS
and observe what effect this has. Researchers in our laboratory investigating fetal
white matter damage use a rat model in which a mild insult of LPS is administered
not sufficient to initiate preterm labour, but which results in lower birth weight pups
and possible white matter injury (personal communication, Dr E Pilley, Clinical
Research Fellow, University of Edinburgh). Similar mouse models have been shown
to alter gene expression in the brains of exposed offspring (Elovitz et al. 2011). Such
a model could be used to compare ANXA1 null animals with wild type animals with
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the hypothesis that ANXA1 null animals would be more likely to labour prematurely
and more likely to have poorer observable outcomes for the offspring.
Ultimately, there is much more that needs to be discovered about the potential role of
ANXA1 in pregnancy and parturition. It seems likely that in the future, therapeutic
agents for preterm labour, will take a multitude of approaches and that anti¬
inflammatory agents may well a vital part of that approach, both to moderate the
inflammatory process that has been initiated and to protect the fetal brain from the




Diagrammatic representation of the interactions between the cortisone-cortisol
shuttle, the formyl peptide receptors and ANXA1 and its N-terminal fragment
peptides.
The production of the active Cortisol from its inactive form cortisone is controlled by
the 1 lpHSD enzymes in the cortisone-cortisol shuttle. There is likely to be control of
local Cortisol levels within the feto-placental unit by these enzymes. Cortisol
upregulates FPR2/ALX and FPR1, through which ANXA1 and its N-terminal
fragment peptides signal. Increased availability of the receptors may provide a




7.1. SUMMARY OF FINDINGS
Preterm and dysfunctional term labour present a significant and ongoing burden to
the health ofwomen and infants worldwide, and we currently lack truly effective
interventions to treat and control these conditions. Human labour is an inflammatory
condition and so better understanding of the inflammatory processes that initiate and
promote term and preterm labour are vital to the development of new therapies to
treat abnormal labour. This thesis examined the role ofpro-resolution mediators in
human pregnancy and parturition, specifically lipoxin A4 and Annexin Al, both of
which signal through the same receptor, FPR2/ALX. The main findings of this work
are summarised below.
• Circulating levels of LXA4 are increased in pregnancy compared to non-
pregnancy, increasing to term, after which there is no further increase
(Chapter 3).
• mRNA expression of FPR2/ALX is greater in the reproductive tissues of the
during labour compared to pre-labour (Chapter 3).
• LPS evokes an inflammatory response in pregnant myometrium that has
similarities to the inflammatory signature of parturition (Chapter 4).
• Hypoxic culture ofmyometrial explants has no effect on myometrial
production ofLXA4 , but possibly may influence expression of FPR2/ALX
(Chapter 5).
• mRNA expression ofANXA1 is not different in labour compared to non-
labour in reproductive tissues and is not affected by Cortisol treatment in a
myometrial explant model (Chapter 6).




The pro-resolution effects of LXA4 are relatively recently described and much is yet
to be learnt about its effects in the reproductive system. It is highly likely that LXA4
has a role within pregnancy because circulating levels are higher in pregnancy and
remain so right up until delivery. Pregnant women are in a state of
immunosuppression in order to allow tolerance of the fetal allograft. They are
therefore at increased risk of infection, which presents an increased risk ofpreterm
labour. Even if infection is insufficient to cause preterm labour, increasing evidence
is emerging that an inflammatory state can cause significant permanent damage to
the developing fetus, even when the inflammatory response has been insufficient to
cause preterm labour (Elovitz et al. 2011). Thus a delicate balance must be struck by
the immune system, to provide vigilant suppression of any invading pathogen and
inflammatory insult to protect the mother and reduce the risk of preterm labour,
whilst at the same time, not responding so avidly to infection or inflammation that
preterm labour initiates inappropriately or the fetus is exposed to an excessively
inflammatory and damaging environment. It is possible that the role of both LXA4
and ANXA1 within pregnancy is that of a 'checkpoint' and that increased levels of
LXA4 in pregnancy are required to act as a braking signal for inappropriate
inflammation.
LXA4 levels are not increased during labour, and the data presented in this thesis
suggest that levels may even fall in the days preceding labour, which would fit with
the concept of the brake being eased off and the cascade of inflammation being
allowed to proceed and labour to initiate. The upstream signalling pathways that
might provoke increased production of LXA4 in pregnancy and potentially
contribute to any reduction as the 'brake' is eased off towards delivery are unknown.
Further work to elucidate the nature of such pathways may provide important clues
towards what initiates labour itself. As discussed in the Introductory chapter of this
thesis, although labour is primarily an inflammatory process, there are complex
interactions with other systems, particularly the endocrine system. Estrogen,
progesterone and CRH in particular have intricate crosstalk with the immune system
and it would be very interesting to examine their interactions with pro-resolution
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mediators. Functional genomics are an exciting way in which many different aspects
of signalling and function of a process can be explored and it was somewhat
disappointing that the microarray performed in the work for this thesis was unable to
give any answers regarding potential pathways involving LXA4 due to the
contamination of the LXA4 used. Certainly the pathways displayed by treating with
LPS provide insights to the type of inflammatory pathways that may prove to be
worthy targets for reducing inappropriate inflammation in myometrial tissue in
pregnancy. Future work may include repeating a similar experiment with an
alternative source of LXA4 that has been demonstrated to have functional effects in
myometrium.
Most of the work in this thesis has focused on working with samples gathered from
women at term in their pregnancy. Term and preterm labour are of course similar
processes, but they are not identical. However, an understanding of the processes of
term labour is important to also understand why it is that some pregnancies do not
proceed to term. The work presented here has produced some data from which it
would be interesting to extrapolate to samples collected from women either at risk of
preterm labour or actually in preterm labour. Specifically, future work may include
examining longitudinal samples taken from women during pregnancy who are at low
or high risk of preterm labour, looking at levels of pro-resolution mediators and the
expression of the relative receptors. Inevitably in any population ofwomen recruited
in early pregnancy, some women would labour preterm, and more information about
pro-resolution mediators in this process could provide ways of developing either a




ANXAl expression does not appear to increase during labour, as is the case with
LXA4. However, recent published data have demonstrated that, also like LXA4,
expression is increased in pregnancy when compared to non-pregnancy (Macdonald
et al. 2011). Again, it may be that ANXAl provides a mechanism of restraint on
pregnancy, to allow quiescence of the feto-placental unit and to allow the fetus to
grow and develop until it is sufficiently mature to meet the outside world.
FPR2/ALX expression is increased in labour, as is the expression of FPR1 through
which short peptides related to ANXAl signal. Thus even though expression of
ANXAl appears to be unchanged in parturition, there is the potential for them to
have increased effect via increased expression of the receptor. However, functional
effects of LXA4 or ANXAl due to the increased FPR2/ALX have not been
demonstrated. FPR2/ALX and FPR1 are both promiscuous receptors and both have
the ability to bind with both pro- and anti-inflammatory ligands (Ye et al. 2009). For
example, FPR2/ALX binds with serum amyloid A, an acute phase protein which has
powerful pro-inflammatory effects. It is not known to what extent FPR2/ALX has
preferential binding toward pro- or anti-inflammatory ligands in the reproductive
system or whether this changes during pregnancy or parturition. It may be that an
increase in expression of the receptor allows increased anti-inflammatory or pro-
resolution effects despite unchanged absolute levels of the pro-resolution ligands, or
it may be that as the overwhelming inflammatory cascade of labour commences,
LXA4 and ANXAl have a less and less significant effect and increased levels of the
receptor serve actually to promote the effects of pro-inflammatory ligands.
Colleagues in our laboratory have begun to explore the effects of pro-inflammatory
ligands of FPR2/ALX in the reproductive system and future work may include
examining competition for binding at the receptor by the different ligands, whether
or not this is important in parturition, and if so, whether or not this can be
manipulated to the advantage of controlling the onset of labour.
ANXAl is known already to be affected by glucocorticoids, and although levels
were not affected in the explant experiment reported in this thesis, levels of both
FPR2/ALX and FPR1 were, thus providing a mechanism by which ANXAl may
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have an altered effect. The glucocorticoid used was Cortisol, an endogenous steroid,
although exogenously administered steroids such as betamethasone and
dexamethasone have been reported to have much more potent effects on ANXA1
than Cortisol (Zhang et al. 2010). Future work may include exploring whether this is
also the case in the reproductive system. The importance of this is that powerful
glucocorticoids like betamethasone and dexamethasone are already in clinical use
and are administered to women at risk of preterm labour as they have been
demonstrated to have a highly beneficial effect in reducing the incidence of
cerebroventricular haemorrhage, necrotising enterocolitis, respiratory distress
syndrome and neonatal death (Roberts and Dalziel 2006). However, antenatally
administered steroids also been shown to have detrimental effects, having been
linked to intrauterine growth restriction (Seckl 2004). A clearer picture of the
functional effects of glucocorticoid-regulated ANXA1 would seem very important to
help guide our use of glucocorticoids antenatally.
Discussion so far has focused on the state of pregnancy and parturition. A vitally
important part of the whole process is of course resolution following delivery and a
return to the physiologically different state of non-pregnancy. Immediately after the
delivery of the infant comes delivery of the placenta, involution of the uterus and a
gradual return of the uterus to its pre-pregnant state. It may be that pro-resolution
mediators are involved in this process and that upregulation of their receptors during
labour is a reflection of the body preparing itself for the next part of the process so
that this may be carried out in a timely fashion to reduce complications of the post¬
partum period such as primary and secondary post-partum haemorrhage. Future work
may include studying samples from women in the post-partum period, monitoring
LXA4 and ANXA1 levels in the hours and days following delivery and using this




This thesis has provided novel findings regarding the role of pro-resolution mediators
in pregnancy and parturition. I hypothesised that the onset of parturition is influenced
not only by pro-inflammatory mediators, but also pro-resolution and anti¬
inflammatory mediators. The evidence presented in this thesis appears to support this
hypothesis. Circulating LXA4 protein levels were elevated in pregnancy, but fall
towards term, suggesting a 'brake' on inflammation during pregnancy that is eased
off as labour approaches. FPR1 and FPR2/ALX mRNA expression were increased
during labour. This represents a mechanism by which ANXA1 and LXA4 may have
increased effects to try and counteract the inflammatory cascade of labour. It may
also be that FPR2/ALX becomes increasingly available to pro-inflammatory
mediators, overwhelming the actions ofLXA4 and ANXA1.
Furthermore, I hypothesised that stimulation of non-labouring reproductive human
tissue by stress mediators such as lipopolysaccharide, hypoxia and Cortisol would
result in a rise in pro-resolution/anti-inflammatory mediators, in order to attenuate
the effect of the external stimulus and maintain the quiescent state of pregnancy. The
pro-inflammatory stimulants LPS and hypoxia did not result in an increase of
secreted LXA4 and mRNA expression of ALOX5 was attenuated by these stimuli.
No statistically significant effect was shown on FPR2/ALX and further work will
help to clarify the interactions between pro-inflammatory mediators and LXA4 and
ANXA1. Cortisol did not affect mRNA expression ofANXA1, but did upregulate
mRNA expression of FPR1 and FPR2/ALX, which could represent a mechanism by
which ANXA1 could have increased action, thus supporting this hypothesis.
The evidence presented suggests that the resolution of inflammation is important in
pregnancy and thus future work will aim to examine this role further to determine
what beneficial effects may be brought from it. Ultimately it would seem that
solutions for preterm and abnormal term labour will not focus on a mono-therapy,
such as an agent purely to halt preterm activity, but will comprise multi-faceted
approaches aiming to target the abnormal process from various angles. I hope and
believe that in the future we will be able to utilise the knowledge being gained from
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the study of pro-resolution mediators to devise novel strategies to treat preterm birth
and abnormal labour at term, and thus reduce the tremendous burden of these
disorders on women and their infants.
Figure 7.1
Diagrammatic Representation of Conclusions
This figure represents the 'balance' between pregnancy and labour tipping towards
labour. LXA4 levels increase during pregnancy, falling towards the end of gestation,
suggesting a pro-pregnancy effect. Labour and Cortisol result in increased expression
of FPR2/ALX. This represents a mechanism by which ANXA1 and LXA4 may have
increased effects to try and counteract the inflammatory cascade of labour. It may
also be that FPR2/ALX becomes increasingly available to pro-inflammatory
mediators, overwhelming the actions of LXA4 and ANXA1. The dashed line
between hypoxia and FPR2/ALX represents that the findings were not statistically
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Sources for all reagents and kits used in the experiments described in this thesis are
listed below.
TISSUE COLLECTION SOURCE
RPMI 1640 Culture medium Sigma-Aldrich, Poole, UK
10% Neutral Buffered Formalin See recipe Appendix 3
37% Formaldehyde Solution Sigma-Aldrich, Poole, UK
Phosphate Buffered Saline (PBS) Sigma-Aldrich, Poole, UK
RNAlater solution Qiagen, Crawley, W Sussex, UK
70% IMS See recipe Appendix 2
Starstedt Monvette blood tubes Starstedt AG & Co, Numbrecht,
Germany
TISSUE CULTURE SOURCE
RPMI 1640 Culture medium Sigma-Aldrich, Poole, UK
Penicillin/Streptomycin Invitrogen, Paisley, UK
Phosphate Buffered Saline (PBS) Invitrogen, Paisley, UK
24 well culture plates Corning, NY, USA
Lipopolysaccharide, from Salmonella
abortus equii
ALEXIS Biochemicals, AXXORA, San
Diego, CA




Absolute ethanol VWR International, Leuven, Belgium
Xylene Fisher Scientific, Loughborough, UK
Citrate buffer See recipe Appendix 2
Citric acid (monohydrate) Sigma-Aldrich, Poole, UK
Hydrogen peroxide VWR International, Leuven, Belgium
Methanol Fisher Scientific, Loughborough, UK
Tris Buffered Saline (TBS) See recipe Appendix 2
Tris(hydroxymethyl)methylamine VWR International, Belgium
Normal goat serum Sigma-Aldrich, Poole, UK
Phosphate Buffered Saline (PBS) See recipe Appendix 2
Bovine Serum Albumin Sigma-Aldrich, Poole, UK
NGS/PBS/BSA blocking serum See recipe Appendix 2
Avidin-Biotin block Vector Labs Inc, Burlinghame, CA, USA
Streptavadin-HRP Boehringer Ingelheim, Berks, UK
ImmPACT DAB substrate Vector Labs Inc, Burlinghame, CA, USA
Haematoxylin Sigma-Aldrich, Poole, UK
Scott's tap water See recipe Appendix 2
Sodium bicarbonate Sigma-Aldrich, Poole, UK
Magnesium sulphate Sigma-Aldrich, Poole, UK
Tyramide Signal Amplification Kits:
TSA™ -Plus Cyanine 3 System (Red)
TSA™ -Plus Fluorescien System
(Green)
Perkin Elmer Inc, Waltham, MA, USA
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DAPI Sigma-Aldrich, Poole, UK
Microscopy slides SuperFrost® Plus VWR International, Leuven, Belgium
Coverslips VWR International, Leuven, Belgium
Permafluor Thermoscientific, Rockford, IL, USA




Rabbit anti-FPR2/ALX Lifespan Biosciences, Seattle, USA
Goat anti-rabbit biotinylated Abeam, Cambridge, UK
Rabbit monoclonal IgG Abeam, Cambridge, UK
Mouse anti-AnnexinAl BD Biosciences, Oxford, UK
Goat anti-mouse biotinylated Abeam, Cambridge, UK
Mouse monoclonal IgG Abeam, Cambridge, UK
Mouse anti-neutrophil elastase Dako, Glostrup, Denmark
Goat anti-mouse peroxidase + Fab Abeam, Cambridge, UK
Goat anti-rabbit peroxidase + Fab Abeam, Cambridge, UK
QUANTITATIVE RT-PCR SOURCE
Trizol Sigma-Aldrich, Poole, UK
RNeasy columns Qiagen, Crawley, W Sussex, UK
Chloroform Sigma-Aldrich, St Louis, MO, USA
Ethanol VWR International, Leuven, Belgium
DNase digestion kit Qiagen, Crawley, W Sussex, UK
DNase free RNase free water Sigma-Aldrich, Irvine, UK
GeneAmp RNA PCR kit Applied Biosystems, Warrington,
Cheshire, UK




RT-PCR Mastermix used in ALOX12
and ALOX15 experiment, TaqMan Fast
Universal PCR Mastermix x2
Invitrogen, Paisley, UK
18S primers and probes mix Applied Biosystems, Warrington,
Cheshire, UK
TaqMan Fast optical PCR plates Applied Biosystems, Warrington,
Cheshire, UK
Adhesive optical films Applied Biosystems, Warrington,
Cheshire, UK
FPR2/ALX primers Eurogentec, Southampton, UK
ALOX5 primers Eurogentec, Southampton, UK
ALOX12 primers Eurogentec, Southampton, UK
ALOX15 primers Eurogentec, Southampton, UK
Universal Probe Library Probes Roche, Indianapolis, IN, USA
E-Selectin primers and probes Applied Biosystems, Warrington,
Cheshire, UK
CCL2 primers and probes Applied Biosystems, Warrington,
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Cheshire, UK
CSF3 primers and probes Applied Biosystems, Warrington,
Cheshire, UK
MMP1 primers and probes Applied Biosystems, Warrington,
Cheshire, UK
ICAM1 primers and probes Applied Biosystems, Warrington,
Cheshire, UK
FPR1 primers and probes Sigma-Aldrich, Poole, UK
ANXA1 primers and probes Sigma-Aldrich, Poole, UK
11PHSD1 primers and probes Applied Biosystems, Warrington,
Cheshire, UK
11BHSD2 primers and probes Applied Biosystems, Warrington,
Cheshire, UK
VEGF Eurogentec, Southampton, UK
LXA4 ELISA SOURCE
ELISA kit Neogen Corporation, Lexington, KY,
USA
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APPENDIX 2: RECIPES FOR SOLUTIONS
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All dilutions are in deionized water, unless otherwise stated.
0.1 M Citrate buffer
42.02g Citric Acid (monohydrate)
1900mls water
Made up to 2 litres and pH 6.0 adding concentrated NaOH as necessary.
Used at 0.01M, diluting in distilled water.
0.5M TRIS-HC1 stock x 10
121.14g Tris(hydroxymethyl)methylamine
1800mls water
Made up to 2 litres and pH 7.4, adding concentrated HC1 as necessary.
0.05M TBS
lOOmls 0.5M Tris-HCl (recipe above)
900mls water
8.5g Sodium Chloride
10 % Neutral Buffered Formalin
37% Formaldehyde Solution diluted 1 in 10 with 0.01M PBS
Phosphate buffered saline




20ml Normal Goat Serum
80 ml Phosphate Buffered Saline
5g Bovine Serum Albumin
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Scott's Tap Water
3.2g Sodium Bicarbonate (Sigma-Aldrich, Poole, Dorset, UK)
36. lg Magnesium Sulphate (Sigma-Aldrich, Poole, Dorset, UK)
lOOOmls water
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APPENDIX 3: LISTS OF UPREGULATED AND
DOWNREGULATED GENES, LPS vs VEHICLE
243
The following table lists all differentially expressed upregulated genes in the
comparison of LPS vs Vehicle from the microarray data reported in Chapter 4.





SELE E selectin 53.07 2.85E-13
CCL3 chemokine (C-C motif) ligand 3 27.07 3.51 E-13
CX3CL1 chemokine (C-X3-C motif) ligand 1 24.93 5.89E-13
CCL4L2 chemokine (C-C motif) ligand 4-like 2 21.19 1.81E-14
CCL3L1 chemokine (C-C motif) ligand 3-like 1 23.16 4.46E-12
LTB
lymphotoxin beta (TNF superfamily, member
3) 19.27 6.45E-13
CCL3L1 chemokine (C-C motif) ligand 3-like 1 19.23 4.76E-12
CCL3L3 chemokine (C-C motif) ligand 3-like 3 22.76 6.72E-11
ILIA interleukin 1, alpha 18.35 7.21E-12
1L1B interleukin 1, beta 42.50 5.96E-10
CCL20 chemokine (C-C motif) ligand 20 23.13 5.38E-10
TRAF1 TNF receptor-associated factor 1 7.79 1.18E-12
CSF3 colony stimulating factor 3 (granulocyte) 13.57 2.02E-10
TNFAIP2
tumor necrosis factor, alpha-induced protein
2 10.75 1.43E-10
CCL4L1 chemokine (C-C motif) ligand 4-like 1 10.01 1.07E-10
IL23A interleukin 23, alpha subunit pl9 22.73 6.81E-09
LTB
lymphotoxin beta (TNF superfamily, member
3) 6.93 8.49E-10
CCL8 chemokine (C-C motif) ligand 8 9.46 6.98E-09
GCH1 GTP cyclohydrolase 1 6.87 5.54E-09
ADORA2A adenosine A2a receptor 5.07 3.64E-10
SLC2A6
solute carrier family 2 (facilitated glucose
transporter), member 6 4.92 2.02E-10
C15orf48 chromosome 15 open reading frame 48 5.85 4.20E-09
CSF3 colony stimulating factor 3 (granulocyte) 17.63 2.51E-08
IL1RN interleukin 1 receptor antagonist 6.78 7.98E-09
TNFRSF4
tumor necrosis factor receptor superfamily,
member 4 4.95 8.38E-10
CCL3L1 chemokine (C-C motif) ligand 3-like 1 9.73 2.62E-08
CXCL2 chemokine (C-X-C motif) ligand 2 10.12 4.59E-08
TN1P1 TNFAIP3 interacting protein 1 3.94 2.30E-11
UBD ubiquitin D 12.39 5.35E-08
CFB complement factor B 6.38 2.24E-08
LIPG lipase, endothelial 6.35 2.44E-08
LIPG lipase, endothelial 4.44 7.06E-09
IL7R interleukin 7 receptor 5.26 3.23E-08
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colony stimulating factor 2 (granulocyte-
macrophage) 9.58 1.50E-07
NFKB2
nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/pl00) 3.42 2.94E-11
VCAM1 vascular cell adhesion molecule 1 8.90 1.39E-07
NFKB2
nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/pl00) 3.18 2.75E-13
G0S2 G0/G1 switch 2 6.41 6.50E-08
CITED4
Cbp/p300-interacting transactivator, with
Glu/Asp-rich carboxy-terminal domain, 4 4.78 4.58E-08
GPR84 G protein-coupled receptor 84 4.49 4.58E-08
IL32 interleukin 32 3.70 5.28E-09
IRAK2 interleukin-1 receptor-associated kinase 2 3.40 2.73E-09
ZC3H12A zinc finger CCCH-type containing 12A 4.09 3.64E-08
HCK hemopoietic cell kinase 3.27 8.49E-10
NFKBIE
nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, epsilon 3.66 9.23E-09
MEOX1 mesenchyme homeobox 1 3.73 1.85E-08
CXCL1
chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating activity,
alpha) 6.90 4.37E-07
C15orf48 chromosome 15 open reading frame 48 3.77 4.91E-08
SERPINB2
serpin peptidase inhibitor, clade B
(ovalbumin), member 2 7.57 6.78E-07
TNFA1P6
tumor necrosis factor, alpha-induced protein
6 4.11 1.82E-07
CXCL10 chemokine (C-X-C motif) ligand 10 17.36 1.02E-06
RIPK2
receptor (TNFRSF)-interacting serine-
threonine kinase 1 3.66 4.91E-08
N1NJ1 Ninjurin 1 3.00 4.29E-09
EBI3 Epstein-Barr induced gene 3 3.02 7.98E-09
L1NCR
neuralized homolog 3 (Drosophila)
pseudogene 5.14 7.23E-07
IL7R Interleukin 7 receptor 3.87 2.87E-07
PRIC285
peroxisomal proliferator-activated receptor A
interacting complex 285 4.51 5.83E-07
IL18R1 Interleukin 18 receptor 1 2.90 1.94E-08
TIFA
TRAF-interacting protein with forkhead-
associated domain 2.65 2.23E-09
NFKBIZ
nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, zeta 3.32 2.09E-07
SLC05A1
solute carrier organic anion transporter
family, member 5A1 2.72 7.98E-09
ALCAM activated leukocyte cell adhesion molecule 2.93 4.91E-08
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TNIP3 TNFAIP3 interacting protein 3 5.18 1.34E-06
APOL3 Apolipoprotein L, 3 3.13 2.31E-07
CD40
CD40 molecule, TNF receptor superfamily
member 5 3.23 3.13E-07
KYNU kynureninase 2.84 1.06E-07
IL15RA interleukin 15 receptor, alpha 2.82 9.30E-08
BIRC3 baculoviral 1AP repeat containing 3 3.56 8.06E-07
IFNGR2
interferon gamma receptor 2 (interferon
gamma transducer 1) 2.60 1.98E-08
PIK3C2B
phosphoinositide-3-kinase, class 2, beta
polypeptide 2.50 2.26E-09
IFNAR2 interferon (alpha, beta and omega) receptor 2 2.57 8.02E-09
RND1 Rho family GTPase 1 3.83 1.17E-06
TNFAIP3
tumor necrosis factor, alpha-induced protein
3 5.04 1.91E-06
SAMD9L sterile alpha motif domain containing 9-like 3.04 3.80E-07
FRMD4A FERM domain containing 4A 2.69 9.80E-08
IFIH1 interferon induced with helicase C domain 1 3.80 1.17E-06
PARP14
poly (ADP-ribose) polymerase family,
member 14 2.97 3.63E-07
v-rel reticuloendotheliosis viral oncogene
RELB homolog B 2.40 8.25E-10
CCL5 chemokine (C-C motif) ligand 5 6.63 2.71E-06
NOD2
nucleotide-binding oligomerization domain
containing 2 4.00 1.53E-06
NLF2 C2 calcium-dependent domain containing 4B 4.56 2.12E-06
RHBDF2 rhomboid 5 homolog 2 (Drosophila) 2.32 2.30E-10
SERP1NB2
serpin peptidase inhibitor, clade B
(ovalbumin), member 2 5.67 2.71E-06
KYNU kynureninase 2.71 2.29E-07
GBP1
guanylate binding protein 1, interferon-
inducible 4.36 2.17E-06
TMEM171 transmembrane protein 171 3.30 1.17E-06
SLC7A2
solute carrier family 7 (cationic amino acid
transporter, y+ system), member 2 4.59 2.39E-06
FAS (TNF receptor superfamily, member 6) 2.61 1.82E-07
CCL5 chemokine (C-C motif) ligand 5 6.53 3.61E-06
CD83 chemokine (C-C motif) ligand 5 3.25 1.22E-06
PDE4B phosphodiesterase 4B, cAMP-specific 2.61 2.31E-07
LOC65377 similar to solute carrier family 25, member
8 37 2.66 3.37E-07
NFS1 nitrogen fixation 1 homolog (S. cerevisiae) 4.58 3.01E-06
EHD1 EH-domain containing 1 2.47 4.99E-08
TAP1 transporter 1 ,ATP-binding cassette,subfam B 2.58 2.29E-07
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GCH1 GTP cyclohydrolase 1 2.84 1.02E-06
CXCR7 chemokine (C-X-C motif) receptor 7 2.68 6.61E-07
IQCA1 IQ motif containing with AAA domain 1 2.81 1.10E-06
SLAMF1
signaling lymphocytic activation molecule
family member 1 5.32 6.22E-06
BDKRB2 Bradykinin receptor B2 3.09 1.57E-06
MEOX1 mesenchyme homeobox 1 2.55 3.86E-07
MCOLN2 Mucolipin 2 2.60 9.85E-07
LRRC49 leucine rich repeat containing 49 2.18 4.20E-09
RHBDF2 rhomboid 5 homolog 2 (Drosophila) 2.21 1.98E-08
ICAM1 intercellular adhesion molecule 1 2.59 1.02E-06
interferon stimulated exonuclease gene
ISG20 20kDa 2.99 2.18E-06
HLA-F major histocompatibility complex, class I, F 2.33 1.99E-07
ICOSLG inducible T-cell co-stimulator ligand 2.20 2.28E-08
CYP27B1
cytochrome P450, family 27, subfamily B,
polypeptide 1 3.74 4.41E-06
CD40 CD40 molecule 2.31 1.82E-07
CCL2 chemokine (C-C motif) ligand 2 3.49 3.77E-06
CD83 CD83 molecule 3.12 2.91E-06
BDKRB1 bradykinin receptor B1 4.16 7.50E-06
VCAM1 vascular cell adhesion molecule 1 4.07 7.22E-06
PDGFB
platelet-derived growth factor beta
polypeptide 2.95 3.21E-06
similar to solute carrier family 25, member
LOC65410 37
3 2.53 1.39E-06
leucine rich repeat and fibronectin type III
LRFN5 domain containing 5 2.28 5.10E-07
TNF Tumor necrosis factor 4.03 8.24E-06
MOBKL2C MOB kinase activator 3C 2.12 4.59E-08
SLC25A37 solute carrier family 25, member 37 2.77 3.11E-06
DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58 2.97 4.46E-06
S100A9 SI00 calcium binding protein A9 2.49 1.55E-06
Clq and tumor necrosis factor related protein
C1QTNF1 1 2.40 1.37E-06
GBP4 guanylate binding protein 4 3.95 1.05E-05
MMP1 Matrix metalloproteinase 1 2.45 1.41E-06
IL4I1 interleukin 4 induced 1 2.13 1.85E-07
STX11 syntaxin 11 2.44 1.55E-06
GBP1
guanylate binding protein 1, interferon-
inducible 4.32 1.21E-05
TNFSF10
tumor necrosis factor (ligand) superfamily,
member 10 2.39 1.55E-06
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SRGN serglycin 2.51 2.47E-06
L1LRB2
leukocyte immunoglobulin-like receptor,
subfamily B (with TM and ITIM domains),
member 2 2.58 3.31E-06
SOCS1 suppressor of cytokine signaling 1 2.59 3.39E-06
NBN nibrin 2.48 2.39E-06
CXCL5 chemokine (C-X-C motif) ligand 5 4.99 1.66E-05
TAP2
transporter 2, ATP-binding cassette, sub¬
family B (MDR/TAP) 2.26 1.41E-06
PI3 peptidase inhibitor 3, skin-derived 3.86 1.43E-05
CXCL5 chemokine (C-X-C motif) ligand 5 5.63 2.13E-05
CBR3 carbonyl reductase 3 2.96 7.85E-06
LIF
leukemia inhibitory factor (cholinergic
differentiation factor) 3.73 1.33E-05
A4GALT alpha 1,4-galactosyltransferase 2.02 1.06E-07
CYLD cylindromatosis (turban tumor syndrome) 2.13 7.26E-07
IQCA1 IQ motif containing with AAA domain 1 2.87 8.23E-06
BIRC3 baculoviral IAP repeat containing 3 2.15 1.01 E-06
signal transducer and activator of
STAT5A transcription 5A 2.25 1.72E-06
PSTPIP2
proline-serine-threonine phosphatase
interacting protein 2 2.29 2.21 E-06
TR1M21 tripartite motif containing 21 2.12 9.29E-07
signal transducer and activator of
STAT4 transcription 4 2.55 5.24E-06
DBI
diazepam binding inhibitor (GABA receptor
modulator, acyl-CoA binding protein) 2.29 2.31 E-06
SLC03A1
solute carrier organic anion transporter
family, member 3A1 2.03 3.19E-07
TAPBP TAP binding protein (tapasin) 2.09 6.79E-07
XAF1 XIAP associated factor 1 3.06 1.24E-05
potassium intermediate/small conductance
KCNN2
calcium-activated channel, subfamily N,
member 2 3.15 1.37E-05





PLAU plasminogen activator, urokinase 2.56 7.84E-06
SLC8A3
solute carrier family 8 (sodium/calcium
exchanger), member 3 4.23 2.80E-05
NFKB1A
nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, 2.16 2.91E-06
SPRY4 sprouty homolog 4 (Drosophila) 2.12 2.81 E-06
CD200 CD200 molecule 2.10 2.36E-06
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S1PR3 sphingosine-1 -phosphate receptor 3 2.02 1.41E-06
CD48 CD48 molecule 2.18 4.94E-06
GJB2 gap junction protein, beta 2, 26kDa 3.18 3.18E-05
IL32 Interleukin 32 2.69 2.19E-05
IRF1 interferon regulatory factor 1 2.98 3.17E-05
SLC41A1 solute carrier family 41, member 1 2.28 1.08E-05
LOC73024
9 immunoresponsive 1 homolog 7.19 7.23E-05
PDGFB
platelet-derived growth factor beta
polypeptide 2.36 1.41E-05
DKFZp686
024166 B7 homolog 6 2.11 6.64E-06
PID1
phosphotyrosine interaction domain
containing 1 2.11 6.94E-06
interferon-induced protein with
IFIT3 tetratricopeptide repeats 3 4.55 6.69E-05
CXCR7 chemokine (C-X-C motif) receptor 7 2.22 1.19E-05
MSC musculin 2.83 4.04E-05
TMEM194 transmembrane protein 194A 2.20 1.31E-05
SRGN serglycin 2.60 3.19E-05
TNFAIP8
tumor necrosis factor, alpha-induced protein
8 3.72 6.39E-05
CA8 carbonic anhydrase VIII 2.23 1.57E-05
AMPD3 adenosine monophosphate deaminase 3 2.15 1.46E-05
IL8 Interleukin 8 3.86 8.58E-05
RGS16 regulator ofG-protein signaling 16 2.59 4.19E-05
GJD3 gap junction protein, delta 3,31,9kDa 2.21 2.22E-05
NLRP3 NLR family, pyrin domain containing 3 2.39 3.26E-05
CXCL6
chemokine (C-X-C motif) ligand 6
(granulocyte chemotactic protein 2) 3.84 0.0001
TREM1
triggering receptor expressed on myeloid
cells 1 2.16 2.38E-05
ABTB2
ankyrin repeat and BTB (POZ) domain
containing 2 2.18 2.68E-05
XAF1 XIAP associated factor 1 2.36 3.73E-05
JAG1 Jagged 1 2.32 3.62E-05
S100A3 SI00 calcium binding protein A3 2.11 1.99E-05
OASL 2'-5'-oligoadenylate synthetase-like 4.02 0.000124
RTP4 receptor (chemosensory) transporter protein 2.26 3.53E-05
FGF2 fibroblast growth factor 2 (basic) 2.01 1.43E-05
NKX3-1 NK3 homeobox 1 2.43 5.99E-05
CLIC6 chloride intracellular channel 6 2.11 2.75E-05
CXCL6
chemokine (C-X-C motif) ligand 6
(granulocyte chemotactic protein 2) 5.47 0.000196
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CYB5A cytochrome b5 type A (microsomal) 2.02 1.99E-05
TNFRSF6
B
tumor necrosis factor receptor superfamily,
member 6b, decoy 2.30 5.60E-05
SGPP2 sphingosine-1-phosphate phosphatase 2 3.46 0.00014
NLRP3 NLR family, pyrin domain containing 3 2.42 6.59E-05
SAM domain, SH3 domain and nuclear
SAMSN1 localization signals 1 2.49 7.78E-05
1L6 Interleukin 6 4.12 0.000216
OAS3 2'-5'-oligoadenylate synthetase 3, lOOkDa 3.19 0.000261
HERC6 hect domain and RLD 6 3.15 0.000305
NAMPT nicotinamide phosphoribosyltransferase 2.05 9.66E-05
EPSTI1 epithelial stromal interaction 1 (breast) 3.11 0.000308
SOX7 SRY (sex determining region Y)-box 7 2.02 8.67E-05
NUAK2 NUAK family, SNFl-like kinase, 2 2.05 0.000104
SLC39A8
solute carrier family 39 (zinc transporter),
member 8 2.59 0.000259
F3
coagulation factor III (thromboplastin, tissue
factor) 2.09 0.000168
LOC72871
5 ovostatin homolog 2-like 2.32 0.000249
PTGS2
prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase) 3.31 0.000511
TMEM166 transmembrane protein 166 2.09 0.000195
CD82 CD82 molecule 2.08 0.000207
FSTL3 follistatin-like 3 (secreted glycoprotein) 2.17 0.000286
WTAP Wilms tumor 1 associated protein 2.06 0.000278
MX1
myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 2.76 0.000632
NGF nerve growth factor (beta polypeptide) 2.17 0.000442
PTGS2
prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase) 2.57 0.000658
CD38 CD38 molecule 2.28 0.000565
FAS (TNF receptor superfamily, member 6) 2.02 0.000381
IRF7 interferon regulatory factor 7 2.19 0.00054
RASSF5
Ras association (RalGDS/AF-6) domain
family member 5 2.44 0.00079
CCL19 chemokine (C-C motif) ligand 19 2.57 0.000855
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 2.74 0.000978
SSTR2 somatostatin receptor 2 2.06 0.000518
IFI44 interferon-induced protein 44 2.53 0.000863
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The following table lists all differentially expressed downregulated genes in the
comparison of LPS vs Vehicle from the microarray data reported in Chapter 4.





GRRP1 glycine/arginine rich protein 1 -5.72 9.87E-09
PPP1R16B
protein phosphatase 1, regulatory (inhibitor)
subunit 16B -2.79 5.38E-10
INHBB inhibin, beta B -3.34 1.38E-07
HAVCR2 hepatitis A virus cellular receptor 2 -2.88 6.02E-08
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -2.48 5.85E-11
LHX6 LIM homeobox 6 -2.72 1.92E-07
CARD 10
caspase recruitment domain family, member
10 -2.56 3.64E-08
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -2.32 7.98E-09
GCHFR GTP cyclohydrolase I feedback regulator -2.50 2.55E-07
FPR3 formyl peptide receptor 3 -3.09 2.14E-06
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble -2.68 1.53E-06
IFI30 interferon, gamma-inducible protein 30 -2.58 1.17E-06
MTUS1 microtubule associated tumor suppressor 1 -2.47 9.92E-07
GAS1 growth arrest-specific 1 -2.55 1.23E-06
GIMAP6 GTPase, IMAP family member 6 -2.28 1.10E-06




FUCA1 fucosidase, alpha-L- 1, tissue -2.67 6.45E-06
C6orfl41 chromosome 6 open reading frame 141 -2.26 1.85E-06
LYVE1
lymphatic vessel endothelial hyaluronan
receptor 1 -2.71 7.72E-06
KBTBD11
kelch repeat and BTB (POZ) domain
containing 11 -2.88 1.09E-05
NOSTRIN nitric oxide synthase trafficker -2.03 4.89E-07
MAN1C1 mannosidase, alpha, class 1C, member 1 -2.10 1.34E-06
CPLX1 complexin 1 -2.22 3.26E-06
HSPA12B heat shock 70kD protein 12B -2.01 1.10E-06
MALL mal, T-cell differentiation protein-like -2.12 3.37E-06
SDS serine dehydratase -3.30 3.31E-05
GALM galactose mutarotase (aldose 1 -epimerase) -2.05 2.75E-06
RNASE6 ribonuclease, RNase A family, k6 -2.60 2.07E-05
NPL
N-acetylneuraminate pyruvate lyase
(dihydrodipicolinate synthase) -2.25 9.83E-06
PDE7B phosphodiesterase 7B -2.04 3.27E-06
ADAP2 ArfGAP with dual PH domains 2 -2.01 3.31E-06
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MBP myelin basic protein -2.16 1.21E-05
DACH1 dachshund homolog 1 (Drosophila) -2.10 1.03E-05
NPL
N-acetylneuraminate pyruvate lyase
(dihydrodipicolinate synthase) -2.15 1.59E-05
CD34 CD34 molecule -2.23 2.62E-05
MTUS1 microtubule associated tumor suppressor 1 -2.09 1.41E-05
MS4A6A
membrane-spanning 4-domains, subfamily
A, member 6A -2.05 1.24E-05
TEK TEK tyrosine kinase, endothelial -2.18 2.04E-05
CD34 CD34 molecule -2.03 1.24E-05
CYTL1 cytokine-like 1 -2.48 4.07E-05
TPD52L1 tumor protein D52-like 1 -2.03 1.44E-05
CYYR1 cysteine/tyrosine-rich 1 -2.15 2.67E-05
LAPTM5 lysosomal protein transmembrane 5 -2.04 1.78E-05
PROX1 prospero homeobox 1 -2.20 3.29E-05
STC2 stanniocalcin 2 -2.05 2.79E-05
vesicle-associated membrane protein 8
VAMP8 (endobrevin) -2.01 2.79E-05
HLA-DMB
major histocompatibility complex, class II,
DM beta -2.19 5.62E-05
CD300A CD300a molecule -2.09 4.07E-05
GRAP GRB2-related adaptor protein 2 -2.03 3.34E-05
GRRP1 glycine/arginine rich protein 1 -5.72 9.87E-09
PPP1R16B
protein phosphatase 1, regulatory (inhibitor)
subunit 16B -2.79 5.38E-10
INHBB inhibin, beta B -3.34 1.38E-07
HAVCR2 hepatitis A virus cellular receptor 2 -2.88 6.02E-08
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -2.48 5.85E-11
LHX6 LIM homeobox 6 -2.72 1.92E-07
CARD 10
caspase recruitment domain family, member
10 -2.56 3.64E-08
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -2.32 7.98E-09
GCHFR GTP cyclohydrolase I feedback regulator -2.50 2.55E-07
FPR3 formyl peptide receptor 3 -3.09 2.14E-06
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble -2.68 1.53E-06
IFI30 interferon, gamma-inducible protein 30 -2.58 1.17E-06
MTUS1 microtubule associated tumor suppressor 1 -2.47 9.92E-07
GAS1 growth arrest-specific 1 -2.55 1.23E-06
GIMAP6 GTPase, IMAP family member 6 -2.28 j 1.10E-06




FUCA1 fucosidase, alpha-L- 1, tissue -2.67 6.45E-06
C6orfl41 chromosome 6 open reading frame 141 -2.26 1.85E-06
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lymphatic vessel endothelial hyaluronan
receptor 1 -2.71 7.72E-06
kelch repeat and BTB (POZ) domain
KBTBD11 containing 11 -2.88 1.09E-05
NOSTRIN nitric oxide synthase trafficker -2.03 4.89E-07
MAN1C1 mannosidase, alpha, class 1C, member 1 -2.10 1.34E-06
CPLX1 complexin 1 -2.22 3.26E-06
HSPA12B heat shock 70kD protein 12B -2.01 1.10E-06
MALL mal, T-cell differentiation protein-like -2.12 3.37E-06
SDS serine dehydratase -3.30 3.31E-05
GALM galactose mutarotase (aldose 1-epimerase) -2.05 2.75E-06
RNASE6 ribonuclease, RNase A family, k6 -2.60 2.07E-05
NPL N-acetylneuraminate pyruvate lyase -2.25 9.83E-06
PDE7B phosphodiesterase 7B -2.04 3.27E-06
ADAP2 ArfGAP with dual PH domains 2 -2.01 3.31E-06
MBP myelin basic protein -2.16 1.21E-05
DACH1 dachshund homolog 1 (Drosophila) -2.10 1.03E-05
NPL
N-acetylneuraminate pyruvate lyase
(dihydrodipicolinate synthase) -2.15 1.59E-05
CD34 CD34 molecule -2.23 2.62E-05
MTUS1 microtubule associated tumor suppressor 1 -2.09 1.41E-05
MS4A6A
membrane-spanning 4-domains, subfamily
A, member 6A -2.05 1.24E-05
TEK TEK tyrosine kinase, endothelial -2.18 2.04E-05
CD34 CD34 molecule -2.03 1.24E-05
CYTL1 cytokine-like 1 -2.48 4.07E-05
TPD52L1 tumor protein D52-like 1 -2.03 1.44E-05
CYYR1 cysteine/tyrosine-rich 1 -2.15 2.67E-05
LAPTM5 lysosomal protein transmembrane 5 -2.04 1.78E-05
PROX1 prospero homeobox 1 -2.20 3.29E-05
STC2 stanniocalcin 2 -2.05 2.79E-05
vesicle-associated membrane protein 8
VAMP8 (endobrevin) -2.01 2.79E-05
HLA-DMB
major histocompatibility complex, class II,
DM beta -2.19 5.62E-05
CD300A CD300a molecule -2.09 4.07E-05
GRAP GRB2-related adaptor protein 2 -2.03 3.34E-05
PTP4A3
protein tyrosine phosphatase type IVA,
member 3 -2.02 4.38E-05
FAM124B family with sequence similarity 124B -2.36 0.000101
CLEC14A C-type lectin domain family 14, member A -2.16 9.47E-05
GIMAP7 GTPase, IMAP family member 7 -2.15 0.0001
SLC40A1
solute carrier family 40 (iron-regulated
transporter), member 1 -2.97 0.000262
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ARHGDIB Rho GDP dissociation inhibitor (GDI) beta -2.03 0.000129
MGST2 microsomal glutathione S-transferase 2 -2.02 0.000148
GDF15 growth differentiation factor 15 -2.1 0.000237
DHRS9
dehydrogenase/reductase (SDR family)
member 9 -2.64 0.000756
SEPP1 selenoprotein P, plasma, 1 -2.06 0.00041
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